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Xu Han 
IDENTIFICATION AND MECHANISTIC INVESTIGATION OF CLINICALLY 
IMPORTANT MYOPATHIC DRUG-DRUG INTERACTIONS 
 
 Drug-drug interactions (DDIs) refer to situations where one drug affects the 
pharmacokinetics or pharmacodynamics of another. DDIs represent a major cause of 
morbidity and mortality. A common adverse drug reaction (ADR) that can result from, or 
be exacerbated by DDIs is drug-induced myopathy. Identifying DDIs and understanding 
their underlying mechanisms is key to the prevention of undesirable effects of DDIs and 
to efforts to optimize therapeutic outcomes. This dissertation is dedicated to identification 
of clinically important myopathic DDIs and to elucidation of their underlying 
mechanisms. Using data mined from the published cytochrome P450 (CYP) drug 
interaction literature, 13,197 drug pairs were predicted to potentially interact by pairing a 
substrate and an inhibitor of a major CYP isoform in humans. Prescribing data for these 
drug pairs and their associations with myopathy were then examined in a large electronic 
medical record database. The analyses identified fifteen drug pairs as DDIs significantly 
associated with an increased risk of myopathy. These significant myopathic DDIs 
involved clinically important drugs including alprazolam, chloroquine, duloxetine, 
hydroxychloroquine, loratadine, omeprazole, promethazine, quetiapine, risperidone, 
ropinirole, trazodone and simvastatin. Data from in vitro experiments indicated that the 
interaction between quetiapine and chloroquine (risk ratio, RR, 2.17, p-value 5.29E-05) 
may result from the inhibitory effects of quetiapine on chloroquine metabolism by 
cytochrome P450s (CYPs). The in vitro data also suggested that the interaction between 
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simvastatin and loratadine (RR 1.6, p-value 4.75E-07) may result from synergistic 
toxicity of simvastatin and desloratadine, the major metabolite of loratadine, to muscle 
cells, and from the inhibitory effect of simvastatin acid, the active metabolite of 
simvastatin, on the hepatic uptake of desloratadine via OATP1B1/1B3. Our data not only 
identified unknown myopathic DDIs of clinical consequence, but also shed light on their 
underlying pharmacokinetic and pharmacodynamic mechanisms. More importantly, our 
approach exemplified a new strategy for identification and investigation of DDIs, one 
that combined literature mining using bioinformatic algorithms, ADR detection using a 
pharmacoepidemiologic design, and mechanistic studies employing in vitro experimental 
models.   
 
David A. Flockhart, M.D., Ph.D., Chair 
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Chapter 1. Introduction to clinical drug-drug interactions (DDIs) 
 
1. Prevalence and significance of drug–drug interactions (DDIs) 
The term “drug-drug interactions” (DDIs) refers to interactions between two 
coadministered drugs in which one drug affects the pharmacokinetics or 
pharmacodynamics of another. The coadministration of two drugs is usually safe with no 
detectable interaction. Some drugs are coadministered purposefully to improve 
therapeutic outcomes. Some coadministered drugs can cause significant pharmacokinetic 
interactions that are not clinically important under usual therapeutic circumstances. 
Clinically important DDIs are drug interactions that cause failure to achieve the 
therapeutic effects of either or both drugs, or that result in or exacerbate severe or life-
threatening adverse drug reactions (ADRs). This thesis is focused on clinically important 
DDIs that are associated with ADRs.   
ADRs are a leading cause of morbidity and mortality in health care. According to 
a report of the Institute of Medicine, an estimated 7,000 deaths occur annually due to 
ADRs [1]. In hospitalized patient populations. It is estimated that 6.7% hospitalized 
patients experience serious ADRs with a fatality rate of 0.32% each year [2]. This means 
that more than 2,216,000 serious ADR events occur, which cause 106,000 deaths 
annually. ADRs are also a huge financial burden on health care. Drug-related morbidity 
and mortality is estimated to cost $30.1 to $136.8 billion in the ambulatory setting in the 
US each year [3].  
DDIs are a significant contributor to preventable ADRs. Leape et al. estimated 
that DDIs represent 3–5% of all in-hospital medication errors [4]. In an analysis with an 
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Italian spontaneous reporting database, it was estimated that 22% of patients exposed to 
potential DDIs experienced associated ADRs [5]. In addition, Becker et al.found that 
DDIs were responsible for approximately 0.054% of emergency department visits, 0.57% 
of hospital admissions and 0.12% of re-hospitalizations [6]. In 2010, there were 129.8 
million emergency department visits, 100.7 million outpatient department visits and 35.1 
million inpatient department discharges in the US [7], suggesting a substantial number of 
hospital visits due to DDIs. It is not surprising that DDIs also contribute to increased cost 
and duration of hospital stays [8].  
The risk of DDIs increases linearly with age and the number of prescribed drugs 
[9]. In a database involving 471,732 individuals, one-third of the population were found 
to be exposed to polypharmacy, and 15% of the population exposed to polypharmacy 
were exposed to potential drug interactions. 
As polypharmacy becomes more common, the prevalence of DDIs is expected to 
increase. The elderly are particularly susceptible to DDIs, due both to their advanced age 
and to polypharmacy. Gurwitz et al. estimated that more than 40% of the elderly 
population aged 65 or older use 5 or more medications, and 12% use 10 or more 
medications [11]. According to Bjerrum et al., among the elderly with polypharmacy, 25% 
aged 60-79 years and 36% over 80 years were potentially exposed to DDIs [10]. DDIs 
were responsible for 4.8% of hospital admissions in the elderly population [7]. It is worth 
noting that, according to Björkman et al., 10% of the potential DDIs could be avoided 
according to the Swedish interaction classification system [12].  
DDIs are also one of the most common reasons for drug withdrawal. When 
alternative medications are available and warnings in drug labels fail to manage the risk 
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of DDIs, DDIs associated with severe or life-threatening ADRs may lead to withdrawal 
of drugs from the market or restriction in drug use [13]. The interaction between the 
nonsedating antihistamine terfenadine and ketoconazole is associated with a significantly 
increased risk of torsade de pointes and fatal arrhythmia [14]. Because fexofenadine and 
loratadine are able to meet the same medical needs with better safety profiles, terfenadine 
was ultimately withdrawn from the market when the warnings in its label failed to 
adequately reduce the incidence of the fatal interaction. The nonsedating antihistamine 
astemizole and gastroprokinetic cisapride were withdrawn for similar reasons [15, 16]. 
The calcium channel blocker mibefradil was withdrawn because its inhibitory effects on 
drug metabolism caused dangerous interactions with at least 25 other drugs, including 
common antibiotics, antihistamines, and cancer drugs [17]. 
 
2. Mechanisms underlying  drug interactions 
There are a number of mechanisms by which drugs interact. These mechanisms 
can be divided into three general categories: pharmaceutical, pharmacokinetic and 
pharmacodynamic. Pharmaceutical drug interactions are those that occur prior to 
systemic administration and are often due to drug incompatibility [18]. Pharmacokinetic 
drug interactions are those in which one drug affects the absorption, distribution, 
metabolism or excretion of another [13]. The drug that causes the interaction is often 
referred to as the precipitant drug, and the drug whose pharmacokinetics is affected is 
often referred to as the victim drug. Pharmacodynamic drug interactions are those in 
which two drugs with overtly similar pharmacological effects produce exaggerated or 
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diminished effects when used in combination without changes in pharmacokinetics [19, 
20].  
The mechanisms by which pharmacokinetic interactions occur are relatively well 
understood. One of the common mechanisms underlying pharmacokinetic DDIs is 
alteration in drug absorption. The absorption of a drug can be altered due to changes in 
gastric pH. For example, didanosine requires a neutral-to-basic pH to be absorbed and its 
formulations are buffered. Medications, such as ketoconazole and itraconazole, are 
known to require an acidic environment for dissolution. The absorption of these drugs 
can be significantly decreased when given concomitantly with didanosine [21, 22]. 
Chelation and adsorption of drugs can also cause changes in absorption. Quinolone 
antibiotics, when combined with magnesium- and aluminum-containing antacids, can 
form insoluble complexes that are unable to permeate the intestinal mucosa and be 
absorbed [23]. Concomitant administration of antibiotics, such as penicillin G and 
tetracycline, with adsorbents, such as cholestyramine, can result in decreased absorption 
of antibiotics [24]. Another mechanism involves changes in gastric emptying and 
intestinal motility. Gastroprokinetic drugs such as cisapride can reduce gastrointestinal 
transit time and decrease the extent of absorption of drugs which are poorly soluble or 
absorbed only in a limited area of the intestine [25]. It has been recognized that inhibition 
or induction of drug-metabolizing enzymes, such as the cytochromes P450s (CYPs) and 
uridine 5’-diphosphate (UDP)-glucuronosyltransferases (UGTs), expressed in enterocytes 
of the intestinal epithelia can affect bioavailability and potentially contribute to DDIs [26]. 
Of similar importance is uptake or efflux drug transporters located on the basolateral 
membrane of the enterocytes. Inhibition of uptake transporters, such as organic anion 
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transporting peptides (OATPs), can lead to decreased absorption. On the other hand, 
inhibition of efflux transporters, such as P-glycoprotein, can enhance bioavailability [27].  
There has been a debate on whether alterations in plasma protein binding can 
cause DDIs by affecting drug distribution. Displacement of a victim drug from its plasma 
protein binding sites, such as albumin, can lead to an increase in the unbound plasma 
concentration. However, this increase is usually transient as redistribution and 
elimination occur immediately after displacement. Thus, DDIs involving plasma protein 
binding displacement may potentially be clinically significant if the victim drug is highly 
bound in plasma, has a narrow therapeutic index and a small volume distribution. A 
transient increase in drug concentrations may be clinically important with drugs such as 
warfarin and phenytoin; however, for majority of drugs, their mean steady-state unbound 
drug concentration will remain unchanged. Alteration in plasma protein binding is 
therefore usually not a significant mechanism of drug interactions [28, 29]. 
The most common and important mechanism of pharmacokinetic drug 
interactions is an alteration in drug metabolism. Inhibition of drug metabolism accounts 
for 76% of case reports involving pharmacokinetic DDIs identified in VigiBaseTM, an 
international database for drug safety maintained by the World Health Organization [30]. 
Most metabolism-based DDIs involve inhibition or induction of CYPs, a class of phase I 
enzyme that catalyze oxidation, reduction and hydrolysis reactions [31]. Drugs that are 
inhibitors or inducer of CYPs can significantly change the pharmacokinetics of other 
drugs, although these interactions may be attenuated by genetic polymorphisms of CYPs 
[32]. Inhibition of CYPs is the major mechanism that has led to regulatory withdrawal of 
drugs and label changes. A more detailed discussion on inhibition of CYPs as a 
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mechanism of DDIs is provided in Chapter 3. Less common is the occurrence of DDIs as 
a result of inhibition of phase II enzymes that are responsible for conjugation. A few 
studies have suggested that inhibition of UGTs can contribute to DDIs [33]. Recently, a 
number of clinically important DDIs have been attributed to inhibition of hepatic uptake 
transporters, OATPs in particular [34]. These transporters determine the availability of 
drugs for hepatic metabolism and can lead to significant changes in pharmacokinetics 
when inhibited. Further discussion on this mechanism of interaction can be found in 
Chapter 4.  
Relatively few DDIs occur due to alterations in renal elimination. The most 
common renal drug interactions occur at the site of tubular secretion, involving 
competition for transporters [35]. A number of important drug transporters are expressed 
in renal proximal tubule cells, including organic cation transporters (OCTs), organic 
anion transporters (OATs), the multidrug resistance-associated proteins (MRPs), p-
glycoprotein, and the multidrug and toxin extrusion proteins (MATEs) [36]. Inhibition of 
these transporters could cause DDIs by decreasing cellular drug uptake and impairing 
renal clearance. For example, MATE1 and OCT1 have been shown to be important for 
the tubular secretion of metformin [37, 38]. The inhibition of MATE1 and OCT1 by 
cimetidine [39] contributed to its interaction with metformin. Cimetidine was shown to 
decrease renal metformin clearance by 27% and to increase the AUC (0 to 24 h) and Cmax 
of metformin by 50% and 81%, respectively [40]. 
In contrast to pharmacokinetic drug interactions, pharmacodynamic interactions 
are less well studied and understood. Based on the outcome of combining two drugs, 
pharmacodynamic interactions can be either synergistic or antagonistic. 
7 
 
Pharmacodynamic DDIs can occur at the site of receptors or downstream signaling 
pathways [18]. The mechanisms underlying pharmacodynamic interactions are often 
difficult to study. This is in part because of the intrinsic complexity of biological systems 
that are usually involved in pharmacodynamic interactions. Also, some DDIs are dose-
dependent and a DDI may not be recognizable unless an appropriately high dose of one 
or both drugs is given. In addition, variability in demographics, physiology, underlying 
disease state and genetic variations can mask the effects of potential DDIs [20]. Recent 
advances in system pharmacology hold promise for promoting discovery and 
understanding of pharmacodynamic DDIs. 
 
3. Approaches to studying drug interactions 
There are three general approaches to discovery and investigation of DDIs, in 
vitro, in vivo and in populo [41]. In vitro pharmacokinetic experiments use cells or cell-
derived systems to characterize changes in drug metabolism and transport activity that 
may underlie DDIs [41]. Commonly used in vitro experimental systems include primary, 
cultured and cryopreserved hepatocytes, human liver microsomes and recombinant CYP 
and UGT enzymes [13]. In vitro methods are used routinely in drug development to 
evaluate the risk of DDIs for investigational drugs. They are particularly helpful means of 
uncovering underlying molecular mechanisms of DDIs observed clinically. The 
information obtained from in vitro experiments can be used to develop mathematical 
models to predict the changes in drug exposure due to DDIs in vivo. In vitro experiments 
thus allow investigation of DDIs without the expense and potential risks involved in 
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conducting human trials. However, data from in vitro experiments are often insufficient 
to assess the clinical significance of a DDI [41]. 
In vivo studies can involve clinical trials conducted in humans to evaluate the 
changes in pharmacokinetics, efficacy and the risk of ADRs that result from DDIs. 
Clinical studies investigating pharmacokinetic DDIs are in general small in size, 
involving 10 – 100 patients, and usually adopt a randomized or cross-over design [13]. 
Plasma concentrations are often closely monitored to estimate drug exposure and other 
important pharmacokinetic parameters. Efficacy and side effects may also be measured. 
Clinical studies, when appropriately designed and performed, can provide the most 
convincing evidence for conclusions as to whether one drug interacts with another [41]. 
Data from these studies serve as the basis for regulatory drug label changes. However, 
clinical studies are usually not able to provide mechanistic insight unless they use a probe 
substrate or an inhibitor that is specific to a target enzyme or a transporter. Also, clinical 
studies are often expensive and time-consuming to conduct. More importantly, it may not 
be ethically defendable to conduct a clinical trial and investigate the effect of a DDI on 
the risk of ADRs.  
Finally, in populo studies are pharmacoepidemiology studies investigating the 
effects of DDIs on efficacy and ADRs in a large population [42]. It is rare to perform a 
large-scale prospective observational study to investigate a drug interaction. Most 
pharmacoepidemiology studies on DDIs are retrospective, taking advantage of existing 
data from past clinical trials and medical databases such as spontaneous reporting 
systems and electronic medical record (EMR) databases [43].  Pharmacoepidemiology 
studies are an important tool used to discover unknown DDIs, especially those leading to 
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significant clinical changes such as in therapeutic efficacy or in ADR risk. They are 
particularly useful in detecting and quantifying rare ADRs resulting from DDIs. 
Compared to prospective clinical trials, pharmacoepidemiology studies have the 
advantages of larger sample size, longer observation periods, a paucity of potential 
ethical issues, and are less expensive, less time consuming, and possess greater ability to 
provide more generalizable results [42]. However, pharmacoepidemiology studies are 
themselves often subject to the limitations inherent in the use of existing data. A biased 
result may be obtained when confounding factors such as demographics, comedications, 
comorbidities and disease states are not appropriately accounted for [42]. 
 
4. Rationale for a translational approach 
The goal of research on DDIs is to identify them, understand them, treat them 
when possible and ultimately prevent them. Traditionally, research on DDIs adopts a 
bottom-up strategy that heavily relies on knowledge about individual drugs or proteins of 
relevance. Such knowledge may relate to how a drug is metabolized or transported, 
which drug-metabolizing enzymes or drug transporters can be inhibited or induced by a 
particular drug, or which common comedications are also substrates or inhibitors of the 
affected enzymes or transporters. This knowledge provides a scientific basis for 
predicting the changes in pharmacokinetics due to a potential DDI in humans. Clinical 
studies are then conducted to examine the clinical significance of DDIs that potentially 
occur. This strategy is well established and has been incorporated as a routine in drug 
development to evaluate the risk of DDIs of investigational drugs. The FDA requires in 
vitro characterization of drug metabolism and inhibition of the major CYPs and important 
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drug transporters for any investigational drug [13]. If a potential risk is predicted based 
on in vitro data, a clinical study is required to assess the potential of clinical DDIs with 
common comedications and probe substrates or inhibitors of the relevant proteins [13].  
This knowledge-based bottom-up approach has well-defined targets. It is applied 
to a particular pair of drugs involving specific pathways, and looks for changes in 
particular effects. Although highly specific, this approach is inefficient for identification 
of unknown DDIs. Only a very small number of targets can be studied at a time [41]. As 
a result, many DDIs remain undetected for a fairly long time until they are suspected 
once we know enough about the metabolism or transport of the involved drugs. This 
approach is particularly inefficient for identification of DDIs that are clinically important 
as most DDIs predicted from in vitro data turn out to have no effect clinically.  
As polypharmacy becomes more common and DDIs occur more frequently, 
research on DDIs must adapt to a high-throughput mode to discover and investigate 
unknown DDIs in a more efficient manner and with a stronger clinical orientation. This 
change can be achieved by taking advantage of the voluminous body of existing 
knowledge stored in the published literature and in large databases, identifying unknown 
DDIs that are actually of clinical consequence, and interpreting them mechanistically. We 
call this a ‘top-down’ approach. 
Identification of unknown, yet clinically important DDIs involves testing the 
clinical significance of possibly interacting drug combinations. This is a challenging task 
when the number of potential DDIs to be studied is prohibitively large. There are 1492 
small-molecule drugs approved by the FDA, and 1,112,286 two-drug combinations that 
could possibly interact. The clinical significance of any specific DDI can, in theory, be 
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tested with either clinical trials or pharmacoepidemiology studies; however, with such a 
large number of potential DDIs, clinical trials are obviously not a feasible option to 
identify clinically important DDIs. Pharmacoepidemiology studies provide a cost-
effective and efficient alternative. Performing pharmacoepidemiology studies requires 
defining an outcome of interest at first. With the aim of identifying clinically important 
DDIs in mind, we need to begin with an outcome of interest that is clinically important. 
An outcome of interest also needs to be identifiable from a data source, phenotypically 
well-defined, and not extremely rare. Myopathy is an outcome that meets all these criteria 
and we have thus selected this phenotypic outcome as our outcome of interest. The 
selection of myopathy as the outcome of interest is discussed in detail later. 
Even for pharmacoepidemiology studies with relatively frequent outcomes, 
evaluating such a huge number of potential DDIs is challenging, because the statistical 
power to detect DDIs decreases with the number of simultaneous tests, given a fixed 
sample size available from a database. It is therefore important to limit our ambition and 
reduce the search space to a subset of drug combinations instead of all of them. The 
question then becomes which subset of possible drug combinations to select for study. A 
reasonable choice is the subgroup of DDIs that we understand better and potentially have 
more confidence in providing mechanistic explanations. Inhibition of CYPs is the most 
important mechanism of pharmacokinetic DDIs [13]. It is also the DDI mechanism 
currently best understood. We have therefore limited our initial screening to DDIs that 
may result from inhibition of CYPs.  
A small number of published studies have taken an approach similar to ours. 
Percha et al. used a network of interrelationships between drugs and enzymes mined from 
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the published literature to provide mechanistic explanations for known DDIs and to infer 
new DDIs [44]. Their work, however, did not distinguish data from in vitro, in vivo or in 
populo studies. Also, they did not examine whether the predicted DDIs were clinically 
relevant. The work by Tatonetti et al. represents a progress as they not only predicted 
DDIs but also examined the association of predicted DDIs with clinical phenotypes using 
data from an EMR database [45]. A limitation of their work is the lack of mechanistic 
investigation. 
The simple presence of a pharmacoepidemiologic DDI does not allow one to infer 
its mechanism. Without knowing by what mechanisms an apparent DDI can occur, one 
cannot conclude with certainty that it is truly an interaction rather than a false positive 
due to methodological flaws. It is similarly difficult to provide a reasonable alternative 
with better therapeutic outcome and without drug interaction. As we predict DDIs from 
inhibition of CYPs, this is naturally the most likely mechanism of DDIs that are 
identified to be clinically important, but we also attempt to explore other possible 
mechanisms by which DDIs can occur as DDIs can be multifactorial.  
 
5. Why is myopathy an appropriate outcome of interest?  
There are a number of reasons for selecting myopathy as our outcome of interest. 
First, myopathy is a clinically important outcome. Drug-induced myopathy is among the 
most common causes of muscle disease [46]. The clinical presentation of drug-induced 
myopathy ranges from asymptomatic muscle enzyme elevation to chronic myopathy with 
severe weakness, and to massive rhabdomyolysis with acute renal failure. A summary of 
clinical presentations of drug-induced myopathy is displayed in Table 1-1 [47]. Muscular 
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weakness, myalgia and myositis are the most common clinical presentations of drug-
induced myopathy [46]. In the SIDER 2 database [48], a database of drug side effects 
mined from the FDA’s drug labels, there are 124 FDA-approved drugs associated with 
muscular weakness, 395 associated with myalgia and 51 associated with myositis. These 
muscle-related side effects can cause incompliance or discontinuation of drug treatment 
and potentially compromise therapeutic outcome. The most severe form of myopathy, 
rhabdomyolysis, is a rare but life-threatening condition. There are over 150 drugs of 
various classes that have been associated with rhabdomyolysis, including statins, 
antimalarials, antihistamines, antidepressants and antipsychotics [49-51].  
Second, myopathy can result from or be exacerbated by DDIs. One well 
recognized example is the interaction between cerivastatin and gemfibrozil. In a 
population-based cohort study, the risk of rhabdomyolysis associated with cerivastatin 
monotherapy was 10-fold higher than that with the use of other statins. The interaction of 
cerivastatin with gemfibrozil increased the risk of rhabdomyolysis 50-fold [52]. This 
interaction led to the withdrawal of cerivastatin from the market. Considering the number 
of drugs that can induce myopathy, it is reasonable to speculate that there potentially 
exists a large number of drug interactions associated with increased risk of myopathy.  
Third, myopathy is an outcome that is relatively phenotypically well-defined and 
readily detectable in EMR databases. Although myopathy has a broad spectrum of 
clinical presentations as shown in Table 1-1, each condition is relatively well-defined. 
Patients with myopathy can be identified from EMR databases using diagnostic codes.  
Lastly, myopathy is a relatively common ADR that enables detection of DDIs 
with sufficient statistical power. Given a fixed number of simultaneous tests, the 
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statistical power to detect DDIs increases with the sample size available from a database. 
If a rare outcome, such as rhabdomyolysis, were selected for pharmacoepidemiologic 
study, it is very likely that only a small number of patients with rhabdomyolysis would be 
identified from available databases. Analyses therefore would likely be under-powered to 
detect DDIs associated with this outcome.  
 
6. Hypothesis and aims 
The overall hypothesis of this thesis is that the combination of data mining and in 
vitro mechanistic studies can identify and shed mechanistic light on new DDIs that are 
associated with an increased risk of clinical myopathy. To test this hypothesis, DDIs 
associated with increased risk of myopathy will first be identified. The likelihood that 
such drug interactions are caused by changes in the activities of drug-metabolizing 
enzymes and/or drug transporters, or direct myotoxicity will then be assessed in vitro. 
Due to the limitations of current experimental techniques for studying drug transporters, 
only the drug transporters of most interest, namely, organic anion transporting 
polypeptide 1B1 and 1B3 (OATP1B1/1B3), will be studied. The mechanisms of drug 
interactions that are particularly important will be further investigated. To test this 
hypothesis, the following specific aims are pursued:  
Aim 1: Predict and identify DDIs associated with increased risk of myopathy by 
mining the published literature and EMR databases. 
Aim 2: Evaluate in vitro the likelihood that DDIs identified in Aim 1 are caused 
by inhibition of the major CYP isoforms. 
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Aim 3: Evaluate in vitro the likelihood that DDIs identified in Aim 1 are caused 
by inhibition of hepatic uptake transporters OATP1B1/1B3. 
Aim 4: Evaluate in vitro the likelihood that DDIs identified in Aim 1 are caused 
by direct myotoxicity using rat L6 myotubes. 
 
  
16 
 
Table 1-1. The clinical spectrum of drug-induced myopathy [47] 
Condition Definition 
Myopathy General term to describe all skeletal muscle-related adverse effects 
Asymptomatic 
CK elevation 
CK elevation without muscle symptoms  
Myalgia Muscle pain or weakness without CK elevation 
Myositis Muscle symptoms with CK elevation typically < 10 x ULN 
Rhabdomyolysis Muscle symptoms with CK elevation typically > 10 x ULN, and 
with creatinine elevation (usually with brown urine and urinary 
myoglobin) 
 
Note: CK, creatine kinase; ULN, upper limit of normal. 
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Chapter 2. Identification of DDIs associated with myopathy in a large scale 
 
1. Introduction 
a. Data sources for large-scale DDI identification 
Historically, clinical DDIs were identified through review of case reports and case 
series in which severe adverse events occur during the coadministration of drugs. In 
recent decades, there has been a rapid growth in both volume and complexity of data that 
have developed into large databases. Traditional pharmacovigilance applies high-
throughput signal detection algorithms to these databases in order to detect drug-event 
associations and more complex drug safety phenomena such as DDIs [53].  
The primary data source for pharmacovigilance has been spontaneous reporting 
systems [53]. Spontaneous reporting systems are passive systems largely maintained by 
regulatory and health agencies collecting reports of suspected ADRs from health-care 
professionals, consumers, and pharmaceutical companies. The two most well-known of 
these are the FDA Adverse Event Reporting System (FAERS) [54] and the VigiBaseTM 
system [55] maintained by the World Health Organization. Spontaneous reporting 
systems largely rely on voluntary reporting, except for pharmaceutical companies, which 
are required to report suspected ADRs [54]. The information provided by spontaneous 
reporting systems include the drug suspected to cause the ADE, concomitant drugs, 
indications, suspected events, and limited demographics [53]. Data within spontaneous 
reporting systems are often used for detecting drug-event signals for follow-up analysis 
via formal pharmacoepidemiologic studies and to discover complex relationships, such as 
DDIs, that are difficult to identify manually. Spontaneous reporting systems have 
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advantages of centralized data collection and processing, large sample size and public 
accessibility. The limitations of spontaneous reporting systems include 1) over-reporting 
of ADRs known to result from a drug and underreporting of those otherwise; 2) the fact 
that only patients who experience ADRs are reported; 3) the fact that they often lack 
enough detail to evaluate the causality between a drug or a drug combination and an 
ADR; 4) duplication of reporting; and 5) missing or incomplete data [56, 57].   
Another data source that has been increasingly used for pharmacovigilance is 
electronic medical records (EMRs) [53]. EMRs contain a vast repository of disease and 
treatment data that could be mined for identification of DDIs. Compared to spontaneous 
reporting systems, the data within EMRs are chronological – they contain a more 
complete record of medical history, treatments, conditions and diagnoses of a patient. 
EMRs thus have more power to examine temporal relationships between drug 
administrations and ADRs [53]. EMRs also contain data from broader populations than 
spontaneous reporting systems can, as they are not restricted to patients who experience 
ADRs only [58]. However, EMRs are designed primarily for clinical care instead of 
research, so re-use of clinical EMR data for identification of DDIs can be challenging 
[53]. EMR data suffer from the common problems of observational data, including 
missing data and incorrect data [53]. ADRs may not be recorded as diagnostic or lab test 
codes, and may require further informatics processing before analysis [53]. Also, EMR 
data contain vast quantities of unstructured clinical narratives that are often the primary 
and richest source of patient information but are difficult to analyze using automated 
methods. In addition, EMR data are largely proprietary and involve legal and privacy 
issues concerning access to patient data [58-60].  
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In addition to spontaneous reporting systems and EMRs, a few other information 
sources have been used for detection and prediction of DDIs. These information sources 
are mined with methods integrating statistics, computer science, medicine, epidemiology, 
chemoinformatics and biology. It has been shown to be a powerful approach to uncover 
hidden relationships between coadministration of drugs and potential clinical 
consequences.  
One such data source is the published literature on biomedical science. PubMed is 
the most widely used online literature search service. It contains over 20 million articles 
and continues to add 40,000 new abstracts each month [61]. The published literature 
contains not only DDIs observed clinically, but also the potential underlying mechanisms 
investigated in experiments. Extracting and summarizing data from the voluminous body 
of biomedical literature using automated algorithms has been shown to be a promising 
approach to identification and prediction of DDIs. One recent example is the work by 
Percha et al., who text-mined the published literature for the interrelationship between 
drugs and proteins such as metabolic enzymes and drug transporters. The resulting 
network provided possible mechanistic explanations for drug pairs that interact, and 
enabled prediction of DDIs from known interacting drug pairs sharing similar 
mechanisms of interaction [44]. In addition, text mining of the biomedical literature has 
the potential to identify large numbers of DDIs in a cost-effective manner. 
Data sources relating to drug information have been increasingly used to study 
and predict DDIs. DrugBank is a bioinformatics and cheminformatics database that 
contains not only detailed chemical, pharmacological and pharmaceutical data of drugs, 
but also information relating to sequence, structure and pathway of drug targets. The 
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drugs in DrugBank include not only FDA-approved small molecule and protein drugs, 
but also experimental ones [62]. The KEGG DRUG is a similar database for all the 
approved drugs in the US, Europe and Japan, and contains information on molecular 
structure, target, metabolizing enzymes, transporters, known DDIs, and other molecular 
interaction network information [63]. The World of Molecular Bioactivity (WOMBAT) 
is a database containing protein-ligand binding data mined from papers published in 
medicinal chemistry journals between 1975 and 2012 [64]. ChEMBL and BindingDB are 
similar databases that are publicly available. Assuming that ADRs are predictable from 
the interaction of drugs with molecular actors, these databases have been used to bridge 
the gap between molecular mechanism and clinically observed ADRs resulting from 
drugs or drug combinations. There are a number of examples using information in these 
databases and ADRs discovered in the post-market phase to develop better models 
predicting ADR profile of drugs [65-67]. The data from DrugBank and KEGG DRUG 
can potentially be used to construct gold-standard sets of known DDIs for development 
of new DDI detection methods. These databases may not only provide a basis for better 
understanding of mechanisms underlying DDIs, but also enable prediction of DDIs and 
the resulting clinical consequences.  
Another useful source of data is drug labels which contain valuable information 
about ADRs and known drug interactions. The full text of drug labels for all the drugs, 
including both prescribed and over-the counter drugs, available in the US are provided on 
the National Library of Medicine DailyMed website 
(http://dailymed.nlm.nih.gov/dailymed/about.cfm). A similar resource for the drugs 
available in Japan can be obtained from the Japan Pharmaceutical Information Center 
21 
 
(JAPIC). The Side Effect Resource (SIDER) database contains drug-side effect 
relationships mined from the text of drug package inserts. In a study by Tatonetti et al., 
data from the SIDER database were used to predict DDIs [45]. PharmGKB is a database 
that provides curated knowledge about the impact of genetic variations on drug response, 
which can be potentially useful to study DDIs with respect to pharmacogenetics. Also 
available from PharmGKB are OFFSIDES and TWOSIDES which are databases of drug 
effects derived from adverse event reports and of DDI side effects, respectively [45]. 
Last but not least, social networks and online forums can also contribute to the 
discovery of DDIs. Health-related social networks such as Ask a Patient 
(http://www.askapatient.com/), DailyStrength (http://www.dailystrength.org/) and Yahoo 
Health (http://health.yahoo.net/) provide patients a platform for discussing and sharing 
experience with medications. Mining those websites is a promising approach to obtaining 
information on DDIs experienced by patients. Although extracting useful information 
from posts on these websites can be very challenging, they have been shown to provide 
supplementary information on side effects and therapeutic effects of drugs [68]. By 
examining the posts related to the use of aromatase inhibitors (AI) on 12 message boards 
between 2002 and 2010, Mao et al. identified common side effects experienced by breast 
cancer patients taking AIs in relation to drug switching and discontinuation [69].  
 
b. Text mining using the published biomedical literature 
Text mining in the biomedical literature has been increasingly recognized as a 
powerful approach that can not only transform the archives of science into rapidly 
accessible searchable data, but also promote the discovery of new knowledge and 
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development of science [70, 71]. It has grown in the last few years to be one of the major 
bioinformatics tools [72]. In general, text mining refers to “the process of extracting 
interesting and nontrivial information and knowledge from unstructured text” [73]. It lies 
at the interface of several computer science disciplines including but not limited to 
artificial intelligence, pattern recognition, neural networks, natural language processing, 
information retrieval and machine learning [73]. 
There are three commonly used approaches to text mining in the biomedical 
literature  [70]. One is co-occurrence-based methods that search for concepts occurring in 
the same sentence or abstract and posit a relationship between them [70]. This approach 
has been used to build many early biomedical text mining systems but is used less 
frequently today because it is error prone [70]. Two more commonly used and more 
sophisticated approaches are the rule- or knowledge- based approaches, and statistical- or 
machine-learning-based approaches [70]. A rule-based system uses certain rules as 
criteria for information extraction. The complexity of a rule-based text mining system 
depends on what rules are applied. Rules can be simply certain linguistic patterns that are 
used to find explicit statements of interest [74]. For example, the pattern “<gene> is 
<associated> with <disease>” can be used as the rule to find the statements about the 
association between a single gene and a disease. In more complicated cases, rules can be 
what relationships exist between sets of subjects, or what variant forms of a gene or a 
protein are mentioned [74]. Sophisticated linguistic and semantic analyses may be needed 
in such cases to recognize a variety of possible ways of making statements of interest 
[74]. In contrast, a statistical- or machine-learning-based approach uses a set of training 
data to build classifiers that serve as the basis for subsequent classification of full 
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sentences or documents to be analysed [74]. Rule-based text mining systems in general, 
although not always, are time-consuming to develop, whereas machine-learning-based 
systems may require a large amount of training data that is not always available [70]. As 
a result of their respective deficiencies, these two approaches are often used together to 
complement each other. Many text mining systems employ initial processing based on 
machine learning to classify whether or not a document is relevant, followed by rule-
based post-processing to extract information from the documents [70].  
Before performing text mining, a corpus needs to be constructed. A corpus is “a 
collection of text or speech material that has been brought together according to a set of 
predetermined criteria” as defined by Ali Farghaly [75]. An example of a 
pharmacokinetic corpus is the work by Wu et al. [76]. As summarized by Rzhetsk et al. 
[71], text mining pipelines in general contain the following major stages. (1) Information 
retrieval (IR). IR is the process that finds relevant information in an unstructured text 
source. It largely relies on PubMed that provides a searchable engine and automated 
methods for abstract download. 2) Named-entity recognition. Once the documents 
containing the information of interest are retrieved, an automated method is applied to 
scan each sentence and to identify the language entities of interest. The target entities are 
often predefined in a dictionary containing their synonyms and homonyms, so that an 
individual entity can be identified even though it may be referred to by several different 
names and acronyms. 3) Information extraction (IE). IE is a process that links the 
identified targeted entities using certain action words and assembles them into simple 
phrases that capture their relationship. For example, one may extract the sentences with 
the structure “gene is associated with disease”, where “gene” and “disease” are the target 
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entities and “associate” is the action word capturing their relationship. 4) Synthesis and 
use of the extracted information. There are a variety of ways to use the extract 
information depending on the goal of text mining [71]. Examples include answering a 
question about the relationship between two objects, collecting published experimental 
evidence supporting a set of conclusions, or examining the consistency of a statement in 
the literature. Extracted information can be used to construct a map or a network, a global 
description of the interrelationships between different categories of objects. One such 
example is the work by Coulet et al., who mined 17 million MEDLINE abstracts and 
built a network of 40,000 relationships between genes, drugs and phenotypes [77]. 
Another example is the work by Wang et al., who mined the published literature for 
numeric pharmacokinetic data of drugs [78]. 
 
c. Pharmacoepidemiology study designs for identification of DDIs 
Cohort and case-control studies are the two major study designs used to examine 
the association between an ADR and a drug exposure in pharmacoepidemiologic research 
[42]. 
A cohort means “a group of people who share similar characteristics or 
experience within a defined period” [79]. A cohort study is a study that “identifies 
subsets of a defined population and follow them over time, looking for differences in 
their outcome”, as defined by Strom et al. [42]. Cohort studies can be either prospective 
or retrospective. The output measure of cohort studies is relative risk, which is the ratio 
of the incidence rate of an outcome in the exposed group to the incidence rate of the 
outcome in the unexposed group [42]. A relative risk of greater than, equal to and less 
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than 1 indicates the risk of the outcome in the exposed group is greater than, equal to and 
less than that of the unexposed group, respectively. An adjusted risk ratio can be 
calculated using regression to account for the effect of confounders [80]. Cohort studies 
are particularly useful when one is interested in studying multiple possible outcomes at a 
time from a single exposure, especially a relatively uncommon exposure [42]. One major 
advantage of cohort studies as compared to case-control studies is not having to select a 
control group [42]. However, retrospective cohort studies often suffer from problems 
associated with retrospectively collected data [42]. Prospective cohort studies can be 
time-consuming and expensive to perform as they require following a large cohort of 
subjects over time. For an event occurs at a low rate, the size of a cohort can be 
prohibitively large [42, 80].  
In contrast, case–control studies are studies looking for differences in antecedent 
exposures between a group of cases with an event to a group of randomly selected control 
subjects without the event [42, 80]. The underlying assumption behind case-control 
studies is that cases and controls are selected from the same source population [80]. The 
exposure distribution in the source population is estimated from controls. For this reason, 
selection of controls is vitally important when performing a case-control study, as 
inappropriate controls can bring bias [42]. At the end of study, an odds ratio is calculated, 
which is a close estimate of relative risk when the disease under study is relatively rare 
[42]. Case–control studies are particularly useful when one is interested in multiple drug 
exposures as causes of an ADR [42]. They are also particularly useful when one is 
studying a relatively rare ADR, as the required sample size is markedly smaller that 
needed for a cohort study [42]. Because case-control studies are generally retrospective, 
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they are subject to limitations in the validity of retrospectively collected exposure 
information [42, 80].  
A variation of the case-control study is the nested case-control study. In a nested 
case-control study, a group of individuals are followed over time, only a sample of 
controls are selected for each case matching on the risk factors [81]. The resulting odds 
ratio from a nested case-control study, when proper sampling is used, closely 
approximates the relative risk obtained from a classic cohort study [81]. One of the 
advantages of nested case-control studies is that they have better control on the 
confounding factors through matching than cohort and classical case-control studies, 
while avoiding complicated statistical analysis such as propensity score [81]. 
 
d. Hypothesis and aims 
In this chapter, I hypothesize that data mining in the published literature and EMR 
databases can be used to predict and identify DDIs associated with increased risk of 
myopathy. To test this hypothesis, the following aims are pursued: 
1) Use text mining to identify substrate and inhibitor drugs of the major CYP 
isoforms and to predict drug pairs that potentially interact via inhibition of CYPs; 
2) Use an electronic medical record (EMR) database to identify predicted interacting 
drug pairs that are associated with increased risk of myopathy. 
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2. Methods 
a. Text mining and prediction of potentially interacting drug pairs 
Text mining was performed to identify the substrate and inhibitor drugs of the 
major drug-metabolizing CYP isoforms, including CYP1A2, CYP2A6, CYP2B6, 
CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5. Using the data in 
DrugBank, our group constructed a list of non-redundant generic names of 1492 small 
molecule drugs approved by the FDA. A rule-based approach was used for information 
retrieval. A template comprising key terms was constructed to retrieve PubMed abstracts 
meeting the following criteria: 1) involving in vitro studies characterizing drug 
metabolism, inhibition or induction of the major CYPs, or mechanisms underlying a 
CYP-based DDI; 2) involving the typical in vitro experimental systems for such studies, 
including recombinant CYP enzymes, human liver microsomes (HLMs) and human 
hepatocytes; 3) involving any of the drugs on our drug list; and 4) involving any of the 
probe substrates and specific inhibitors of the major CYPs defined by the FDA [13].  
A filter based on natural language processing was then applied to examine the 
linguistic expression pattern of each sentence in the retrieved abstracts and to identify the 
sentences with entities of interest. The identified sentences were those describing the 
relationship of a drug with a major CYP isoform or with another drug. Examples include 
‘drug D is (not) metabolized/a substrate of CYP isoform E’, ‘drug D (not) inhibit CYP 
isoform E’, ‘drug D is (not) an inducer of CYP isoform E’, ‘there is (not) interaction 
between drug A and B’.  
For information extraction, two students in our laboratory independently and 
manually curated all the extracted sentences in the context of the relevant abstracts to 
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make a call on the role of a drug to a CYP isoform, i.e. a substrate, an inhibitor or an 
inducer. There were a number of cases where the two curators could not agree. I then 
curated all the abstracts that were not agreed by them, and also a random subset (20%) of 
the abstracts for which they reached an agreement.  
The information extracted was summarized as lists of substrates, inhibitors, and 
inducers of each of the major CYP isoforms. Assuming that a substrate and an inhibitor 
of a particular CYP isoform have a metabolic interaction, potentially interacting drug 
pairs were predicted by pairing a substrate and an inhibitor of a CYP isoform. Since the 
primary interest was in DDIs associated with increased risk of myopathy, which are more 
likely to result from increased systemic exposure, DDIs that potentially result from 
induction of CYP enzymes were not considered.  
 
b. Preparing data for pharmacoepidemiology analyses 
A subset of data from the Indiana Network for Patient Care (INPC) Common 
Data Model (CDM) was used for the subsequent analysis. The INPC is a health 
information exchange data repository containing electronic medical records on over 11 
million patients throughout the state of Indiana. Derived from the INPC, the CDM 
contains coded prescribed medications, diagnosis, and observation data of 2.2 million 
patients between 2004 and 2009. The CDM also contains over 60 million drug dispensing 
events, 140 million patient diagnoses, and 360 million clinical observations such as 
laboratory values. A subset of the CDM data involving 817, 059 patients whose 
prescribed medication data were available were used for analysis. These data have been 
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anonymized and constructed specifically for research on adverse drug reactions through 
collaboration with the Observational Medical Outcomes Partnership project.  
Before performing the analyses, the drugs on our list were first mapped to those in 
the dataset. In the CDM, a prescribed medication is coded as a “Concept” identified by its 
“Concept ID” and described in detail in its “Concept Name”. The concept name of a 
medication typically describes the generic name(s) of the drug ingredient(s), the 
dosage(s), the route of administration, the formulation, and the trade name. An example 
of the concept name of a combination medication is “Atropine 0.025 MG / difenoxin 1 
MG Oral Tablet [Motofen]”. The data set has in total 54,490 unique medication concepts. 
The drugs on our list were mapped to the medication concepts in the CDM using lexical 
expression matching followed by manual review. Our group also examined in the data set 
which pairs of predicted interacting drugs were coadministered to patients. 
Coadministration was defined as the prescription windows of two drugs less than 30 days 
apart. This helped our group to filter out the predicted drug pairs that were not used 
together in clinical settings.  
The diagnoses relevant to myopathy, our health outcome of interest, were then 
identified in the data set. A diagnosis is coded as a “Condition Concept” in the CDM, 
also identified by its “Concept ID” and described in detail in its “Concept Name”. 
Myopathy has a broad spectrum of clinical presentations (Table 1-1), ranging from 
asymptotic creatine kinase (CK) elevation without any muscle symptoms to life-
threatening rhabdomyolysis. Our group focused on the myopathy diagnoses with muscle 
symptoms including, but not limited to, myalgia, myositis, muscle weakness, 
polymyositis and rhabdomyolysis.  
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c. Identification of DDIs associated with myopathy using case-control studies  
For each predicted potentially interacting drug pair, a retrospective case-control 
study was performed to examine the association between myopathy diagnosis and the 
concomitant use of the pair of drugs. Only myopathy diagnoses preceded by drug 
prescriptions were considered because the group attempted to infer the causal relationship 
between myopathy and drug exposures. In addition, only the association of drug 
prescriptions with the first diagnosis of myopathy in a sequence of myopathy diagnoses 
was considered, because drug prescribed following the first diagnosis may be used to 
treat myopathy and may be confounded. All the patients whose medication data were 
available were included in the study, except those who had their first diagnoses of 
myopathy within the first six months of the data set. This was because it was assumed 
that patients who did not have any subsequent diagnosis of myopathy within six months 
following the first diagnosis were cured, and that those who had the first diagnoses of 
myopathy within the first six months of the data set may have preexisting myopathy that 
was not captured in the data set.  
The exposure window of a drug was defined as the prescription duration of the 
drug and 30 days after the prescription supply. It was assumed that the risk of myopathy 
due to a drug exposure was highest within this window. Cases were considered to include 
patients who had at least one myopathy diagnosis. For each case, an index time was 
defined as the time of the first myopathy diagnosis. If an index time was within the 
exposure window of a drug, then the case was considered to be exposed to the drug. For a 
given predicted interacting drug pair, the cases of the substrate-only (or the inhibitor-only) 
group were the cases who were exposed to the substrate only (or the inhibitor only), and 
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the cases of the combination group were the cases exposed to both the substrate and the 
inhibitor. Patients who had no myopathy diagnosis were considered to be in a control 
pool. To select controls for the substrate-only group, an index time was defined as the 
same as that of a randomly selected case who was exposed to the substrate. The controls 
for the substrate-only group were considered to include all the patients in the control pool 
who were exposed only to the substrate at the index time. The controls for the inhibitor-
only group and the combination group were defined similarly. 
The synergistic effect of the substrate and inhibitor drugs on myopathy was tested 
using logistic regression. For a given drug, the risk of myopathy was determined by the 
number of cases divided by the total number of cases and controls. The risk ratio (RR) 
was calculated as risk ratio = risk12 / (risk1 + risk2), where risk1, risk2 and risk12 were the 
risk of myopathy in the subjects of the substrate-only group, the inhibitor-only group and 
the combination group, respectively. A risk ratio of greater than, equal to and less than 
unity indicates synergism, additive effect or antagonism, respectively. Of our interest 
were drug pairs with RRs greater than unity, indicating increased risk of myopathy when 
combined. Because the risk of myopathy is known to be correlated with age and gender 
[82], these two factors were incorporated into the model as covariates. The type I error 
rate was corrected for multiple testing using the Bonferroni method. The p-value 
threshold was therefore 0.0000136 (0.05/3670). The analyses were performed using SAS 
(Cary, NC). 
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3. Original results 
a. Substrate and inhibitor drugs mined from the published literature 
The sentences of interest extracted from PubMed abstracts were manually 
reviewed to identify substrates, inhibitors and inducers of the major CYP isoforms, 
including CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, 
CYP2E1 and CYP3A4/5. The first two student curators reached agreement on 78% of the 
extracted sentences. I made the call for the remaining 22% of the abstracts where the 
disagreement existed, and verified the 20% of randomly selected subset for which the 
other two curators agreed upon. This manual curation performed in the information 
retrieval step ensured a high quality of the literature mining data.  
Our data show that among the 1492 drugs approved by the FDA, 232 drugs were 
either substrates or inhibitors of at least one of the major CYP isoforms. The numbers of 
substrate inhibitor drugs for each of the major CYP isoforms are presented in Table 2-1. 
One hundred and forty nine drugs were identified as substrates of any major CYP 
isoforms, 102 (68%) of which were substrates of CYP3A4/5. This is consistent with the 
observation that CYP3A alone is responsible for the metabolism of over 50% of the 
prescription drugs metabolized by the liver [83]. 59 drugs were found to be substrates of 
multiple CYP isoforms. 123 drugs were identified as inhibitors of any major CYP 
isoforms, 50 of which were found to inhibit multiple isoforms. The number of inhibitors 
of CYP3A4/5, CYP2D6, CYP2C9, CYP1A2 and CYP2C19 were comparable.  
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b. Demographics and characteristics of the CDM dataset 
Assuming that a substrate and an inhibitor of a particular CYP isoform had a 
metabolic interaction, 13,197 pairs of drugs in total were predicted to be potentially 
interacting via inhibition of the relevant CYP isoforms by pairing a substrate with an 
inhibitor of a CYP isoform. Because not all these theoretical drug combinations are 
coadministered clinically, the analyses were limited only to those that are clinically 
relevant. To identify the drug pairs coadministered clinically, the drugs approved by the 
FDA were first mapped to the medication concepts in the database. Of these, 1,293 out of 
1492 drugs were mapped successfully, while 199 drugs could not be matched. The 
unmatched drugs were found to be banned drugs, illicit drugs, organic compounds, 
herbicide/insecticides, functional group derivatives, herbal extracts, DrugBank drugs 
absent from the CDM, and drug names that only exist in the published literature. By 
screening for drug pairs whose prescription windows were less than 30 days apart, 3670 
out of 13,197 predicted DDIs were identified to be coadministered to the patients in the 
database.  
59,572 out of 828,905 (7.2%) patients had at least one diagnosis of myopathy. 
The age and gender were missing for 11,846 (1.4%) patients in the population. For the 
59,572 patients who were diagnosed with myopathy, the average age was 40.2 ± 23 years, 
and 489,669 (59.1%) were female. The average number of medications taken by this 
population was 3.8 ± 2.5. Race is known to be a risk factor for myopathy, but data 
identifying patients’ race were only available for 11.84% of the total population, and 
were not included in the subsequent analyses. 
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Twelve concept IDs relevant to myopathy were identified in our data set (Table 2-
2). “Myalgia and myositis” was the most frequent diagnosis, accounting for 78% of the 
total myopathy diagnoses, followed by “Muscle weakness” (20%). There were in total 53 
cases of rhabdomyolysis identified from the date set.  
 
c. DDIs significantly associated with an increased risk of myopathy 
Using a case-control study design, the effect of each individual predicted drug 
pair on myopathy was tested using a synergistic model. This model was used since it is 
relatively conservative and since it lends itself to providing useful mechanistic insights. 
The model tested whether the risk of coadministration of both drugs was significantly 
higher than the additive risk from taking either drug alone. The risk was adjusted for age 
and gender, two known risk factors for myopathy. Both factors were significantly 
predictive of the risk of myopathy. Females were found to have a higher risk of myopathy 
than males with an odds ratio of 1.64 ± 0.0039. The risk of myopathy increased with age 
at a rate of 0.15% ± 0.0012% per year. 
There were 27 drug pairs significantly associated with the risk of myopathy. 
Many of these drug pairs involved narcotic analgesics such as fentanyl, hydrocodone, 
oxycodone, and a muscle relaxant tizanidine, which were likely administered to patients 
with myopathy to relieve muscle symptoms. The significant drug pairs involving these 
drugs were therefore not considered as myopathic. The remaining 15 pairs of drugs 
significantly associated with an increased risk of myopathy are shown in Table 2-3.  
The identified significant DDIs involved clinically important drugs including 
alprazolam, chloroquine, duloxetine, hydroxychloroquine, loratadine, omeprazole, 
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promethazine, quetiapine, risperidone, ropinirole, trazodone and simvastatin. Apart from 
the interaction between promethazine and tegaserod, all the other interactions involved 
chloroquine, hydroxychloroquine, or loratadine. Eight significant DDIs involved 
chloroquine and hydroxychloroquine. They were found to interact with risperidone, 
quetiapine, loratadine, trazodone and duloxetine. The highest relative risks (RRs) were 
observed with the interactions of risperidone with chloroquine and hydroxychloroquine 
(RR = 3.36 and RR = 2.88, respectively). Six significant DDIs involved loratadine. In 
addition to the interactions with chloroquine and hydroxychloroquine, loratadine was 
found to also interact with ropinirole, simvastatin, duloxetine, alprazolam, and 
omeprazole.  
 
4. Discussion 
In this chapter, I have addressed the hypothesis that literature mining and large 
databases can be used to predict and identify DDIs associated with myopathy. Using 
automated algorithms and rigorous manual review, the published literature was text-
mined. There were 232 drugs identified as either substrates or inhibitors of the major 
CYPs. 13,197 pairs of drugs were predicted to have metabolic interactions via inhibition 
of CYPs, 3670 of which were found to be coadministered to patients in an EMR database. 
Using a case-control study design and a synergistic model, fifteen drug pairs were further 
identified to be significantly associated with an increased risk of myopathy as compared 
to the additive risk from taking either of the drugs alone.  
Only a small number of studies designed to identify and predict DDIs using 
knowledge mined from the published literature have been published. Percha et al. [44] 
36 
 
and Tari et al. [84] identified through text mining the interrelationships between drugs 
and metabolic enzymes from which DDIs were inferred. Our work shared a similar 
assumption that a DDI can arise when a substrate drug and an inhibitor drug of a CYP 
enzyme are coadministered. The goal of our text mining work was to predict CYP-based 
metabolic DDIs for which there is more supporting evidence in the published literature. 
Consequently, our approach had the following features that distinguished our work from 
those published previously. First, our approach was strongly mechanism-oriented. We 
aimed only to mine from the literature the drugs that are substrates or inhibitors of the 
major CYPs, from which we could predict CYP-based metabolic DDIs. A resulting 
limitation of our work was that we could not obtain an exhaustive list of potentially 
interacting drug pairs. Second, we defined substrate and inhibitor of the major CYPs 
using a set of strict criteria – the drugs that had been investigated in a typical in vitro 
experimental system using probe substrates or specific inhibitors defined by the FDA. 
We recognize that this likely led to exclusion of some true substrates and inhibitors and 
consequently a smaller number of predicted drug pairs. Of 1492 small molecule drugs 
approved by the FDA, only 149 (10%) and 123 (8.2%) drugs were identified as substrates 
and inhibitors of any major CYP isoform, respectively. However, these identified drugs 
met the “norm” definition of a substrate or an inhibition of a CYP isoform. Third, the 
information extraction process was performed manually by three curators, including me, 
reviewing the extracted relevant sentences. Although less efficient than automated 
methods, manual curation ensured a high accuracy in identifying substrate and inhibitors 
of the major CYPs. All these features add our confidence in predicting CYP-based 
metabolic DDIs. Similar to the work of Percha et al. [44] and Tari et al. [84], the text 
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mining performed by our group was limited to PubMed abstracts. As pointed out by 
Cohen et al. [70],  extracting information from full text of the published literature 
remains a challenging task in the field of text mining. 
When compared to work published previously, our approach also differs in that 
we took a step forward from predicting novel metabolic DDIs to identifying those of 
clinical consequence from predicted DDIs. By testing the association of the predicted 
DDIs with myopathy diagnoses in an EMR database, fifteen pairs of drugs were found to 
increase the risk of myopathy when coadministered. This is similar to the approach used 
by Tatonetti et al., who identified DDIs shared by an entire drug class using a database of 
side effects and corroborated those DDIs in an EMR database [45].  
None of the fifteen DDIs identified by us has been reported before. Eight of these 
DDIs involved chloroquine and hydroxychloroquine. Both chloroquine and 
hydroxychloroquine are antimalarial drugs indicated for the suppressive treatment and for 
acute attacks of malaria. In developed countries such as in the US, they are mainly used 
to treat rheumatoid arthritis and systemic lupus erythematosus. The labels of both drugs 
note skeletal muscle myopathy or neuromyopathy as one of the side effects. There are a 
number of case reports on chloroquine and hydroxychloroquine induced neuropathy, 
myopathy, and cardiomyopathy [85, 86]. In a prospective cohort study by Casado et al., 
119 Spanish rheumatic patients treated with chloroquine or hydroxychloroquine were 
followed over three years. Of those patients, 22 (18.5%) were found to have persistently 
elevated serum levels of muscle enzymes. The prevalence of antimalarial induced 
myopathy was estimated to be 9.2% with an annual incidence of 1.2% during follow-up. 
The prevalence of antimalarial induced muscle weakness was estimated to be 6.7%. The 
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authors also pointed out that in rheumatic patients, the initial mild symptoms of muscular 
injury are often masked by the underlying disease, which may explain why the diagnosis 
of antimalarial myopathy is usually difficult and often delayed [87]. Their data suggest 
that the prevalence of myopathy in patients taking antimalarial drugs are higher than that 
expected previously [86]. Our data show that chloroquine and hydroxychloroquine can 
interact with a variety of drugs to bring about an even higher risk of myopathy. However, 
to date, there is no published study investigating drug interactions with chloroquine and 
hydroxychloroquine with respect to the risk of myopathy. Our data thus call for scientific 
attention to drug interactions that may lead to exacerbated antimalarial induced myopathy. 
Similarly, the risk of myopathy associated with the antihistamine loratadine has 
largely been unnoted. Loratadine was involved in six of 15 significant DDIs. Myalgia is 
one of the side effects of both loratadine and its major pharmacologically active 
metabolite, desloratadine [88, 89]. Desloratadine seems to be more myotoxic than 
loratadine. In randomized clinical trials, 2.1% of subjects treated with desloratadine 
experienced myalgia as compared to 1.8% treated with placebo, whereas less than 2% of 
subjects treated with loratadine experienced myalgia [88, 89]. Our data indicate that 
loratadine or desloratadine may be more myotoxic than they have been recognized, and 
they can pose even higher risk of myopathy when coadministered with other drugs.  
A review of drug labels revealed that myopathy is also one of the side effects of 
several other drugs involved in the significant DDIs. Statin-induced myopathy is one of 
the well-known side effects of statins. The risk of rhabdomyolysis associated with high 
dose of simvastatin is so well recognized that the FDA issued a black box warning 
against daily use of the 80 mg dose of simvastatin. Alprazolam is an anxiolytic indicated 
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for the management of anxiety disorder and panic disorder. Its side effects include 
muscular cramps and muscle stiffness which can be associated with myopathy. The use 
of trazodone, an antidepressant, can cause musculoskeletal pains. Back pain, muscle 
weakness, myalgia, muscle cramps and leg pain have been reported with the use of 
omeprazole, a proton pump inhibitor. Some other drugs can cause back pain, which may 
also be associated with myopathy. Those include risperidone and quetiapine, two 
antipsychotic drugs indicated for the treatment of schizophrenia and bipolar disorder 
mania, ropinirole, a dopamine agonist used to treat Parkinson's disease and restless legs 
syndrome, and tegaserod, a serotonin agonist used to treat irritable bowel syndrome and 
constipation. There are also a number of case reports in which rhabdomyolysis occurred 
in patients treated with risperidone [90-93] or quetiapine [94-99]. The muscle-related side 
effects of these drugs indicate that it is possible that interaction with these drugs may 
cause increased risk of myopathy. 
In addition to having a synergistically myopathic interaction, there are other 
possible explanations for the association of these drugs with increased risk of myopathy. 
One is that they may be used to treat diseases that co-occur with myopathy and related 
muscle symptoms. For example, risperidone [100], quetiapine [100, 101], alprazolam 
[102], tegaserod [103] and duloxetine [104] may be used to manage the symptoms of 
fibromyalgia. Notably, duloxetine is indicated for the management of chronic 
musculoskeletal pain, including fibromyalgia. In addition, these drugs can be associated 
because their common comedications are used to manage myopathy or other diseases co-
occur with myopathy. Not being able to establish a causal relationship is one of the 
inherent limitations of any pharmacoepidemiologic study. This issue can potentially be 
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addressed by performing carefully designed pharmacoepidemiology study that account 
for confounding factors such as comedications and comorbidities. However, it can be 
challenging to perform such studies for a large number of potentially interacting drug 
pairs. 
There are a number of known clinical drug interactions that are associated with an 
increased risk of myopathy, including the interactions between CYP3A4-metabolized 
statins (e.g. simvastatin, atorvastatin and lovastatin) and strong inhibitors of CYP3A4 
such as ketoconazole, itraconazole, and erythromycin, and the interactions between 
OATP-transported statins (e.g. cerivastatin, pravastatin and rosuvastatin) and strong 
inhibitors of OATPs such as gemfibrozil and cyclosporine. However, none of these 
known myopathic drug interactions were identified in our analyses. One possible 
explanation is that physicians and pharmacists were aware of such interactions and 
advised the patients not to take the interacting drugs together.  
There are a few limitations of our study due to the use of diagnostic codes to 
identify myopathy cases. Muscle weakness and muscle pain are relatively subjective 
feelings that rely on patients’ self-report and are subject to psychological factors [105]. 
There is therefore a potential risk of misidentification of patients who actually 
experienced myopathy using diagnostic codes. This may be particularly problematic for 
identification of myopathy cases taking antipsychotic drugs such as risperidone and 
quetiapine. The plasma level of creatine kinase has been proposed to be used as a 
biomarker for myopathy [106]. However, according to our primary analysis, data on the 
plasma level of creatine kinase in the EMR database are not helpful in the identification 
of patients with myopathy for two reasons: 1) there are only a small number of patients 
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with such data, indicating that analysis to detect DDIs may be underpowered due to a 
small sample size; 2) the majority of data are indicative of myocardial infarction instead 
of myopathy. Another problem with identification of cases and controls is that we only 
identified patients with symptomatic myopathy and those with asymptomatic creatinine 
kinase elevation could not be identified. A potential improvement in identification of 
cases and controls may be achieved by reviewing clinical narratives, but this is 
technically challenging. 
Our analyses using the data existing in an EMR database also suffer from the 
weaknesses shared by retrospective observational studies in general. First, the data in the 
CDM dataset are incomplete. Age and gender information was missing for 11,846 (1.4%) 
patients, and race data were only available for 11.84% of the population. Second, the 
validity of the data is difficult to verify. For example, coadministration of drugs was 
identified using prescription codes, which could be unreliable. Third, our analyses are 
subject to potential population biases introduced by the EMR database.  
The synergistic model used to evaluate the combined effect of two drugs has a 
number of limitations as well. Suppose that there is a background prevalence, B, of 
myopathy that is independent of the effect of any drug. Then the true relative risk can be 
calculated as RR’ = (R12 – B) / [(R1 – B) + (R2 – B)], where (R12 – B), (R1 – B) and (R2 – 
B) are the risk of myopathy in the combination, substrate and inhibitor group that are due 
only to the drugs. When R12 is greater than the sum of R1 and R2 as in the case of 
synergistic interaction, this RR’ is greater than the RR we estimated as RR = R12 / (R1 + 
R2). In other words, the methods underestimated the relative risk when two drugs under 
study interact synergistically. B was, however, not estimable in our case because any 
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patient with a myopathy diagnosis was classified into a treatment group. As a result of 
underestimated RRs, a number of drug pairs that in fact had small synergistic effects 
when used in combination were probably misidentified as not having interactions. A 
potential solution to this issue is to select a group of controls for each case, matching on 
demographics, comorbidity and comedication distribution and other confounding factors. 
In addition, for some drug pairs the number of cases in the combination group was small, 
and that may limit our power to detect significant DDIs. 
Additional limitations of this specific pharmacoepidemiologic study include that 
dose and duration of exposure were not taken into consideration. The risk of myopathy is 
known to be both dose- and time- dependent for some drugs including statins. Unlike 
spontaneous reporting systems, data from EMR databases are longitudinal where time-to-
event methods are applicable. However, we could not apply such methods to evaluate the 
effect of duration of exposure because the current methods cannot be directly applied to 
EMRs for detection of DDIs.  
In spite of the limitations discussed above, we demonstrated that it is possible to 
identify new and clinically important DDIs using data mined from the published literature, 
followed by screening for DDIs associated with myopathy in an EMR database.  
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Table 2-1. The number of substrate and inhibitor drugs of the major CYPs mined 
from the published literature 
CYP Pathway The number of substrates The number of inhibitors 
CYP1A2 30 39 
CYP2A6 1 9 
CYP2B6 5 15 
CYP2C19 5 31 
CYP2C8 11 2 
CYP2C9 30 39 
CYP2D6 34 39 
CYP2E1 8 6 
CYP3A4/5 102 48 
Total 149 123 
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Table 2-2. Categories and frequencies of myopathy diagnoses 
Concept ID Concept Name Frequency 
84675 Myalgia and myositis 48877 
79908 Muscle weakness 12720 
80800 Polymyositis 372 
446370 
Antilipemic and antiarteriosclerotic drugs causing adverse 
effects in therapeutic use 206 
4217978 Myalgia and myositis, unspecified 185 
73001 Myositis 53 
439142 Myoglobinuria 52 
4345578 Rhabdomyolysis 52 
4218609 Muscle weakness (generalized) 22 
4262118 Other myopathies 7 
4147768 Myopathy, unspecified 1 
4248141 Rhabdomyolysis 1 
  
4
5
 
Table 2-3. Drug pairs significantly associated with an increased risk of myopathy 
Drug 1 Drug 2 Risk Ratio P-value Risk1 Risk2 Risk12 M1 N1 M2 N2 M12 N12 
Chloroquine Risperidone 3.36 4.47E-05 0.16 0.04 0.65 689 4417 373 10233 11 17 
Hydroxychloroquine Risperidone 2.88 1.37E-04 0.19 0.04 0.65 684 3634 373 10233 11 17 
Loratadine Chloroquine 2.21 1.27E-05 0.03 0.16 0.42 1528 45104 683 4405 35 84 
Promethazine Tegaserod 2.20 1.28E-05 0.03 0.07 0.21 2325 80012 259 3893 48 228 
Chloroquine Quetiapine 2.17 5.29E-05 0.15 0.08 0.50 676 4394 1055 13813 26 52 
Loratadine Ropinirole 2.05 3.47E-05 0.03 0.12 0.31 1527 45107 713 6121 42 136 
Chloroquine Trazodone 1.99 2.23E-05 0.15 0.09 0.49 674 4391 875 9635 35 72 
Loratadine Hydroxychloroquine 1.95 7.02E-05 0.03 0.19 0.43 1528 45105 678 3622 35 81 
Hydroxychloroquine Trazodone 1.76 2.02E-04 0.19 0.09 0.49 669 3608 875 9635 35 72 
Chloroquine Duloxetine 1.65 1.34E-10 0.14 0.15 0.48 614 4289 3688 25173 138 288 
Loratadine Simvastatin 1.60 4.75E-07 0.03 0.05 0.13 1447 44623 4256 88683 152 1184 
Loratadine Duloxetine 1.56 7.43E-09 0.03 0.15 0.28 1446 44914 3685 25117 181 647 
Loratadine Alprazolam 1.56 1.06E-09 0.03 0.07 0.16 1372 44426 3726 50734 236 1447 
Hydroxychloroquine Duloxetine 1.53 1.46E-08 0.17 0.15 0.49 609 3509 3688 25173 138 282 
Loratadine Omeprazole 1.33 4.45E-07 0.03 0.07 0.13 1322 44207 4617 70800 354 2796 
 
Note: Risk1, Risk2 and Risk12 designate the risk of myopathy in the subjects of the substrate drug group, the inhibitor drug group and 
the combination group, respectively;  M1, M2 and M12 are the number of cases of the substrate drug group, the inhibitor drug group 
and the combination group, respectively; N1, N2 and N12 are the number of controls of the substrate drug group, the inhibitor drug 
group and the combination group, respectively.  
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Chapter 3. In vitro assessment of inhibition of Cytochrome P450s 
 
i. Screening for inhibition of CYPs 
1. Introduction 
a. CYP450s are the major drug-metabolizing enzymes in humans 
The cytochrome P450 superfamily (CYPs) is a large and diverse group of heme-
containing enzymes. The name P450 is derived from the maximum spectral absorbance 
peak at 450 nm when they are in the reduced and CO-bound form [31]. They catalyze the 
oxidation, peroxidation and reduction of endogenous metabolic intermediates such as 
steroids, prostaglandins and fatty acids, as well as xenobiotic substances such as drugs, 
toxins and environmental pollutants [31]. In humans, CYPs play a central role in phase I 
drug metabolism. They are responsible for metabolizing the vast majority of therapeutic 
drugs and thus have been the most studied xenobiotic metabolizing enzymes [83].  
The activity of CYPs requires both a reducing agent (nicotinamide adenine 
dinucleotide phosphate [NADPH]) and molecular oxygen. A typical reaction catalyzed 
by CYPs is a monooxygenase reaction, in which one molecule of oxygen is reduced per 
substrate molecule (RH), with one oxygen atom appearing in the product and the other in 
the form of water [107, 108]: 
RH + O2 + NADPH + H
+ → ROH + H2O + NADP+ 
In contrast to most enzymes in the body, CYPs are promiscuous [83]. A single 
CYP isoform can metabolize many structurally distinct chemicals, owning to their large 
and fluid binding pockets. A substrate drug can be metabolized by several CYPs at the 
same time, although this may occur at different rates. As a result, there is significant 
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overlapping substrate specificity amongst CYPs. This is one of the underlying reasons for 
drug interactions as one drug may compete for the binding pocket and reduce the 
metabolic rate of another drug [83]. 
There are 55 individual CYPs in 16 families have been identified in humans [108]. 
The isoforms that are most significant in drug metabolism are members of the CYP1, 
CYP2 and CYP3 families [109, 110]. Drug-metabolizing CYPs are most abundant in the 
liver [83]. They are also expressed throughout the gastrointestinal tract, and in lower 
amounts in lung, kidney, and even in the central nervous system [83]. Intracellularly, 
these enzymes are located in the lipophilic endoplasmic reticulum membranes [83]. In the 
liver, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 appear 
to be the most important forms [109]. Together, they are responsible for the metabolism 
of about 75% of all marketed drugs [111]. It is worth noting that CYP3A4 is the most 
abundant isoform in the liver, accounting for about 30% of the total liver CYP content 
[112]. CYP3A4 alone is responsible for the metabolism of nearly 50% of the prescription 
drugs metabolized by the liver [111]. CYP3A4 is also the most abundant isoform in the 
gastrointestinal tract and is subject to DDIs occurring during drug absorption [110]. 
 
b. Inhibition of CYPs is an important mechanism of DDIs 
The central role of CYPs in drug metabolism render them a particularly important 
site of DDIs [111]. Clinically observed metabolic DDIs involving CYPs can be due to 
either induction or inhibition of enzyme activity. Compared to induction-mediated DDIs, 
inhibition-mediated DDIs are more common and more clinically significant. Amongst the 
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drugs that have been withdrawn from the market, a significant number have been due to 
inhibition-mediated interaction with a commonly co-administered drug [113].   
Enzyme inhibition can occur via two main biochemical mechanisms, reversible or 
irreversible. Competitive inhibition and noncompetitive inhibition are the two most 
commonly observed mechanisms that result in reversible inhibition [107]. When a 
reversible inhibition occurs, a drug reversibly binds to the affected enzyme(s), either 
competing for the binding pocket, or allosterically reducing the metabolic capacity. As a 
result, there is a reduction in the metabolism and an increase in the systemic exposure of 
another drug, which may lead to an increased in the risk of adverse drug reactions [107]. 
An example is inhibition of terfenadine metabolism by ketoconazole. Terfenadine is an 
antihistamine primarily metabolized by CYP3A4. At clinical doses, terfenadine is almost 
undetectable in plasma due to high first pass metabolism and efficient systemic clearance. 
However, when co-administered with ketoconazole, an antifungal and a very potent 
inhibitor of CYP3A4, the plasma concentration of terfenadine dramatically increases to a 
level that prolongs the electrocardiographic QT interval. The severe inhibition of 
terfenadine metabolism by ketoconazole led to episodes of torsade de pointes and fatal 
arrhythmias in many patients [114]. The drug was ultimately withdrawn from clinical use. 
Irreversible inhibition, or mechanism-based inhibition, can occur when a drug is 
metabolized by a CYP to a reactive intermediate which binds to the active site of the 
enzyme and inactivates it permanently. The body has to restore the pool through de novo 
synthesis of the enzyme which may take weeks. Irreversible inhibition thus has more 
profound effects on drug metabolism and accounts for some of the most potent clinically 
observed DDIs [13, 107]. One such example is mibefradil. Mibefradil is a calcium 
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channel antagonist and a potent metabolism-based inhibitor of CYP3A4/5 with a Kinact of 
0.4 min-1 [115]. It was withdrawn from the market due to unacceptable risk of DDIs with 
many CYP3A4 substrate drugs, including midazolam and triazolam, whose AUC was 
increased by 8-fold and 9-fold, respectively, when coadministered with mibefradil [116, 
117]. 
 
c. In vitro systems for mechanistic studies of DDIs  
Understanding the underlying mechanism of a DDI enables physicians to prevent 
and treat them, and allows scientists to predict future DDIs sharing similar mechanisms. 
Thus elucidation of the mechanism of individual DDIs is key. In vitro experimental 
systems are one approach to characterizing metabolism-based DDIs. Commonly used in 
vitro experimental systems include recombinant CYP enzymes, human liver microsomes 
(HLMs), and human hepatocytes [118]. 
Recombinant CYP enzymes are human CYP enzymes heterologously expressed 
in baculovirus-cultured insect cells or an E. coli-based expression system [119]. Because 
these enzymes are easy and affordable to prepare and in general offer high reproducibility, 
they have become a routine and reliable resource for characterization of metabolism 
during drug development [13]. Since there is only a single CYP enzyme present in the 
system, these enzymes have the advantage of not requiring the use of a highly selective 
probe substrate [120]. They are particularly useful in studying metabolic routes that exist 
in low abundance in vivo, such as CYP2D6 and CYP2B6 [112]. On the other hand, the 
kinetics in the presence of a single CYP are less predictive of that in vivo, where multiple 
CYPs may compete and metabolism of a drug may be diverted to alternative routes when 
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the primary route is blocked [118]. Also, the levels of nonspecific binding, accessory 
proteins and/or protein-protein interactions are different from those of other systems, 
further widening the difference in in vitro kinetics between recombinant and native 
systems [118]. 
HLMs are vesicle-like artifacts that are prepared from human liver tissue. After 
homogenization and differential centrifugation, the endoplasmic reticulum membranes of 
hepatocytes reform into vesicles that are enriched with a panel of drug metabolizing 
enzymes including CYPs, flavinmonooxygenases, carboxylesterases, epoxide hydrolase 
and UGTs [121]. The level of cytochrome b5 and the relative abundance of proteins are 
more similar to what is observed in vivo as compared to recombinant enzymes [121]. 
HLMs thus represent a more physiologically relevant system in terms of enzyme 
composition. They have been routinely used to evaluate the metabolic stability and 
inhibition of CYPs and UGTs by drugs, and to identify which enzyme or enzymes are 
responsible for oxidizing or glucuronidating a drug [13, 118]. One of the disadvantages, 
though, is that they require the use of a highly selective probe substrate for studying a 
particular enzyme of interest, potentially complicating analytical procedures [118]. Also, 
certain CYP isoforms may be absent or in low abundance in the liver of a donor due to 
genetic variations, which can introduce variability in results obtained using HLMs 
prepared from such a donor [118]. The commonly used HLMs are therefore pooled from 
HLMs prepared using livers from many donors. 
In recent years, human hepatocytes have been increasingly used to characterize 
drug metabolism and to evaluate DDIs. The most commonly used preparations include 
isolated primary hepatocytes and cryopreserved hepatocytes [122, 123]. These 
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preparations are particularly appealing as they are most representative of what occurs in 
vivo – they contain a full range of drug-metabolizing enzymes, including both phase I and 
phase II, and membrane drug transporters, as well as the intracellular apparatus for gene 
expression and protein modification [123]. This gives hepatocytes a unique advantage in 
studying (1) DDIs involving enzymes that are absent or present in low abundance in 
HLMs, (2) the interplay of drug transport and metabolism, and (3) enzyme induction and 
transporter regulation in response to drug treatment. However, the use of hepatocytes has 
been largely limited by availability [123]. In contrast to HLMs or recombinant CYPs, it is 
difficult to pool sufficiently large quantities of hepatocytes for detailed kinetic analysis 
[118]. Consequentially, CYP activity in hepatocytes is often measured under non-
Michaelis-Menten conditions. In addition, metabolites produced from substrates may be 
conjugated, further complicating the analysis. Inter-individual variability and variation in 
preparation procedure also add difficulty to promoting their use [118]. Recent progress in 
culturing hepatic cell lines in 2D and 3D has shown a promise to overcome some of the 
limitations and may become a substitute of hepatocytes for in vitro studies in the future 
[124]. 
Due to the advantages and limitations of the systems discussed above, data 
generated using any individual system can only provide a piece of knowledge in the 
picture of drug metabolism. These systems therefore often need to be used together to 
obtain a more comprehensive understanding on the metabolism of a drug. 
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d. Approaches to evaluating enzyme kinetics 
Biochemical reactions involving a single substrate are often assumed to follow 
Michaelis–Menten kinetics, as are most CYP-mediated drug metabolism reactions [125]. 
Determination of the kinetic parameters, Km, Vmax, and CLint, for CYP catalyzed reactions 
is important to the characterization of drug metabolism. These parameters not only enable 
scientists to predict the clearance of a drug in humans, but also provide insights into non-
linear pharmacokinetic behaviors and mechanisms of DDIs. There are two approaches to 
measuring Michaelis-Menten kinetics of a CYP reaction in vitro, namely, metabolite 
formation and substrate depletion. 
Conventionally, evaluation of Km and Vmax involves the incubation of a substrate 
with a single recombinant CYP enzyme or HLM preparation. The rate of metabolites 
formation then is measured under the conditions where the initial reaction velocity is 
linear. In cases where a drug has multiple metabolites, this approach requires 
identification and analytical method development for quantifying each of the individual 
metabolites [118]. This approach thus may not be feasible in some cases.  
Using the substrate depletion approach, incubations are conducted in the same 
way as using the conventional approach. Instead of following the rate of metabolite 
formation, the reaction velocity is measured by the rate of substrate disappearance from 
the incubation mixture. Consequently, Km and Vmax describe the overall metabolism of 
the substrate instead of formation of individual metabolites. When a predominant 
metabolite is formed, the kinetics estimates using the substrate depletion approach have 
been shown to be close to those obtained using the conventional approach [126]. The 
substrate depletion approach has several limitations as it requires consumption of a 
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substantial fraction of substrate to estimate the kinetics accurately. One is that it may 
violate the fundamental assumptions required for Michaelis-Menten kinetics. Also, it may 
not be applicable to drugs that have low intrinsic clearance. Furthermore, it may require a 
high enzyme concentration which could increase nonspecific binding and the 
experimental errors incurred in evaluation of kinetic parameters [126, 127].  
 
e. Bioanalytical methods for studying DDIs 
Advances in bioanalytical techniques used to study DDI have largely been made 
due to the need for screening of drug candidates with favorable metabolic and safety 
profiles in the early stages of drug development [128]. The traditional approach to in 
vitro DDI studies involves incubation of known probe substrates with CYP enzymes and 
measurement of change in the rate of metabolism in the presence of test compounds [13]. 
For example, inhibitors of CYP3A4 are usually identified by a decreased rate of the 1-
hydroxylation of midazolam or the 6’-hydroxylation of testosterone in the presence of a 
test compound [129]. Such assays require time-consuming and labor-intensive analytical 
tools such as liquid chromatography (LC) coupled with UV detection or mass 
spectrometry (MS). The principle bottleneck in the application of LC/UV and LC/MS is 
the limited throughput, largely owing to the need for extracting analytes from an 
incubation mixture [128]. Although throughput has been significantly improved by newer 
techniques, it remains a challenge in the application of LC/UV or LC/MS in a drug 
development setting [118].  
Absorbance- or fluorescence-based assays that do not require metabolite 
separation allow for simultaneous monitoring of a large number of reactions on plate 
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readers, thus enhancing sample throughput [130]. Examination of various O-alkyl 
derivatives of resorufin, fluorescein, 7-hydroxycoumarins, and 6-hydroxyquinolines as 
substrates of CYPs resulted in commercialization of some of these compounds for 
fluorometric assays testing inhibition of CYPs [131]. These assays in general involve 
non- or low- fluorescent substrates which produce high-fluorescent metabolites when 
incubated with CYPs. The rate of metabolism can be readily determined by monitoring 
the change in fluorescence which reflects the amount of fluorescent metabolites produced 
during a fixed period of time [130]. These assays can be easily adapted to a high-
throughput setting where multiple compounds at various concentrations can be tested in 
one application. Compared with the traditional LC/MS, fluorometric assays are a highly 
efficient means for assessing DDIs. However, because these assays involve substrates 
which in general lack specificity for individual CYPs, their application has been largely 
limited to recombinant CYP enzymes where only a single enzyme is present [132]. Also, 
because of the complex kinetic patterns of CYPs, occasionally, IC50s and Kis resulted 
from fluorometric assays are poorly correlated with those obtained using conventional 
probe substrates [132].   
 
f. Quantitative assessment of the risk of clinical drug interactions 
Tremendous efforts have been made to develop an overarching prediction of the 
risk of DDIs in vivo using in vitro experiment data. A variety of mathematical models 
have been developed using data from experiments involving drug metabolism and 
inhibition of drug-metabolizing enzymes. These models fall into three categories with 
increasing level of complexity: basic models, mechanistic static models, and 
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comprehensive dynamic models that include physiological-based pharmacokinetic 
models (PBPK) [133].  
The basic model is the one that has been most widely used largely due to its 
simplicity. It estimates the ratio (R value) of intrinsic clearance of a victim drug in the 
absence and presence of an inhibitor drug as R = 1 + [I]/Ki,u, where [I] is the maximal 
total (free and bound) systemic inhibitor concentration in plasma, and Ki,u is the unbound 
reversible inhibition constant determined in vitro for the affected pathway [134]. This 
model assumes reversible CYP inhibition (competitive or non-competitive), that the 
victim drug is orally administered, cleared exclusively by a single metabolic pathway that 
is affected by the inhibitor, that the ‘well-stirred liver’ model for hepatic clearance 
applies, that negligible inhibition of first-pass metabolism in the gastrointestinal tract 
occurs, and constant inhibitor concentration [133]. To be conservative, [I] is estimated as 
the systemic total peak concentration, Cmax, total (bound and free), of an inhibitor drug at 
the highest proposed clinical dose. For CYP3A inhibitors that are dosed orally, [I] is 
estimated by [I] = Igut = molar dose/250 ml. For time-dependent inhibitors, the R value is 
estimated as R = (Kobs+Kdeg)/Kdeg and Kobs=kinact([I]/(KI+[I]), where Kdeg is the apparent 
first order degradation rate constant of the affected enzyme, kinact and KI are maximal 
inactivation rate constant and apparent inactivation constant, respectively, Kobs is the 
apparent inactivation rate constant and Kobs = kinact ([I]/(KI+[I]) [13]. This approach in 
general over-predicts the risk of DDI, often due to the assumption of a single exclusive 
pathway [133]. 
In many cases, DDIs occur via simultaneous inhibition of multiple metabolic 
pathways. Mechanistic static models take into account all the interaction mechanisms by 
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incorporating the fraction of the affected drug metabolized by the inhibited enzyme 
(fm,CYP), thus improving prediction accuracy [133]. These models also include parameters 
reflecting the change in bioavailability in the gut due to inhibition of enzymes in 
enterocytes and/or the change in first-pass metabolism. They share assumptions with 
those used in the basic model. A generalized form of this approach is as follows [135],  
𝐴𝑈𝐶𝑅 =
𝐴𝑈𝐶𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑒𝑑
𝐴𝑈𝐶
=
𝐹𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑒𝑑
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∑
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𝑚
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 Eq. 3-1 
where Finhibited and F are the bioavailability of a victim drug in the presence and absence 
of one or multiple inhibitor drugs, i and j denote multiple affected CYPs and inhibitors, 
respectively. These models have been shown to represent an improvement over the basic 
model and can provide more accurate predictions. One of the limitations of this model is 
that it “uses a single static estimate of in vivo concentration of an inhibitor drug to 
provide a point estimate of the average magnitude of change in the exposure to a victim 
drug” as made clear by Einolf et al. [133].  
Mechanistic dynamic models take into account the dynamics of drug 
concentration after a dose. A typical example of such models is the Simcyp simulator. 
This software simulates the concentration-time profile of a target drug under a 
mechanistic framework with parameters describing the human body in demographic, 
anatomical, genetic and physiological aspects on a population level, the physicochemical 
characteristics of drugs, and clinical study design. Compared with the static models 
discussed above, it allows one to investigate the dynamics of a DDI and the effects of 
inhibitory metabolites, and to predict the variability in the magnitude of DDI in a 
representative population [112, 136].  
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Because the basic model provides a conservative prediction, the R value can serve 
as an initial estimate. Currently, the FDA recommends a stepwise model-based strategy 
for assessing the risk for a drug-drug interaction.  For drugs with R values greater than 
1.1 (or greater than 11 for CYP3A4 inhibitors), the use of a mechanistic model, either 
static or dynamic, is recommended for further evaluation. A predicted AUCR outside the 
window of 0.8-1.25 indicates a possible clinical DDI and conduct of a clinical study is 
required [13].  
 
g. Hypothesis and aims 
In this chapter, I hypothesize that alterations in CYP metabolic activity contribute 
to the significant myopathic DDIs identified previously. To test this hypothesis, the 
following aims are pursued: 
1) Evaluate in vitro the drugs involved in the significant myopathic DDIs for their 
potential to inhibit the major drug-metabolizing CYPs; 
2) Investigate in detail the mode of inhibition for significant inhibitors identified in 
Aim 1); 
3) Quantitatively predict the risk of metabolism-based DDIs. 
 
2. Methods  
a. Materials 
All drugs and metabolites were purchased from Toronto Research Chemicals Inc. 
(North York, ON, Canada). The fluorometric cytochrome P450 inhibition kits for 
CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4 were purchased from BD Biosciences 
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(San Jose, CA). Methanol and acetonitrile were purchased from Sigma-Aldrich (St. Louis, 
MO). Corning™ black 96-well polypropylene assay plates were purchased from Fisher 
Scientific (Pittsburgh, PA). 
 
b. Screening for inhibition of the major CYPs and determining IC50s 
Cytochrome P450 inhibition kits were used to determine the IC50s of the drugs for 
the major CYPs, including CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 
and CYP3A4. The assays were conducted following the manufacturer’s manuals using 
the conditions that are summarized in Table 3-1 [130]. Briefly, the components were 
thawed and pre-warmed to 37 °C. The drugs were dissolved in methanol or acetonitrile. 
Organic solvents were kept below 2% for acetonitrile (1% for methanol and 0.2% for 
DMSO) of the final reaction volume since these solvents are known to inhibit CYP 
enzymes [137, 138]. In 96-well plates (maximum volume 300 μL), the drugs were diluted 
to a series of concentrations in a solution containing nicotinamide adenine dinucleotide 
phosphate (NADP+, final concentration 1.3 mM), MgCl2 (final concentration 3.3 mM), 
glucose-6-phosphate (G6P, final concentration 3.3 mM) and glucose 6-phosphate 
dehydrogenase (final concentration 0.4 U/mL). The enzymes and substrates were diluted 
to desired concentrations in sodium phosphate reaction buffer (pH 7.4, final 
concentration 200 mM) and mixed. The mixture was pre-incubated at 37 °C for 10 min. 
Reactions were initiated with addition of the enzyme and substrate mixture to the 
cofactor and drug mixture. The final reaction volume of all assays was 200 μL. After 
incubating at 37 °C for a pre-specified period of time (15 to 45 min, see Table 3-1), the 
reactions were stopped by adding 75 μL of quenching solution (0.5M Tris base or 2N 
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NaOH, see Table 3-1). Fluorescence was determined using a BioTek Synergy 2 
(Winooski, VT) fluorescence reader at excitation and emission wavelengths optimized to 
detect the metabolites. Each of the drugs was tested at eight concentrations in duplicate. 
The highest final concentration of the drugs ranged from 100 to 1000 μM depending on 
its solubility and the enzyme tolerance to organic solvents. The lowest final concentration 
ranged from 0.023 to 0.46 μM. Positive controls (see Table 3-1) were used to 
demonstrate the reproducibility of the assays. Fluorescence emission of the drugs alone at 
the relevant wavelengths was examined at the same concentrations as in assays. To 
estimate IC50s, percent of inhibition was calculated using net fluorescence that was 
corrected for the background. The values of percent of inhibition were then fitted to a 
two- (Eq. 3-2) or four- (Eq. 3-3) parameter log-logistic model as follows, 
% 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =
100
1+10(𝑙𝑜𝑔𝐼𝐶50−log[𝐼])×𝐻𝑖𝑙𝑙 𝑠𝑙𝑜𝑝𝑒
  Eq. 3-2 
% 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = 𝐵𝑜𝑡𝑡𝑜𝑚 +
𝑇𝑜𝑝−𝐵𝑜𝑡𝑡𝑜𝑚
1+10(𝑙𝑜𝑔𝐼𝐶50−log[𝐼])×𝐻𝑖𝑙𝑙 𝑠𝑙𝑜𝑝𝑒
 Eq. 3-3 
where top and bottom are the top and bottom asymptote of a sigmoidal inhibition curve, 
respectively. Data were analyzed using GraphPad Prism 5 software (La Jolla, CA). 
 
c. Determining dissociation constant (Ki) and mode of inhibition 
For the drug and pathway pairs which yielded IC50 values less than 20 μM, 
indicating a relatively potent inhibition, the mode of inhibition and Ki were determined. 
Fluorometric assays were adapted to test multiple substrate and inhibitor concentrations 
for a specific drug-enzyme pair in one setting. The reaction conditions and experimental 
procedures were the same as above except where indicated. More specifically, on a 96-
well plate, the test drug was diluted to the desired concentrations in solutions containing 
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cofactors. A mixture of the enzyme and the substrate was created for each of the desired 
substrate concentrations before being added to the test drug. Since the substrate and 
inhibitor concentrations in such assays can affect the estimate of Ki, the selection of 
concentrations was guided by the IC50 estimates and the reported Kms. In each 
experiment, the substrate was tested around 5x, 2x, 1x, 0.5x, and 0.2x Km, and the 
inhibitor drug was tested around 5x, 2x, 1x, 0.5x, 0.2x, and 0x IC50. Each combination of 
inhibitor drug and substrate concentration was tested in duplicate. 
The net fluorescence signals were obtained by subtracting the background from 
the original readouts after correction for the fluorescence produced by the drugs alone, 
and were fitted to the model of competitive inhibition, non-competitive inhibition, 
uncompetitive inhibition or mixed inhibition using GraphPad Prism 5 software. The final 
model was identified using Dixon plots with the aid of the method described by Geng et 
al. [139]. Briefly, the apparent inhibition constants regardless of the inhibition 
mechanism (Ki,NR) were calculated using Ki,NR = [I] * r/(1 - r), where [I] is inhibitor 
concentration, and r is the ratio of the reaction velocity in the presence and absence of 
inhibitors. When the values of Ki,NR were plotted against substrate concentrations, 
uncompetitive inhibitory reactions were identified with the characteristic decreasing trend, 
whereas data of competitive inhibition and noncompetitive inhibition formed a straight 
line with the slope being a positive number or zero, respectively.  
 
d. Assessing the risk of DDI using R values  
Following the recommendations from the FDA [13], for each inhibitor-pathway 
pair for which a Ki value was observed, I estimated the R values as 1+ [I]/Ki, u, where [I] 
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is the peak total plasma inhibitor concentration, and (Cmax) is the concentration at the 
highest proposed clinical dose obtained from the published literature (see Table 3-5). The 
highest Cmax was used as a conservative prediction when multiple such Cmax values had 
been reported. Because inhibition of CYP3A expressed in the gastrointestinal gut can 
cause changes in bioavailability and potentially lead to DDIs, the prediction involving 
inhibition of CYP3A uses an estimated concentration in the gut for inhibitors 
administered orally. Therefore, for drugs that inhibited CYP3A4 and are administered 
orally, [I] is estimated as [I] = Igut = molar dose/250 mL. Ki,u is the unbound dissociation 
constant of an inhibitor drug, estimated by Ki,u= fu,inc* Ki,  where Ki is the dissociation 
constant of an inhibitor determined in vitro, fu,inc is the fraction of unbound inhibitor drug 
in in vitro incubation. The value of fu,inc was predicted using the Hallifax-Houston model 
in the following equation (Eq. 3-4) [140], 
𝑓𝑢,𝑖𝑛𝑐 =
1
1+10
0.072(𝑙𝑜𝑔
𝑃
𝐷
)2+0.067𝑙𝑜𝑔
𝑃
𝐷
−1.126
  Eq. 3-4 
where log P and log D are the predicted partition coefficient and the distribution 
coefficient, respectively, obtained from DrugBank.  
Consistent with the FDA guidelines for metabolism-based inhibitory DDIs [13], 
inhibitors of CYP3A4 with an R value of >11, or inhibitor of other CYPs with an R value 
of >1.1, were interpreted as possibly involving clinically meaningful DDIs. For inhibitor 
drugs with an R value greater than the cutoffs, AUCR was further predicted for the 
relevant myopathic drug pairs using the mechanistic static model in Eq. 3-1. To predict 
AUCR, the fraction of metabolism (fm) of a victim drug via the affected pathway(s) was 
estimated by fm,CYPi = CLint,CYPi / CLint, total, where CLint,CYPi is the intrinsic clearance via 
the affected pathway under consideration (CYPi), and CLint,total is the total intrinsic 
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clearance. CLint,CYPi and CLint,total were obtained from the published literature. AUCRs 
between 1.25 and 2 were considered as clinically weak interactions; those between 2 and 
5 as moderate inhibitory interactions; and those greater than 5 as clinically strong 
inhibitory interactions [13]. 
 
3. Original experimental results 
To test the hypothesis that the DDIs identified previously are due, in part, to 
inhibition of important CYPs, I examined in vitro the potential of these drugs to inhibit 
the major CYPs using high-throughput fluorometric assays, and then predicted how likely 
inhibition of the CYPs contributes to the DDIs.  
 
a. IC50 estimates 
The thirteen drugs involved in the significant myopathic DDIs identified were 
screened for inhibition of the major CYP isoforms, including CYP1A2, CYP2B6, 
CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. IC50s are shown in Table 3-2, 
and the inhibition curves are displayed in Figure 3-1. At the highest concentration tested, 
some of the drugs did not show any inhibition, e.g. omeprazole for CYP2B6, or failed to 
produce 50% inhibition, e. g. chloroquine for CYP1A2 and CYP2B6. In either of these 
two situations, IC50 was designated as greater than the highest concentration tested. Some 
drugs exhibited abnormal kinetics in the assays for CYP2C8, CYP2C9 and CYP2C19. 
For example, omeprazole and trazodone showed activation rather than inhibition (Figure 
3-2 A and B); loratadine and omeprazole seemed to inhibit CYP2C8 and CYP2C9, 
respectively, at lower concentrations but activate the enzymes at higher concentrations 
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(Figure 3-2 C and D); alprazolam and quetiapine exhibited inhibition at lower 
concentrations but activation at higher concentrations for CYP2C9, respectively (Figure 
3-2 E and F). IC50 could not be determined for such cases and they are therefore labeled 
as ND in Table 3-2. The causes of such unusual kinetics are addressed in detail later.  
IC50s were evaluated for 60 drug-enzyme pairs. The inhibitory potential of 
individual drugs was highly variable across the CYPs, which was reflected in a wide 
range of IC50 values spanning from 0.34 µM to 540 µM. Using arbitrary cutoffs, the 
inhibitors were classified as relatively potent (IC50 ≤ 20 µM), relatively moderate (20 µM 
≤ IC50 ≤ 200 µM), or relatively weak (IC50 ≥ 200 µM). Twenty inhibitory reactions were 
identified as involving relatively potent inhibition, 28 as relatively moderate inhibition 
and 12 as relatively weak inhibition. It should be noted that a number of relatively potent 
inhibitors discovered here had not been reported before. For example, promethazine was 
identified as a relatively potent inhibitor of CYP1A2 (IC50 = 1.0 (0.8, 1.2); ropinirole was 
a relatively potent and specific inhibitor of CYP2D6 (IC50 = 0.85 (0.79, 0.92)); tegaserod 
exhibited relatively potent inhibition for CYP2D6, 3A4 and 2C9 with an IC50 of 0.34, 5.6 
and 7.9 µM, respectively.  
 
b. Mode of inhibition and Ki estimates 
Since IC50 is substrate-dependent and therefore has limited ability to predict the 
risk of DDIs, the potency and mode of inhibition were further characterized. Considering 
that estimating dissociate constant (Ki) requires a large number of incubations, I focused 
on the drug-pathway pairs which were more likely to be involved in DDIs – those that 
exhibited a relatively potent inhibition with an IC50 less than 20 µM. Drug-pathway pairs 
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involving omeprazole and CYP2C8 exhibited unusual kinetics, Ki and the mode of 
inhibition thus could not be determined. Inhibition was characterized in detail for 
eighteen drug – enzyme pairs (Table 3-3). The mode of inhibition was predominantly 
competitive, with Ki ranging from 0.25 µM to 20.1 µM. Noncompetitive inhibition was 
only observed for the inhibition of CYP2C19 by duloxetine.  
 
c. Predicted risk of clinical DDIs 
Following the FDA guidelines, I first estimated R values to obtain an initial 
assessment of the risk of clinical DDIs associated with the inhibitory reactions 
characterized above. To estimate R values, fu,inc, the fraction of unbound drug in in vitro 
incubation, was predicted for each individual drug of interest and is shown in Table 3-4. 
The estimated Ki,us and R values are shown in Table 3-5. With the R cutoff value of 11 
for CYP3A4 inhibitor drugs and 1.1 for inhibitor drugs of other CYPs, six inhibitory 
reactions were considered as having potential to inhibit intrinsic clearance of other drugs 
via the affected pathway and cause clinical DDIs. With a predicted R value of 13, 
quetiapine was the only CYP3A4 inhibitor drug predicted to potentially be involved in 
clinical DDIs at its highest proposed clinical dose (800 mg). The other drugs that 
inhibited CYP3A4, including simvastatin, tegaserod and duloxetine, had R values that 
were much smaller than 11, suggesting a remote chance to interact with drugs mainly 
metabolized by CYP3A4. Duloxetine, promethazine, risperidone and ropinirole exhibited 
relatively potent inhibition for CYP2D6 and had estimated R values of 1.8, 1.3, 1.2 and 
1.2, respectively. Because of the high peak plasma concentration, chloroquine also had an 
estimated R value across the borderline (R value =1.3), although its inhibition for 
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CYP2D6 was only relatively moderate (Ki,u = 14.03 µM). These drugs therefore had 
potential to interact with drugs that are exclusively metabolized by CYP2D6. The 
predicted risk of clinical DDIs for the other inhibitory reaction was considered to be 
negligible.  
The six drugs with significant R values above the cut off limits were involved in 
eight significant myopathic DDIs identified previously. Since R values usually 
overestimate the risk of DDIs and are not specific for interacting drugs, the contribution 
of inhibition of CYPs to those significant DDIs was further evaluated using a 
mechanistic-static model. To account for the contribution of the affected pathway to the 
total metabolism of a victim drug, the fraction of metabolism (fm) of the affected 
pathways, mostly CYP3A4 and CYP2D6, was estimated using data from the published 
literature. The AUCR was then predicted for scenarios where any of the six drugs was the 
perpetrator drug and the interacting drug was the victim drug. The estimated fm and 
predicted R values are shown in Table 3-6.  
The inhibition of CYP3A4 by quetiapine was predicted to result in a 1.25-fold 
increase in the AUC of chloroquine, although CYP3A4 only accounts for 25% of 
chloroquine metabolism [141]. Consistent with the definition by the FDA, this small 
predicted AUCRs indicates a weak clinical DDI between quetiapine and chloroquine. The 
predicted AUCRs suggested that the other drug pairs would not have significant 
interactions clinically. 
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4. Discussion 
In the first part of this chapter, I have addressed the hypothesis that inhibition of 
the major CYPs contributes to the significant drug interactions previously identified. I 
first screened the thirteen drugs involved in those DDIs for inhibition of the major CYPs. 
Then I characterized the mode of inhibition and potency in detail for eighteen inhibitory 
reactions that yielded IC50s less than 20 µM. Next, I predicted the risk of metabolism-
based DDI via inhibiting a single pathway for the reactions characterized in detail, and 
identified six drugs with significant potential to act as precipitant drugs and cause clinical 
DDIs. Lastly, for the myopathic DDIs involving any of these six drugs, I predicted the 
change in the AUC of the victim drugs in the presence of these drugs, and found that 
quetiapine and chloroquine may have a weak clinical drug interaction. 
The examination of the potential to inhibit the CYPs provides a relatively 
comprehensive view on the drugs’ inhibitory profile for the major drug-metabolizing 
enzymes. The inhibitory potential for CYP2B6 and CYP2C8 is particularly valuable 
since these two isoforms have been understudied. Such inhibitory profiles may not be 
available to the public, and are often lacking for drugs that were developed decades ago 
since the requirement by the FDA on evaluation of CYP inhibition by investigational 
drugs is only relatively recent. In general, the IC50s presented in Table 3-2 and the Kis 
presented in Table 3-3 are consistent with the inhibitory potential of these drugs 
published previously. My data represent not only a confirmation of some inhibitory 
profiles that have been published, but are also the first to provide such information on 
alprazolam, hydroxychloroquine, promethazine and quetiapine. Here, I discuss first the 
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consistency between my data and those that have been published. The clinical implication 
of these inhibitory profiles will be addressed later. 
Alprazolam had a rather favorable inhibitory profile for the major CYPs by exhibiting 
only relatively weak inhibitory effects on CYP2B6, CYP2C8, CYP2C19 and CYP3A4. 
This may explain the lack of publications on its inhibitory potential for CYPs.  
Chloroquine was identified as a relatively potent inhibitor of CYP2D6, a 
relatively moderate inhibitor of CYP2C8 and a relatively weak inhibitor of CYP3A4. It 
showed little inhibitory effect on the other isoforms. Further characterization of the 
inhibition of CYP2D6 revealed that chloroquine is a competitive inhibitor of this isoform 
with a Ki of 20.1 µM, that is consistent with the data of Biparo et al. and Masimirembwa 
et al. [142, 143], who reported that chloroquine was a competitive inhibitor of CYP2D6 
with Kis of 12.4 µM and 15.3 µM, respectively. These data are consistent with the results 
of Projean et al., who found that chloroquine was metabolized, in part, by CYP2D6 [141].  
Duloxetine exhibited relatively potent inhibition of CYP1A2, CYP2C9, 
CYP2C19, CYP2D6 and CYP3A4, and relatively moderate inhibition of CYP2B6 and 
CYP2C8. The broad inhibitory effect of duloxetine across CYP isoforms suggests that 
duloxetine could be involved in drug interactions by simultaneously inhibiting multiple 
pathways. Paris et al. showed that duloxetine inhibited CYP isoforms 1A2, 2B6, 2C8, 
2C9, 2C19, 2D6 and 3A4/5 with IC50s of 50, 15, 60, >100, 27, 7 and 38 µM, respectively 
[144], which are comparable to our IC50 estimates of  9.6, 33.3, 35.9, 26.3, 12, 0.9 and 
10.2 µM, respectively. It is worth noting that both sets of data identify CYP2D6 as the 
isoform most sensitive to duloxetine inhibition. Because duloxetine is a substrate of 
CYP2D6 [145], it was suspected that duloxetine is a mechanism-based inhibitor of 
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CYP2D6. However, the data of Chan et al. clearly showed that the inhibition of CYPs by 
duloxetine was not time-dependent [146]. I found that the inhibition of CYP1A2, 
CYP2D6 and CYP3A4 was competitive with Kis of 4.7, 0.3 and 10.5 µM, respectively, 
and that of CYP2C19 was noncompetitive with a Ki of 2.9 µM. Knadler et al. reported 
that the Ki for the inhibition of CYP1A2, CYP2C19, CYP2D6 and CYP3A4 by 
duloxetine was 17.7, 7.1, 2.4 and 133 µM, respectively [147]. Compared with these Ki 
values determined using conventional CYP probe substrates, my Ki estimates are in a 
similar range for CYPs but are in general of smaller values.  
The inhibitory profile of hydroxychloroquine resembles that of chloroquine in that 
it showed a relatively strong inhibition for CYP2D6, a relatively moderate inhibition for 
CYP2C8, a relatively weak inhibition for CYP3A4 and no inhibition for the other 
isoforms. The potential of hydroxychloroquine to inhibit CYPs in vitro has not been 
reported before, and my data are the first to provide such information.  
Loratadine also exhibited a broad inhibitory effect on CYPs. It was a relatively 
potent inhibitor of CYP2D6, CYP2B6 and CYP2C9, a relatively moderate inhibitor of 
CYP2C19 and CYP3A4 and a relatively weak inhibitor of CYP1A2. My data showing 
the relatively potent inhibition of CYP2D6 and CYP2B6 by loratadine are consistent with 
the results of Nicolas et al. [148] and Walsky et al. [149], who reported that IC50s of 
loratadine for CYP2D6 and CYP2B6 were 15 µM and 7.69 µM, respectively. I further 
found that the inhibitions of CYP2B6 and CYP2D6 by loratadine were both competitive 
with Kis of 2.0 and 0.5 µM, respectively. The relatively moderate inhibition of CYP3A4 
and weak inhibition of CYP1A2 are also consistent with the data presented by Nicolas et 
al. [148], who showed that IC50s for these isoforms were 32 µM and >100 µM, 
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respectively. Discrepancy exists in the inhibitory potencies for CYP2C9 and, more 
prominently, for CYP2C19. Lee et al. found that loratadine did not show significant 
inhibition for CYP2C9 and the IC50 was higher than 30 µM [150]; whereas my data 
indicate that loratadine was a relatively potent inhibitor of CYP2C9 with an IC50 of 12.35 
µM and a Ki of 7.6 µM. A relatively potent inhibition of CYP2C19 by loratadine has 
been reported by many groups with IC50 ranging from 0.76 µM [151] to 2.80 µM [150], 
whereas my data show that this inhibition is only relatively moderate in potency with an 
IC50 of 21.3 µM. The inhibition of CYP2C19 by loratadine has been identified by other 
groups as competitive with a Ki ranging from 0.006 µM [152] to 0.61 µM [151]. The 
cause of these discrepancies may lie in the estimation of IC50s. In the case of both 
CYP2C9 and CYP2C19, the observed inhibition-concentration curve of loratadine was in 
an incomplete sigmoidal shape and was rather flat across the concentrations (the light 
blue curves in Figure 3-1 CYP2C9A and CYP2C19.A), which would usually lead to 
inaccurate estimation of the model parameters. In addition, the IC50 of loratadine for 
CYP2C8 could not be evaluated due to unusual kinetics (Figure 3-2 C). A relatively 
potent inhibition of CYP2C8 by loratadine was reported by Walsky et al. with an IC50 of 
3.36 µM [153].  
Omeprazole was found to be a relatively potent inhibitor of CYP3A4, a relatively 
moderate inhibitor of CYP2C19, CYP1A2 and CYP2D6. The relatively moderate 
inhibition of CYP1A2 is consistent with the IC50 of 78 µM observed by Moody et al. 
[154]. The relatively weak the inhibition of CYP2D6 is consistent with the Ki values 
determined by others, ranging from 181.8 µM [155] to 302 µM [156]. Omeprazole has 
been identified as a mechanism-based inhibitor of CYP2C19 and CYP3A4 with Kinacts of 
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0.044 /min [157] and 0.099 /min [158], respectively. Since the inhibitory effect of a 
mechanism-based inhibitor is less apparent with shorter pre-incubation time as in the 
experiments, this may explain the discrepancy between my data and those showing 
omeprazole to be a relatively potent inhibitor of CYP2C19 [159, 160].  In addition, IC50 
of omeprazole for CYP2C9 could not be determined. Other groups have reported that 
omeprazole is a potent to moderate inhibitor of this isoform with a highly variable Ki 
ranging from 0.41 µM[161] [162] to 74. 9 µM [163].  
Promethazine was able to inhibit all the CYPs of interest. It was identified as a 
relatively inhibitor of CYP1A2 and CYP2D6, and a relatively moderate inhibitor of the 
other isoforms. I further found that promethazine was a competitive inhibitor of CYP2D6 
with a Ki of 0.25 µM, which represents a more potent inhibition than those reported by 
Hamelin et al. [164] and He et al. [165] who reported a Ki of 1.9 µM and 9 µM, 
respectively, for this inhibitory reaction. He et al. also reported a relatively moderate 
inhibition of CYP2C9 by loratadine with an IC50 of 88 µM [165], which is comparable to 
my IC50 estimate (12.4 µM) in magnitude. The inhibitory effect of promethazine on the 
other CYP isoforms has never been reported.  
Quetiapine exhibited a relatively potent inhibition for CYP3A4 and a relatively 
moderate inhibition for CYP2B6 and CYP2D6. Its potential to inhibit CYP2C8, CYP2C9 
and CYP2C19 could not be evaluated. The inhibition of CYP3A4 was identified as 
competitive with a Ki of 0.75 µM. The inhibitory effects of quetiapine on CYPs have 
never been reported before.  
Risperidone was found to be a relatively potent inhibitor of CYP2D6, a relatively 
moderate inhibitor of CYP2C9, CYP2C19 and CYP3A4, and a relatively weak inhibitor 
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of CYP2B6. The potent inhibition of CYP2D6 was identified as competitive with a Ki of 
1.62 µM. Zimmerline et al. found that risperidone is a mechanism-based inhibitor of 
CYP2D6 with a Kinact of 0.005 /min [158]. The moderate inhibition of CYP3A4 was 
consistent with the Ki of 67 µM observed by Prakash et al.[166]. The same group also 
reported that the IC50s of risperidone for CYP1A2, CYP2C9 and CYP2C19 were greater 
than 100 µM.  
Ropinirole exhibited a relatively potent inhibition for CYP2D6 and weak or no 
inhibition for the other CYP isoforms. The potent inhibition of CYP2D6 was also 
observed by Wynalda et al. who reported an IC50 of 0.54 µM [167]. I further found that 
this inhibitory reaction was competitive with a Ki of 0.85 µM.  
Tegaserod was a relatively potent inhibitor of CYP2D6, CYP2C9 and CYP3A4, a 
relatively moderate inhibitor of CYP2B6, and a relatively weak inhibitor of CYP1A2. 
The inhibition of CYP2D6, CYP2C9 and CYP3A4 was all found to be competitive with 
Kis of 0.51 µM, 11.4 µM and 5 µM. A thorough investigation on the inhibitory effect of 
tegaserod on CYPs was conducted by Vickers et al. using conventional VYP probe 
substrates and HLMs [168]. They found that tegaserod was a relatively potent inhibitor of 
CYP1A2 and CYP2D6 with Kis of 0.84 µM and 0.85 µM, respectively, and a relatively 
moderate inhibitor of CYP2C8, CYP2C9, CYP2C19 and CYP3A4 with IC50s of ~130 
µM, ~74 µM, ~153 µM, and ~107 µM, respectively. My data are consistent with those of 
Vickers et al. only with respect to the inhibition of CYP2D6.  
Trazodone was found to be a moderate inhibitor of CYP2B6, CYP2D6 and 
CYP3A4. The inhibition of CYP3A4 is consistent with the IC50 of 22.7 µM reported by 
Kalgutkar et al. [169]. A stronger inhibitory effect on CYP2D6 was observed by Otton et 
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al., who showed that trazodone was a competitive inhibitor of this isoform with a Ki of 9 
µM [170]. 
Simvastatin also exhibited inhibitory effect on many CYP isoforms. My data 
showed that simvastatin was a relatively potent inhibitor of CYP3A4, CYP2C9 and 
CYP2C8, and a relatively moderate inhibitor of CYP2C19, CYP2D6 and CYP2B6. The 
relatively moderate inhibition of CYP2C19 and the relatively potent inhibition of 
CYP2C8 and CYP2D4 are consistent with those observed elsewhere [129, 153, 171-173]. 
My estimate of Ki equal to 0.51 µM for inhibition of CYP3A4 is very close to that 
reported by Foti et al. (0.54 µM) [129]. Compared with my data, the inhibition of 
CYP2C9 was found to be much less potent with an IC50 ranging from 111.6 µM [174] to 
287 µM [171]. Also, a slightly more potent inhibition of CYP2B6 was observed (IC50 = 
15.9 µM) by Walsky et al. [149].  
Evaluating the inhibitory effects of these drugs on the CYPs in a consistent 
system also allows comparing the inhibitory potential across the major CYPs. Figure 3-3 
shows the inhibition-concentration curves grouped drug-wise. These drugs share a 
common trend of losing inhibitory selectivity at higher concentrations. Consistent with 
the values of IC50s and Kis, these plots suggest that some of the drugs can serve as 
selective inhibitors of specific CYP isoforms within certain concentration windows. For 
example, on the plot of chloroquine, the inhibition-concentration curve for CYP2D6 (hot 
pink) is clearly separated with those for the other isoforms on the right, indicating a more 
potent inhibition of CYP2D6. The blank space between the curve of CYP2D6 and those 
of the others corresponds to a window of concentration within which the inhibitory effect 
of chloroquine is relatively selective for CYP2D6. Apparently, chloroquine has a broad 
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“window of selectivity”. The range of concentration in which 70% inhibition of CYP2D6 
was observed with no significant inhibitory effect on other isoforms was approximately 
from 20 µM to 100 µM. The same also applies to risperidone and ropinirole for inhibition 
of CYP2D6. The concentration window of ropinirole for selective inhibition of CYP2D6 
is approximately 2 µM to 100 µM, and that of risperidone is approximately 3 µM to 20 
µM. It should be noted that the inhibition-concentrations curves were obtained using 
recombinant CYP enzymes and fluorogenic probes. Further studies are warranted to 
examine the selectivity of inhibition using conventional CYP probes in HLMs where 
multiple isoforms are present.  
The window of selective inhibition discussed above only applies to the CYP 
isoforms for which inhibitory potential could be evaluated, including those with IC50s 
designated as greater than the highest concentration tested. There are a number of cases 
where abnormal kinetics were observed and inhibitory potential could not be determined. 
The possibility remains that, in these cases, the test drug may be a potent inhibitor of the 
CYP isoform, and its window of selective inhibition taking account of all the major CYPs 
may consequently be different. 
Among the abnormal kinetics observed, an apparent enzyme activation was 
observed with omeprazole in the assay of CYP2C8 and with trazodone in the assay of 
CYP2C19 (Figure 3-2 A and B). There are a few possible explanations for these apparent 
enzyme activations. One is that the test drug is also fluorescent at the wavelength that the 
metabolite of the fluorogenic probe is being detected. Amongst the drugs tested, only 
omeprazole, chloroquine and hydroxychloroquine exhibited fluorescence at the relevant 
wavelengths. However, enzyme activation observed with omeprazole remained even after 
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correction for the fluorescence of this drug. Another possibility is that the metabolites of 
the test drugs may be highly fluorescent at the relevant wavelengths, so the fluorescent 
signal may largely represent the amount of the metabolites of the test drug. It is also 
possible that the test drugs and/or its metabolites allosterically bind to the enzyme, 
rendering the enzyme more efficient in metabolizing the fluorogenic probes (positive 
cooperativity). These possible mechanisms, and their combination, may explain the 
monotonic increase in fluorescent signal with the test drug concentration. For the other 
abnormal kinetics showing activation at lower concentrations and inhibition at higher 
concentrations, or the opposite, the mechanism may be even more complex.    
High-throughput fluorometric CYP inhibition assays enabled me to evaluate 
inhibitory potential of CYPs in a highly efficient way. However, this approach also 
represents one of the limitations of my study. While there is in general a good correlation 
between IC50 values determined using fluorogenic and conventional probes [132, 175], 
occasionally, IC50 values generated using  fluorogenic probes can be very different from 
those using conventional probes [132, 175]. It is well recognized that IC50 values are 
dependent on probe substrate, which is particularly true for CYP3A4. CYP3A4 
simultaneously binds and metabolizes multiple compounds in its active site. Therefore, 
cooperativity, activation, and complex inhibition kinetics are much more common with 
CYP3A4 than with enzymes of the CYP1 and CYP2 families [176, 177]. Also, the 
structural and physiochemical properties of fluorogenic probes are different from those of 
conventional probes [132]. These may explain the inconsistency between the IC50 values 
I observed and those from the published literature, all of which were determined with 
conventional probes. It follows that caution should be exercised when interpreting the 
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data from such fluorometric assays. In addition, I could not evaluate IC50 for some of the 
drugs in the assays involving CYP2C8, CYP2C9 and CYP2C19. It may be possible to 
evaluate the IC50s in such cases using conventional probes.  
In addition to the use of fluorescent probes, the use of recombinant CYP enzymes 
may also be problematic. The activities of purified recombinant CYP enzymes are known 
to be different in som respects from that observed in the liver or in HLMs [178]. This 
difference in enzymatic activity may cause inconsistency between IC50s determined here 
and those that have been published. Future studies thus are warranted to validate the 
inhibitory potencies using HLMs or hepatocytes and conventional probes. 
Another limitation of my in vitro study is that I did not examine the potential of 
these drugs as mechanism-based inhibitors of the CYPs. Some of these drugs are already 
known to be mechanism-based inhibitors, e.g. omeprazole for CYP2C19 and CYP3A4, 
and risperidone for CYP2D6. Since mechanism-based inhibition requires substrate 
activation, an inhibitory reaction involving a CYP isoform that also metabolizes its 
inhibitor drug can potentially be mechanism-based. For example, inhibition of CYP2D6 
by chloroquine and promethazine might be mechanism-based because CYP2D6 is 
involved in the metabolism of these drugs. The predicted R values and AUCRs may 
consequently underestimate the risk of clinical DDIs for mechanism-based inhibitory 
reactions due to their more profound effects on enzyme activity than reversible 
inhibitions. This underestimation may result in a false conclusion that some DDIs 
identified previously are not caused by inhibition of CYPs. 
The inhibitory potential obtained in vitro provided the basis for prediction of the 
risk of clinical DDIs in vivo. Applying the R value approach, I screened for inhibitory 
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reactions that potentially have clinical consequences. For the majority of the six drugs 
predicted with significant R values, there is little evidence for their potential to interact 
with other drugs clinically as precipitant drugs. 
As a relatively potent inhibitor of CYP2D6, duloxetine had an R value of 1.78 and 
was predicted to interact with CYP2D6 substrate drugs. This is consistent with drug 
interactions that have been observed with duloxetine clinically. Skinner et al. showed that 
duloxetine increased the AUC of desipramine, an in vivo probe of CYP2D6, by 192% and 
122% at a dose of 60 mg twice daily and 30 mg twice daily, respectively [145]. 
Coadministration of 40 mg of duloxetine twice daily with the CYP2D6 substrate 
tolterodine (2 mg twice daily) increased tolterodine steady state AUC and Cmax by 71% 
and 64%, respectively, and prolonged the half-life of tolterodine by 14% [179]. Also, 
duloxetine increased the Cmax and half-life of metoprolol, a CYP2D6 substrate, and 
decreased its clearance, leading to a 180% increase in the AUC [180]. However, 
duloxetine did not significantly change the pharmacokinetics of risperidone and 
aripiprazole [181], which are also CYP2D6 substrates. It therefore seems that the 
inhibitory effect of duloxetine on CYP2D6 is moderate from a clinical perspective. 
Chloroquine was predicted to interact clinically with drugs that are exclusively 
metabolized by CYP2D6. The R value of 1.36 is due mostly to the high Cmax (1547 ng/ml) 
that was reported for patients with malaria after receiving 1500 mg chloroquine for 3 
days [182]. But even if predicted with a much lower Cmax observed in healthy volunteers 
(838 ng/ml) [183], the resulting R value of 1.19 would still be significant. Since 
chloroquine has a long half-life of 146 to 333 hours [184], these Cmax values are likely 
lower than that at steady state. More importantly, chloroquine is known to accumulate in 
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tissues including the liver and muscles [185]. The accumulation ratio of chloroquine was 
795 ± 33 in viable isolated rat hepatocytes [186]. Therefore, the risk of chloroquine as a 
precipitant drug is likely substantially underestimated. Similar to the case of quetiapine, 
reports on pharmacokinetic drug interactions involving chloroquine as a precipitant drug 
are limited. Chloroquine increased the Cmax and AUC of paracetamol without affecting 
the elimination rate [187]. Chloroquine was also reported to reduce the bioavailability of 
ampicillin [188]. These studies, however, do not suggest a role of chloroquine in drug 
interactions by inhibiting CYP2D6. Future studies are needed to further evaluate the 
potential of chloroquine to act as a precipitant drug and its effect of the metabolism of 
other drugs by CYP2D6. 
Promethazine was also predicted to interact with CYP2D6 substrate drugs with an 
R value of 1.31. There are very few studies suggesting the role of promethazine as a 
precipitant drug in DDIs by inhibiting CYP2D6. The steady state plasma concentration of 
haloperidol, a substrate of CYP2D6, during promethazine coadministration was 
significantly higher than those before the coadministration or 1 week after the 
discontinuation of promethazine [189]. Coadministration of promethazine was found to 
increase the plasma concentration and AUC of chloroquine, a substrate of CYP2D6, 
suggesting a possible mechanism of CYP26 inhibition [190]. 
Both ropinirole and risperidone were predicted with R values of 1.15, suggesting 
a small risk of interacting with CYP2D6 substrate drugs clinically. The R value of 
risperidone is likely to be an underestimate since the drug is known to be a mechanism-
based inhibitor of CYP2D6. Both ropinirole and risperidone lack evidence of having 
clinical drug interactions as a precipitant drug. The only published study involving drug 
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interaction with ropinirole reported a small change in the Cmax and AUC of digoxin with 
coadministration of ropinirole [191]. This weak interaction is unlikely due to inhibition of 
CYP2D6 by ropinirole. No published DDI study showing risperidone as a precipitant 
drug was found.  
With a gut concentration estimated at the dose of 800 mg, quetiapine was 
predicted to cause DDIs with drugs that are exclusively metabolized by CYP3A4 (R 
value = 13). This seems at odds with the lack of publication on CYP3A4-based 
interactions with quetiapine given that CYP3A4 has such a broad substrate spectrum. The 
published DDIs studies involving quetiapine all observed it as a victim drug. Its 
pharmacokinetics were found to be affected by ketoconazole and carbamazepine, a 
CYP3A4 inhibitor and inducer, respectively [192], or by fluoxetine, a CYP2D6 inhibitor 
[193].  
It is possible that the general lack of publications on clinical drug interactions 
with the drugs discussed here are because these drugs have rarely been evaluated 
clinically as precipitant drugs. Another possibility is that the clinical risk of drug 
interactions with these drugs were overpredicted using the R value approach. Future 
studies are warranted to investigate the potential of these drugs to act as inhibitors of 
CYPs in vivo and their clinical consequences. 
Over-prediction of the risk of clinical DDIs using R values may be more 
prominent with the inhibitors of CYP3A4, for which a gut concentration that is normally 
much higher than the circulating concentration was assumed. However, in the case of 
quetiapine, the predicted risk using R value is supported by the predicted AUCR for the 
interaction of chloroquine with quetiapine. It should be noted that, even for chloroquine, 
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whose fraction of metabolism through CYP3A4 is only 0.25, quetiapine was predicted to 
result in 1.25-fold increase in the AUC when coadministered. The inhibitory effect of 
quetiapine on CYP3A4 would be more profound if a victim drug were metabolized by 
CYP3A4 to a larger extent. Considering that prediction of AUCR ignores the change in 
bioavailability due to inhibition of first-pass metabolism, this AUCR is likely an 
underestimate. On the other hand, the elimination of chloroquine is largely rate-limited 
by distribution rather than hepatic metabolism [184, 194]. The documented accumulation 
of chloroquine in the liver and muscles may further attenuate the overall effect of 
quetiapine on its pharmacokinetics.  
The risk of clinical DDIs is likely under-predicted when chloroquine is the 
precipitant drug due to its hepatic accumulation. Since the Cmax of chloroquine used for 
predicting AUCRs is likely much lower than its hepatic concentration, the AUCRs of 
chloroquine vs. duloxetine and of chloroquine vs. risperidone likely under-predicted the 
effects of chloroquine on the pharmacokinetics of the victim drugs. PBPK models that 
incorporate the hepatic concentration of chloroquine and the victim drugs may provide 
better predictions. Clinical studies that evaluate chloroquine as a precipitant drug will be 
very helpful.  
Aside from over-prediction in general and potential under-predictions in the case 
of chloroquine, the prediction of the risk of clinical DDIs has a major limitation that 
results from using the R value and AUCR approach. It is problematic to use a single 
static estimate of in vivo concentration of an inhibitor drug to provide a point estimate of 
the average magnitude of change in the exposure to a victim drug. The static nature of the 
two models may be particularly problematic for drugs that have relatively short half-lives 
 80 
 
and whose circulating concentrations drop rapidly following a dose. One example is 
simvastatin, whose half-life can be as short as two hours [195]. The inhibitory effects of 
such drugs on the overall metabolism of a victim drug may be limited even when they are 
strong inhibitors of the relevant CYPs. In addition, the major CYPs, CYP2D6, CYP2C9 
and CYP2C19 in particular, are known to be polymorphic. The risk of clinical DDIs with 
the drugs of interest may be overpredicted for some individual and under-predicted for 
others.  
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Table 3-1. Summary of incubation conditions of CYP fluorometric assays. 
 CYP1A2 CYP2B6 CYP2C8 CYP2C9 CYP2C19 CYP2D6 CYP3A4 
Substrate CEC EFC DBF MFC CEC AMMC BFC 
Substrate 
Concentration (μM) 
5 2.5 1 75 25 1.5 50 
Enzyme 
Concentration (nM) 
2.5 5 9 5 2.5 7.5 5 
Km,app (μM) 3.5  1 78 29 1 >200 
Vmax,app (min-1) 3.4  0.4 2.1 0.016 1 1.5 @40uM 
Buffer 50mM KPO4 50mM KPO4 50mM KPO4 50mM KPO4 50mM KPO4 50mM KPO4 200mM KPO4 
pH 7.4 7.4 7.4 7.4 7.4 7.4 7.4 
Incubation Time (min) 15 30 40 45 30 30 30 
Quenching Solution 0.5M Tris base 0.5M Tris base 2N NaOH 0.5M Tris base 0.5M Tris base 0.5M Tris base 0.5M Tris base 
Metabolite CHC HFC Fluorescetin HFC CHC AHMC HFC 
Ex/Em (nm) 410/460 410/530 485/538 410/530 410/460 390/460 410/530 
Control inhibitor Furafyline Tranylcypromine Quercetin Sulfaphenazole Tranylcypromine Quinidine Ketoconazole 
 
Note: CEC, 3-cyano-7-ethoxycoumarin; EFC, 7-Ethoxy-4-trifluoromethylcoumarin; DBF, Dibenzylfluorescein; MFC, 7-methoxy-4-
trifluoromethylcoumarin; AMMC, 3-[2-(N,N-diethyl-N-methylammonium) ethyl]-7-methoxy-4-methylcoumarin; BFC, 7-benzyloxy-
4-trifluoromethylcoumarin; CHC, 3-Cyano-7-hydroxycoumarin; 7-HC, 7-Hydroxycoumarin; HFC, 7-hydroxy-4-
trifluoromethylcoumarin; AHMC, 3-[2-(N,N-diethylamino)ethyl]-7-hydroxy-4-methylcoumarin hydrochloride. 
Km,app, apparent Michealis Menton constant; Vmax,app, apparent maximum reaction velocity; Ex, excitation wavelength; Em, emission 
wavelength. 
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Table 3-2. IC50s (95% CI) (µM) for the inhibition of the major CYPs 
 CYP1A2 CYP2B6 CYP2C8 CYP2C9 CYP2C19 CYP2D6 CYP3A4 
Alprazolam >100 
773 
(723.3, 826.1) 
396.4  
(321.3, 489.2) 
ND 
443.9 
very wide 
>1000 
303.8 
(261.7, 352.6) 
Chloroquine >1000 >1000 
147.8  
(80.2, 272.5) 
>1000 >1000 
8.0 
(6.8, 9.4) 
367.0 
(326.5, 412.6) 
Duloxetine 
9.6 
(8.3, 11.0) 
33.3 
(30.7, 36.1) 
35.9 
(31.7, 40.6) 
26.3 
(22.9, 30.2) 
12.0 
(8.6, 16.8) 
0.9 
(0.8, 1.1) 
10.2 
(9.7, 10.6) 
Hydroxychloroquine >1000 >1000 
176.6  
(75.43, 413.5) 
>1000 >1000 
27.1 
(24.2, 30.5) 
352.4 
(323.9, 383.3) 
Loratadine 
630 
(438, 906.3) 
11.9 
(9.9, 14.4) 
ND 
12.35 
(7.8, 19.45) 
21.3 
(15.3, 29.7) 
9.1 
(8.3, 9.9) 
33.2 
(30.1, 36.6) 
Omeprazole 
112.1 
(97.3, 129) 
>1000 ND ND 
32.0 
(25.9, 39.5) 
190.7 
(158.4, 229.5) 
7.4 
(7.0, 7.8) 
Promethazine 
1.0 
(0.8, 1.2) 
51.1 
(46.7, 56) 
106.9  
(86.4, 131.9) 
43.8 
(39.3, 48.8) 
40.8 
(28.8, 57.8) 
0.39 
(0.35, 0.44) 
48.5 
(44.8, 52.6) 
Quetiapine >100 
51.2 
(42, 62.4) 
ND ND ND 
25.7 
(21.7, 30.6) 
4.5 
(3.7, 5.5) 
Risperidone >500 
358.9 
(297.3, 433.3) 
ND 
75.0 
(58.2, 99.3) 
169.9 
(140, 206.2) 
1.0 
(0.5, 2.0) 
169.2 
(143.7, 199.2) 
Ropinirole 
540.5 
(319.9, 913.2) 
>500 
407.8 
(279.2, 595.7) 
>1000 >1000 
0.85 
(0.79, 0.92) 
707.9 
(648.2, 773.2) 
Tegaserod 
347.1 
(307.4, 391.9) 
20.8 
(19.6, 22.1) 
>500 
7.9 
(4.9, 12.9) 
1.17 
(0.95, 1.43) 
0.34 
(0.31, 0.38) 
5.6 
(4.8, 6.4) 
Trazodone >100 
55.0 
(48.8, 62.1) 
ND >100 ND 
67.1 
(59.6, 75.7) 
67.7 
(54.4, 84.4) 
Simvastatin >100 
89.3 
(65.8, 121.2) 
17.2 
(13.1, 22.7) 
6.4 
(5.3, 7.6) 
43.4 
(37.1, 50.7) 
41.3 
(35.1, 48.5) 
4.3 
(2.4, 7.8) 
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Figure 3-1. Inhibition-concentration curves grouped by CYP. The inhibitions by 
alprazolam (black), chloroquine (red), duloxetine (green), hydroxychloroquine (dark 
blue), loratadine (light blue), omeprazole (hot pink) and promethazine (yellow) are 
shown in panel A for the CYPs tested. The inhibitions by quetiapine (red), risperidone 
(green), ropinirole (dark blue), tegaserod (light blue), trazodone (hot pink) and 
simvastatin (yellow) are shown in panel B for the CYPs tested. Each drug was tested in 
duplicate shown in open circles. The lines connect the average % inhibition values of the 
two replicates at each concentration. 
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Figure 3-2. Examples of abnormal kinetics observed from fluorometric assays. 
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Figure 3-3. Inhibition-concentration curves grouped by drug. The fraction of inhibition is 
shown for CYP1A2 (black), CYP2B6 (red), CYP2C8 (green), CYP2C9 (dark blue), 
CYP2C19 (light blue), CYP2D6 (hot pink) and CYP3A4 (yellow) for each individual test 
drug. Each drug was tested in duplicate with individual values shown in open circles. The 
lines connect the average % inhibition values of the two replicates at each concentration. 
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Table 3-3. Mode of inhibition and Ki ± SD (µM) 
 CYP1A2 CYP 2B6 CYP 2C9 CYP 2C19 CYP 2D6 CYP 3A4 
Chloroquine     
Competitive 
20.1 ± 2.9 
 
Duloxetine 
Competitive 
4.7 ± 0.6 
  
Noncompetitive 
2.9 ± 0.3 
Competitive 
0.3 ± 0.03 
Competitive 
10.5 ± 0.4 
Loratadine  
Competitive 
2.0 ± 0.3 
Competitive 
7.6 ± 1.0 
 
Competitive 
0.5 ± 0.08 
 
Promethazine     
Competitive 
0.25 ± 0.03 
 
Quetiapine      
Competitive 
0.75 ± 0.07 
Risperidone     
Competitive 
1.62 ± 0.19 
 
Ropinirole     
Competitive 
0.85 ± 0.09 
 
Tegaserod   
Competitive 
11.4 ± 2.8 
Competitive 
9.2 ± 2.8 
Competitive 
0.51 ± 0.06 
Competitive 
5.0 ± 0.7 
Simvastatin   
Competitive 
18.3 ± 3.5 
  
Competitive 
0.51 ± 0.1 
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Table 3-4 Predicted fu,inc 
Drug Log D Log P Log ka fu,inc 
Chloroquine 1.59 4.412 -0.364 0.698 
Duloxetine 2.31 4.809 -0.509 0.763 
Loratadine 3.895 3.9 -1.126 0.930 
Promethazine 3.4 4.887 -0.867 0.880 
Quetiapine 2.51 2.6 -1.119 0.929 
Risperidone 1.89 2.678 -1.028 0.914 
Ropinirole 0.49 2.486 -0.705 0.835 
Simvastatin 4.72 4.7 -1.127 0.931 
  
  
9
2
 
Table 3-5 Predicted R values 
Drug Pathway 
Ki 
(µM) 
fu,inc 
Ki,u 
(µM) 
Cmax 
(ng/ml) 
MW 
(g/mol) 
[I] 
(µM) 
R 
R > 1.1 
or > 11 
for 3A4 
Cmax 
Reference 
Quetiapine 3A4 0.75 0.93 0.70 - 383.5 8.3441 12.97 + - 
Simvastatin 3A4 0.51 0.93 0.47 - 418.7 0.7642 2.61  - 
Duloxetine 2D6 0.3 0.76 0.23 53.2 297.4 0.179 1.78 + [196] 
Chloroquine 2D6 20.1 0.70 14.03 1547 319.9 4.836 1.34 + [183] 
Promethazine 2D6 0.25 0.88 0.22 19.3 284.4 0.068 1.31 + [197] 
Tegaserod 3A4 5 0.92 4.61 - 301.39 0.7963 1.17  - 
Risperidone 2D6 1.62 0.91 1.48 89.1 410.5 0.217 1.15  [198] 
Ropinirole 2D6 0.85 0.84 0.71 26.9 260.4 0.103 1.15 + [199] 
Duloxetine 3A4 10.5 0.76 8.02 - 297.4 0.8074 1.10  - 
Duloxetine 2C19 2.9 0.76 2.21 53.2 297.4 0.179 1.08  [196] 
Duloxetine 1A2 4.7 0.76 3.59 53.2 297.4 0.179 1.05  [196] 
Loratadine 2D6 0.5 0.93 0.47 4.12 382.9 0.011 1.02  [200] 
Tegaserod 2D6 0.51 0.92 0.47 2.7 301.39 0.009 1.02  [201] 
Loratadine 2B6 2 0.93 1.86 4.12 382.9 0.011 1.01  [200] 
Simvastatin 2C9 18.3 0.93 17.03 25.4 418.7 0.061 1.00  [202] 
Loratadine 2C9 7.6 0.93 7.07 4.12 382.9 0.011 1.00  [200] 
Tegaserod 2C19 9.2 0.92 8.48 2.7 301.39 0.009 1.00  [201] 
Tegaserod 2C9 11.4 0.92 10.51 2.7 301.39 0.009 1.00  [201] 
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Note:   
1. [I] of quetiapine was estimated as the highest proposed clinical dose (800 mg /383.5 
g/mol) divided by 250 mL. 
2. [I] of simvastatin was estimated as the highest proposed clinical dose (80 mg/418.7 
g/mol) divided by 250 mL. 
3. [I] of tegaserod was estimated as the highest proposed clinical dose (6 mg/ 301.39 
g/mol) divided by 250 mL. 
4. [I] of duloxetine was estimated as the highest proposed clinical dose (60 mg/ 297.4 
g/mol) divided by 250 mL. 
 
Pathway designates the inhibited CYP isoform; Ki is the dissociation constant; fu,inc is 
the fraction of unbound in incubation mixture; Cmax (ng/ml) is the maximal plasma 
concentration of the inhibitor drug at the highest proposed clinical dose; MW is the 
molecular weight of the inhibitor drug; [I] is the inhibitor concentration used for R value 
prediction, and is equal to the highest proposed clinical dose divided by 250 ml for 
inhibitors of CYP3A4 or equal to Cmax otherwise; R is the predicted  R value.  
 
  
9
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Table 3-6. Predicted AUCRs 
Precipitant Drug Victim Drug Pathway fm Ki,u (µM) [I] (µM) AUCR RR P value 
[I]  
Reference 
fm 
Reference 
Quetiapine Chloroquine CYP3A4 0.25 0.70 2.82 1.25 2.17 5.29E-05 [203] [141] 
Chloroquine Duloxetine CYP2D6 0.65 14.03 4.84 1.20 1.65 1.34E-10 [183] [204] 
Chloroquine Risperidone CYP2D6 0.4 14.03 4.84 1.11 3.36 4.47E-05 [183] [205] 
Duloxetine Chloroquine 
CYP2D6 0.16 0.23 
0.18 1.08 1.65 1.34E-10 [196] [141] 
CYP3A4 0.25 8.02 
Duloxetine Loratadine 
CYP2C19 0.2 2.21 
0.18 1.08 1.56 7.43E-09 [196] [206] CYP2D6 0.1 0.23 
CYP3A4 0.7 8.02 
Chloroquine Quetiapine CYP2D6 0.11 14.03 4.84 1.03 2.17 5.29E-05 [183] [207] 
Chloroquine Loratadine CYP2D6 0.1 14.03 4.84 1.03 2.21 1.27E-05 [183] [206] 
Ropinirole Loratadine CYP2D6 0.1 0.71 0.10 1.01 2.05 3.47E-05 [199] [206] 
Chloroquine Trazodone CYP2D6 0 14.03 4.84 1.00 1.99 2.23E-05 [183] [208] 
Promethazine Tegaserod CYP2D6 0 0.22 0.07 1.00 2.2 1.28E-05 [197] [168] 
Risperidone Chloroquine CYP2D6 0 1.48 0.22 1.00 3.36 4.47E-05 [198] [141] 
 
Note: Pathway designates the CYP isoforms that are inhibited by the precipitant drugs; fm, fraction of metabolism carried out by the 
inhibited CYP pathway; Ki,u, unbound dissociation constant; [I], the maximal plasma concentration of the precipitant drug at the 
highest proposed clinical dose; AUCR, the predicted ratio of area under plasma concentration-time curve of the victim drug in the 
presence vs. absence of the precipitant drug; RR, the relative risk of myopathy; P value, p value of RR. 
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ii. Investigating mechanisms involved in the interaction between simvastatin and 
loratadine 
 
1. Introduction 
Amongst the fifteen DDIs identified in Chapter 2, the interaction between 
simvastatin and loratadine was of particular interest. The second part of this chapter is 
dedicated to the mechanistic investigations on this specific interaction with regard to 
inhibition of CYP-mediated metabolism by the two drugs. 
 
a. Why is the interaction between simvastatin and loratadine of particular interest? 
First, the interaction involves drugs that are both widely prescribed to millions of 
patients. It may thus be relevant to a large patient population, and have a significant 
impact on public health. It follows that understanding the mechanism underlying the 
interaction could also benefit a large number of patients. Simvastatin (trade name 
Zocor™) is an antihypercholesterolemic agent in the “statin” class of HMG-CoA 
reductase inhibitors, and is indicated for hyperlipidemia and secondary prevention of 
coronary heart diseases and cardiovascular events. It has become standard practice to 
initiate statin therapy immediately after acute coronary syndromes, regardless of lipid 
levels. Simvastatin is the second-best selling statin of the seven statins currently on the 
market. Loratadine (trade name Claritin™, Alavert™) is a long-acting, non-sedating 
tricyclic antihistamine with selective peripheral histamine H1 – receptor antagonistic 
activity. It is indicated for the relief of nasal and non-nasal symptoms of seasonal allergic 
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rhinitis and for the treatment of chronic idiopathic urticarial. Loratadine is one of most 
prescribed antihistamine [209].  
Second, statin-induced myopathy represents a significant barrier to maximizing 
the benefits of statin therapy and can be exacerbated by DDIs. This compliance-limiting 
adverse drug reaction occurs in 5-20% of patients treated with statins [210]. Typical 
features of statin induced myopathy include fatigue, muscle pain, muscle weakness, 
muscle tenderness, cramping and tendon pain [211]. In 2012, the FDA issued a black box 
warning against the use of the 80 mg dose of simvastatin because of increased risk of 
myopathy and rhabdomyolysis with this dose [212]. Concomitant use of drugs that are 
known to increase the systemic exposure to simvastatin are contraindicated for increased 
risk of myopathy and rhabdomyolysis. A few examples of these drugs are gemfibrozil, 
ketoconazole, itroconazole, cyclosporine and danazol [213]. Investigations into the 
mechanism of the simvastatin-loratadine interaction may help us to identify other drugs 
interactions with simvastatin, or statins in general, that share similar mechanisms.  
Third, myalgia is one of the common side effects of both loratadine and its major 
pharmacologically metabolite, desloratadine [88, 89]. Investigations on the interaction of 
simvastatin and loratadine may call public and scientific attention to loratadine-induced 
myopathy and DDIs that increase the risk for it, thereby potentially improving the 
outcomes of patients treated with loratadine. 
 
b. Pharmacokinetics and biotransformation of simvastatin 
Simvastatin is administered orally as an inactive lactone prodrug at doses of 10, 
20 and 40 mg daily. The drug is well absorbed (60 – 85%) but its bioavailability is low 
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(5%) because of high hepatic extraction (>80%). Food has little effect on absorption or 
bioavailability of simvastatin. In plasma, 95-98% of the drug is protein-bound [214]. The 
plasma concentration of simvastatin was 25.4 ± 9.5 ng/mL (0.06 ± 0.02 µM) following a 
80-mg oral dose given once daily for 7 days to healthy adults [202].  
Simvastatin lactone is hydrolyzed to the active β-hydroxyl form, simvastatin acid, 
both in the gastrointestinal tract and in the liver [215, 216]. The lactone and the acid exist 
in an equilibrium which is both pH- and temperature-dependent. The lactone is 
hydrolyzed to the acid both chemically and enzymatically by esterase and by paraoxonase, 
and the acid can be converted back to the lactone [216]. In the liver, both simvastatin and 
the acid are extensively metabolized. The major metabolites of simvastatin observed in 
human bile are 3’-hydroxy, 6’β-hydroxy and 6’-carboxy simvastatin [216]. Upon 
incubation of simvastatin with HLMs, 3’-hydroxy, 6’-exomethylene and 3’, 5’-
dihydrodiol simvastatin were the major metabolites identified in addition to the acid 
[217]. CYP3A4/5 were the major enzymes responsible for the metabolism of simvastatin 
in HLMs, with CYP3A4 exhibiting a 3-fold higher affinity than CYP3A5. TAO, a 
selective inhibitor of CYP3A4, inhibited the formation of 3’-hydroxy, 6’-exomethylene 
and 3’, 5’-dihydrodiol simvastatin from simvastatin in HLMs by 25%, 75% and 40%, 
respectively. CYP2E1, and possibly CYP2B6, also contributed to simvastatin metabolism, 
but to a much less extent [26]. Simvastatin acid is also primarily metabolized by CYP3A 
(86%) with a minor contribution from CYP2C8 (14%) [218]. Upon incubation with 
HLMs, 3’-hydroxy, 6’-exomethylene and 3’,5’-dihydrodiol simvastatin hydroxyl acid 
were the major metabolites formed from simvastatin acid [218]. Biotransformation of 
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simvastatin and the structures of its metabolites are illustrated in Figure 3-4. The kinetics 
of simvastatin metabolism in HLMs are described in Table 3-7. 
Simvastatin is mainly eliminated through hepatic metabolism, with only 13% 
being renally excreted unchanged. The serum half-life of simvastatin is 2-5 hours, thus 
the optimal time of dosing is in the evening when hepatic cholesterol synthesis is most 
active [25-27].  
 
c. Pharmacokinetics and biotransformation of loratadine 
Loratadine is given orally at a recommended dose of 10 mg daily. It is rapidly 
absorbed following a single 10 mg dose. Maximal plasma concentrations are observed 
1.3 hours and 2.4 hours after administration for loratadine and its major metabolite, 
desloratadine, respectively. The Cmaxs of loratadine and desloratadine were 4.1 ± 4.4 
ng/mL (10.7 ± 11.4 nM) and 3.9 ± 2.4 ng/mL (12.5 ± 7.7 nM), respectively, following a 
10 mg oral dose of loratadine [200]. Food and water intake can improve the 
bioavailability of loratadine [200]. In the plasma, 95-98% of loratadine is protein-bound. 
In the liver, loratadine is extensively metabolized via descarboethoxylation to 
desloratadine, and by oxidation or glucuronidation. Desloratadine is a pharmacologically 
active metabolite. The major circulating metabolites of loratadine include 3-hydroxy-
desloratadine glucuronide, dihydroxy-desloratadine-glucuronide, and several metabolites 
resulting from descarboethoxylation and oxidation. Upon incubation of loratadine with 
HLMs, the major metabolite formed is desloratadine. CYP3A4 is the predominant 
enzyme (70%) responsible for the conversion of loratadine to desloratadine, followed by 
CYP2C19 (20%) and CYP2D6 (10%) [206]. Desloratadine itself is eliminated by further 
 99 
 
metabolism. Biotransformation of loratadine and the structures of its metabolites are 
illustrated in Figure 3-5.  
 Approximately 84% of a 10 mg dose of loratadine was excreted into urine (41%) 
and feces (43%) in the form of metabolites within 10 days after oral administration. The 
half-life of loratadine is 8 hours, while that of desloratadine is 28 hours [209].  
 
d. Mechanisms of DDIs with simvastatin or loratadine 
Almost all the clinically significant DDIs with simvastatin that have been 
documented are pharmacokinetic, with the one exception being ezetimibe. Ezetimibe 
enhances the cholesterol-lowering effect of simvastatin in humans by selectively 
inhibiting dietary cholesterol absorption in the gastrointestinal tract [219]. One of the 
major mechanisms underlying the pharmacokinetic DDIs with simvastatin is inhibition of 
simvastatin metabolism. Drugs that are strong inhibitors of CYP3A4, including certain 
antifungal medications (itraconazole, ketoconazole, posaconazole) and macrolide 
antibiotics (erythromycin, clarithromycin, telithromycin) as well as HIV protease 
inhibitors, have been found to significantly increase the systemic exposure to simvastatin 
and are contraindicated with any dose of the drug. For example, erythromycin increased 
the AUC of simvastatin and simvastatin acid by 6.2-fold and 3.9-fold, respectively [220]; 
the AUC of simvastatin was 3059% higher in the presence of ritonavir/saquinavir 
compared to that of simvastatin alone [221]; posaconazole increased the AUC of 
simvastatin by 5- to 11-fold and that of simvastatin acid by 5- to 8-fold during co-
administration [222]. Some other drugs that inhibit CYP3A4 to a lesser extent are 
contraindicated with certain higher doses of simvastatin. These examples include 
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verapamil, diltiazem, amlodipine, ranolazine, amiodarone, dronedarone and ticagrelor. 
Since the incidence of statin-induced myopathy is dose-dependent, it is not surprising that 
the risk of myopathy in patients treated with simvastatin is higher during concomitant use 
of the above mentioned drugs. Patients receiving 20 to 80 mg of simvastatin daily were 
found to be 10-times more likely to experience myopathy with co-administration of 
verapamil than those without co-administration of verapamil [223]. 
As is the case for simvastatin, DDIs with loratadine are mostly due to inhibition 
of its metabolism. Loratadine has been found to interact with CYP3A4 inhibitors such as 
ketoconazole [224], clarithromycin [200], nefazodone [225] and cimetidine[224], which 
lead to a significantly increased systemic exposure to loratadine. The AUC of loratadine 
and desloratadine was increased by 76% and 49%, respectively, after coadministration 
with clarithromycin [200]. The plasma concentrations of loratadine and desloratadine 
were increased by 307% and 73%, respectively, after coadministration with ketoconazole 
[224]. Nefazodone increased the AUCs of loratadine and desloratadine by 39% and 12%, 
respectively. Moreover, the increased exposure to loratadine by nefazodone was 
associated with marked QTc prolongation that was correlated with loratadine plasma 
concentration [225]. These studies clearly demonstrate that CYP3A4 inhibitor drugs can 
significantly increase the systemic exposure to loratadine, thereby increasing the risk of 
adverse reactions to loratadine.  
 
e. Hypothesis and aims 
I wish to test the hypothesis that the interaction of simvastatin and loratadine is 
due, in part, to inhibition of metabolism, thereby leading to an increase in the systemic 
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exposure to either or both drugs and thus an increased risk of myopathy. To test this 
hypothesis, the following aims were pursued: 
1) Assess in vitro to what extent loratadine and its active metabolite, desloratadine, 
inhibit the metabolism of simvastatin and its active form, simvastatin acid, 
through incubation with HLMs; 
2) Assess in vitro to what extent simvastatin and simvastatin acid inhibit the 
metabolism of loratadine and desloratadine through incubation with HLMs. 
 
2. Methods  
a. Materials 
All the drugs and the metabolites were purchased from Toronto Research 
Chemicals (North York, Ontario, Canada). Glucose-6-phosphate, NADP and glucose-6-
phosphate dehydrogenase, acetonitrile (HPLC grade), methanol (HPLC grade), 
ammonium acetate and ammonium formate were purchased from Sigma-Aldrich (St. 
Louis, MO). Pooled human liver microsomes (HLMs) from 50 donors were purchased 
from BD Biosciences (Wobum, MA).  
 
b. Incubation with HLMs 
The drugs were dissolved and diluted in methanol to desired concentrations and 
were dried in a speed vacuum, followed by the addition of 200 mM potassium phosphate 
reaction buffer (pH 7.4) and HLMs. After pre-warming at 37 ◦C in a water bath for 5 min, 
reactions were initiated with the addition of a NADPH-regenerating system consisting of 
1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 3.3 mM MgCl2, and 0.4 U/mL glucose-
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6-phosphate dehydrogenase. In the negative control samples, the NADPH-regenerating 
system was replaced with the same volume of potassium phosphate reaction buffer. The 
final volume of the reaction mixture was 250 µL. The mixture was then incubated at 37 
◦C for an additional length of time that allows the reaction to be linear. The reaction was 
stopped with the addition of 500 µL ice-cold acetonitrile, followed by vigorous vortex-
mixing.  
 
c. Sample preparation 
25 µL of internal standard (1 µM lovastatin for simvastatin and simvastatin acid, 
1 µM fluoxetine for loratadine) were added to each sample. After brief centrifugation, the 
liquid phase was transferred to a disposable clean capped glass tube. Next, 500 µL of 100 
mM ammonium acetate (pH 4.5) and 6 mL of hexane/ethyl acetate (50/50, v/v) were 
added to the samples of simvastatin and simvastatin acid; and 500 µL of glycine/NaOH 
and 6 mL of hexane/ethyl acetate (50/50, v/v) were added to the samples of loratadine. 
The samples were agitated for 15 min on a shaker, followed by centrifugation at 13,000 
rpm and 4 ◦C for 10 min. The upper organic phase was transferred to a clean glass culture 
tube and was dried in a speed vacuum. The samples were reconstituted with 100 µL of 
mobile phase, and 80 µL were injected into the LC/MS/MS for analysis. 
 
d. Analytical methods using LC/MS/MS  
LC/MS/MS assays were developed for quantification of simvastatin, simvastatin 
acid and desloratadine. The MS/MS system was an API2000 MS/MS triple quadruple 
system (Applied Biosystems, Foster City, CA) equipped with a turbo ion spray, coupled 
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with a Shimadzu (Columbia, MD) HPLC system consisting of an LC-20 AB pump and 
SIL-20A HT auto-sampler (Applied Biosystems/MDS Sciex, Foster City, CA), operating 
under Analyst 1.5.1 software. A flow rate of 0.3 mL/min was used for sample analysis on 
a Sonoma C8 (West Berlin, NJ) analytical column (3 μ, 100 Å, 7.5 cm X 4.6 mm). The 
column was maintained at ambient temperature (∼23 ◦C), while the auto-sampler 
temperature was set at 25 ◦C.  
For quantification of simvastatin and simvastatin acid, an isocratic HPLC elution 
mobile phase was used, consisting of 85% acetonitrile and 15% ammonium acetate 5 mM 
(v/v). Lovastatin served as the internal standard. The turbo ionspray source temperature 
was optimized at 550 ◦C. The analytes were detected by monitoring the 
precursor→product ion transition using multiple reaction monitoring (MRM) scan mode. 
For simvastatin quantification, the MRM was performed at m/z 419.425→119.2 for 
simvastatin and 405.4→199.1 for lovastatin. Results were obtained using the following 
settings: curtain gas at 12, collision gas at 3, nebulizer gas (GS1) at 44, the turbo ionspray 
gas (GS2) at 35 and ionspray voltage at 5000. For simvastatin acid quantification, the 
MRM was performed at m/z 437.4→199.2 for simvastatin acid and 405.4→199.1 for 
lovastatin. Results were obtained using the following settings: curtain gas at 16, collision 
gas at 4, nebulizer gas (GS1) at 48, turbo ionspray gas (GS2) at 35 and ionspray voltage 
at 5500. The peak area was measured, and the peak area ratio of drug to internal standard 
and the concentration were calculated using Analyst 1.5.1 software. The limit of 
quantification was 50 nM for both simvastatin and simvastatin acid. The chromatography 
of simvastatin and simvastatin acid are presented in panel A and B of Figure 3-6.  
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For quantification of desloratadine, the mobile phase consisted of 85% methanol 
and 15% 25 mM ammonium formate. Fluoxetine served as the internal standard. The 
turbo ionspray source temperature was optimized at 500 ◦C. The MRM was performed at 
m/z 311.2→258.9 for desloratadine and 310.3→44.0 for fluoxetine. Results were 
obtained using the following settings: curtain gas at 14, collision gas at 6, nebulizer gas 
(GS1) at 40, turbo ionspray gas (GS2) at 30 and ionspray voltage at 5500. The peak area 
was measured, and the peak area ratio of drug to internal standard and the concentration 
were calculated using Analyst 1.5.1 software. The limit of quantification for 
desloratadine was 25 nM. The chromatography of desloratadine is presented in panel C of 
Figure 3-6. 
 
3. Original experimental results 
a. Inhibition of simvastatin and simvastatin acid metabolism by loratadine and 
desloratadine 
I hypothesize that loratadine and/or desloratadine inhibit the hepatic metabolism 
of simvastatin and/or simvastatin acid, thereby increasing the systemic exposure to 
simvastatin and/or simvastatin acid. To test this hypothesis, I first examined in vitro the 
CYP inhibition profile of loratadine and desloratadine using fluorometric assays, in order 
to assess whether or not they have potential to inhibit the metabolism of simvastatin and 
simvastatin acid. Then I evaluated the impact of loratadine and desloratadine on the 
hepatic metabolism of simvastatin and simvastatin acid in a more physiologically 
relevant system, HLMs.  
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1) Inhibition profiles of loratadine and desloratadine for the major CYPs 
Using fluorometric assays, the IC50s of loratadine and desloratadine for the major 
CYPs were evaluated and are shown in Table 3-8. The IC50 of CYP2C8 could not be 
determined because of abnormal kinetics. Consistent with the previous definitions on 
inhibitory potency, the inhibitors with IC50s less than 20 µM were considered as 
relatively potent, those with IC50s between 20 µM and 200 µM were considered as 
relatively moderate, and those with IC50s greater than 200 µM were considered as 
relatively weak.  Loratadine was therefore a relatively potent inhibitor of CYP2D6, 
CYP2C9 and CYP2B6, a relatively moderate inhibitor of CYP2C19 and CYP3A4, and a 
relatively weak inhibitor of CYP1A2. Desloratadine exhibited relatively potent inhibition 
for CYP2D6 and CYP 3A4, relatively moderate inhibition for CYP2B6 and CYP 2C19, 
and relatively weak inhibition of CYP1A2 and CYP 2C9. The inhibitions, particularly 
those involving CYP3A4, indicated that both loratadine and desloratadine have the 
potential to inhibit the metabolism of simvastatin and simvastatin acid.  
 
2) IC50s of loratadine and desloratadine for the depletion of simvastatin and 
simvastatin acid  in HLMs 
Because both simvastatin and simvastatin acid are converted into multiple 
metabolites, measuring disappearance of substrate is preferred over monitoring 
metabolite formation as an approach to evaluating the rate of metabolism.  
I first defined the experimental conditions under which the initial reaction 
velocity is linear. Upon incubation of 1 μM simvastatin with 0.05 or 0.1 mg/ml HLMs for 
up to 30 min, simvastatin disappeared from the incubation mixture linearly for up to 10 
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min at both the HLM concentrations (Figure 3-7 A). Similarly, incubation of simvastatin 
acid with 0.2 or 0.4 mg/ml HLM showed that the metabolism was linear for up to 20 min 
(Figure 3-7 B). Since a sufficient amount of substrate needs to be depleted to detect an 
inhibition, in the subsequent incubations, simvastatin was incubated with 0.1 mg/ml 
HLMs for 10 min, and simvastatin acid was incubated with 0.4 mg/ml HLMs for 20 min. 
To test whether loratadine and desloratadine inhibit the metabolism of simvastatin 
in HLMs, a single concentration of simvastatin was incubated with various 
concentrations of loratadine or desloratadine. Ketoconazole was used as a control 
inhibitor because it is well known to inhibit CYP3A4 and simvastatin metabolism. The 
IC50s (95% CI) of loratadine, desloratadine and ketoconazole for simvastatin metabolism 
were 20.3 (11, 37.1) μM, 12.3 (4.6, 33.2) μM, and 1.7 (1.1, 2.8) μM, respectively (Figure 
3-8 A, C, E). Similarly, the effects of these drugs on the metabolism of simvastatin acid 
were evaluated. The IC50s (95% CI) were 129.5 (75, 223.4) μM, 86.0 (38.1, 194.3), and 
0.48 (0.17, 1.38) μM for loratadine, desloratadine and ketoconazole, respectively (Figure 
3-8 B, D, F). The IC50s suggested that loratadine and desloratadine had a greater impact 
on the hepatic metabolism of simvastatin than on that of simvastatin acid.  In addition, 
desloratadine had more potential than loratadine to inhibit the metabolism of both 
simvastatin and simvastatin acid, consistent with its smaller IC50 for CYP3A4.  
 
b. Inhibition of loratadine metabolism by simvastatin and simvastatin acid 
I hypothesize that simvastatin and/or simvastatin acid inhibit the hepatic 
metabolism of loratadine, thereby increasing the systemic exposure to loratadine. Using 
the same approach, I tested this hypothesis first using CYP fluorometric assays to assess 
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whether or not simvastatin and simvastatin acid is able to inhibit loratadine metabolism. I 
then evaluated the impact of simvastatin and simvastatin acid on the hepatic metabolism 
of loratadine in HLMs.  
 
1) Inhibition profiles of simvastatin and simvastatin acid for the major CYPs 
Using fluorometric assays, the IC50s of simvastatin and simvastatin acid that were 
estimated for the major CYPs are shown in Table 3-9. Simvastatin showed a relatively 
potent inhibition for CYP3A4, CYP2C9 and 2C8, relatively mild inhibition of CYP2D6, 
CYP2C19 and CYP2B6 and no inhibition of CYP1A2 at concentrations up to 100 μM. 
Simvastatin acid showed a relatively potent inhibition of CYP3A4, a relatively mild 
inhibition for CYP2C8 and 2C9, and no effect on the other isoforms at concentrations up 
to 100 μM.  
 
2) IC50s of simvastatin and simvastatin acid for desloratadine formation in HLMs 
Because desloratadine is the major metabolite of loratadine, its formation rate was 
used to evaluate inhibition of loratadine metabolism. Since the Km and Vmax of loratadine 
metabolism had not been reported, I first investigated the kinetics of loratadine 
metabolism in HLMs in order to optimize experimental conditions for accurate 
estimation of inhibitory potency. Upon incubation of 50 μM loratadine with 0.1 mg/ml 
HLMs for up to 60 min, the initial reaction velocity measured by the formation of 
desloratadine was found to be linear for up to 10 min (Figure 3-9 A). The metabolism of 
loratadine in HLMs exhibited typical Michaelis-Menten kinetics with a Km of 0.90 ± 0.23 
μM and a Vmax of 4.41 ± 0.25 nmol/min/mg HLMs (Figure 3-9 B).  
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To test whether simvastatin and simvastatin acid inhibit loratadine metabolism in 
HLMs, a single concentration of loratadine was incubated with various concentrations of 
simvastatin or simvastatin acid. The IC50s (95%CI) of simvastatin and simvastatin acid 
for desloratadine formation was 8.2 (4.9, 13.8) μM and 11.8 (6.8, 20.5) μM, respectively 
(Figure 3-10). 
 
3) Mode of inhibition and Ki estimates 
 Upon incubation of loratadine at various concentrations, both the inhibition by 
simvastatin and that by simvastatin acid were identified as noncompetitive with Kis of 6.9 
± 0.8 µM and 18.0 ± 3.6 µM, respectively (Figure 3-11). 
 
4. Discussion 
During this work, I have addressed the hypothesis that the interaction of 
simvastatin and loratadine was due, in part, to the mutual inhibition of their metabolism. I 
found that both loratadine and desloratadine were able to inhibit the major CYP isoform 
involved in simvastatin metabolism - CYP3A4. They could also inhibit the metabolism of 
its active metabolite, simvastatin acid. To confirm these inhibitory effects, I further 
examined the metabolism of simvastatin and simvastatin acid in the presence of 
loratadine and desloratadine in pooled HLMs. I found that loratadine and desloratadine 
inhibited the depletion of simvastatin with IC50s of 20.3 μM and 12.3 μM, respectively, 
and that of simvastatin acid with IC50s of 129.5 μM and 86.0 μM, respectively. Assuming 
that these inhibitions are reversible, Kis of these inhibitory reactions can be approximated 
using IC50 / (1 + [S] / Km). Given that these experiments were carried out at a substrate 
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concentration (1 μM) that was far below the Km (> 20.9 μM for simvastatin and > 47 μM 
for simvastatin acid), the Kis can be approximated by the IC50s since [S] / Km approaches 
zero in these cases.  
Because the IC50s determined in HLMs represent the inhibitory potential for the 
total metabolism of the substrates, R = 1 + [I]/Ki,u can be applied to estimate the ratio of 
total intrinsic clearance in the presence and absence of the inhibitor drugs. An R value in 
such cases can also be interpreted as a crude estimate of the change in the AUC of the 
substrate. With respect to the metabolism of simvastatin and simvastatin acid, the 
predicted R values of loratadine and desloratadine were close to unity due to the low 
circulating plasma concentrations (Table 3-10). These data imply that the inhibitory 
effects of loratadine and desloratadine on the metabolism of simvastatin and simvastatin 
acid observed in vitro are unlikely to produce any significant clinical consequences.  
Using a similar approach, I also tested the effects of simvastatin and simvastatin 
acid on the metabolism of loratadine. Both simvastatin and simvastatin acid exhibited 
inhibition for the major CYPs, especially for CYP3A4, the isoform primarily responsible 
for loratadine metabolism, suggesting a possible inhibition of loratadine metabolism in 
vivo. The follow-up experiments using HLMs showed that simvastatin and simvastatin 
acid were able to inhibit the metabolism of loratadine to desloratadine with IC50s of 8.2 
μM and 11.8 μM, respectively. Both inhibitory reactions were further identified as 
noncompetitive with Kis of 6.9 µM and 3.6 µM. The R values predicted for simvastatin 
and simvastatin acid, assuming the Cmax of simvastatin acid equal to that of simvastatin 
(0.06 µM), were also close to unity (Table 3-10), indicating that the exposure to 
loratadine would not be significantly different with coadministration of simvastatin. 
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These data together suggest that inhibition of metabolism is unlikely to be an 
important mechanism underlying the interaction between simvastatin and loratadine 
observed in the population studies carried out as part of this work. 
 
  
1
1
1
 
Table 3-7. Kinetics of simvastatin and simvastatin acid metabolism in HLMs [217, 218]. 
 Simvastatin Simvastatin Acid 
Metabolite 3'-Hydroxy 6'-Exomethylene 3', 5'-Dihydrodiol 3'-Hydroxy 6'-Exomethylene 3', 5'-Dihydrodiol 
Km (µM) 20.9 ± 7.8 36.2 ± 15.5 35. 0 ± 5.6 47 ± 12 47 ± 21 76 ± 35 
Vmax 
(pmol/min/mg) 
2066.1 ± 799.5 1293.4 ± 447.1 2536.1 ± 1124.1 0.86 ± 0.26 0.59 ± 0.16 1.9 ± 1.8 
CLint 
(ml/min/mg) 
0.098 ± 0.007 0.037 ± 0.011 0.072 ± 0.026 0.02 ± 0.01 0.015 ± 0.01 0.02 ± 0.01 
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Figure 3-4. Biotransformation of simvastatin in humans [216, 218]. Note that the 
metabolism of simvastatin and simvastatin acid exists in parallel. The figure shows only 
the structures of simvastatin metabolites. Those of simvastatin acid metabolites are 
similar except that the lactone is replaced by an open acid. 
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Figure 3-5. Biotransformation of loratadine in humans [209, 226]. 
  
Loratadine Descarboethoxyloratadine 
(Desloratadine, DL) 
3-Hydroxy-desloratadine 
(3-OH-DL) 
3-OH-DL-glucuronide Dihydroxy-DL-glucuronide 
CYP3A4 (70%) 
CYP2D6 
CYP2C19 
UGT1A1 
UGT1A3 
UGT2B15 
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Figure 3-6. Chromatography of simvastatin (A), simvastatin acid (B) and desloratadine 
(C). Lovastatin served as the internal standard for simvastatin and simvastatin acid, and 
fluoxetine served as the internal standard for desloratadine. The analytes and the internal 
standards are shown in blue and red, respectively. 
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Table 3-8. IC50s of loratadine and desloratadine for the major CYPs 
 IC50 (95% CI, μM) 
1A2 2B6 2C8 2C9 2C19 2D6 3A4 
Loratadine 630 
(438, 906.3) 
11.9 
(9.9, 14.4) 
ND 
12.35 
(7.8, 19.45) 
21.3 
(15.3, 29.7) 
9.1 
(8.3, 9.9) 
33.2 
(30.1, 36.6) 
Desloratadine 506.6 
(397.2, 646.3) 
29.3 
(25.8, 33.4) 
ND 
158.9 
(107.1, 235.7) 
59.0 
(43.2, 80.7) 
14.0 
(13.2, 14.9) 
19.2 
(17.6, 21.0) 
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Figure 3-7. Depletion of simvastatin (A) and simvastatin acid (B) in relation to incubation 
time and HLM concentration. 1 µM simvastatin was incubated with 0.05 (●) and 0.1 (□) 
mg/ml HLMs and disappeared linearly up to 10 min. 1 µM simvastatin acid was 
incubated with 0.2 (●) and 0.4 (□) mg/ml HLMs and disappeared linearly also up to 10 
min.   
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Figure 3-8. Inhibition of simvastatin (A, C, E) and simvastatin acid (B, D, F) metabolism 
in HLMs by loratadine (A and B), desloratadine (C and D), and ketoconazole (E and F). 
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Table 3-9. IC50s of simvastatin and simvastatin acid for the major CYPs 
 IC50 (95% CI, μM) 
1A2 2B6 2C8 2C9 2C19 2D6 3A4 
Simvastatin 
>100 
89.3 
(65.8, 121.2) 
17.2 
(13.1, 22.7) 
6.2 
(5.4, 7.0) 
43.4 
(37.1, 50.7) 
41.3 
(35.1, 48.5) 
3.1 
(1.4, 7.2) 
Simvastatin acid 
>100 >100 
50.7 
(14.3, 179.7) 
96.6 
(53.5, 174.4) 
>100 >100 
10.7 
(4.9, 23.3) 
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Figure 3-9. Kinetics of loratadine metabolism in HLMs. The metabolism of loratadine 
was linear for up to 10 min (A). The Michaelis-Menten kinetics of loratadine metabolism 
in HLMs is shown in (B). DL, desloratadine.  
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Figure 3-10. IC50 curves of the inhibition of desloratadine (DL) formation by simvastatin 
(A) and simvastatin acid (B) in HLMs.  
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Figure 3-11. Kis for the inhibition of desloratdine formation by simvastatin (A) and 
simvastatin acid (B) in HLMs. 
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Table 3-8 Predicted R values 
Precipitant 
Drug 
Victim Drug 
Ki 
(µM) 
fu,inc 
Ki,u 
(µM) 
Cmax 
(ng/ml) 
MW 
(g/mol) 
Cmax 
(µM) 
R 
value 
Cmax 
Reference 
Loratadine Simvastatin 20.3 0.93 18.89 4.12 382.9 0.01 1.00 [200] 
Desloratadine Simvastatin 12.3 0.73 9.02 3.891 310.8 0.01 1.00 [200] 
Desloratadine Simvastatin 12.3 0.73 9.02 4.692 310.8 0.02 1.00 [227] 
Loratadine 
Simvastatin 
Acid 
129.5 0.93 120.48 4.12 382.9 0.01 1.00 [200] 
Desloratadine 
Simvastatin 
Acid 
86 0.73 63.08 3.89 310.8 0.01 1.00 [200] 
Desloratadine 
Simvastatin 
Acid 
86 0.73 63.08 4.69 310.8 0.02 1.00 [227] 
Simvastatin Loratadine 6.9 0.93 6.42 25.4 418.7 0.06 1.01 [202] 
Simvastatin 
Acid 
Loratadine 3.6 0.93 3.35 25.4 436.6 0.06 1.02 [202] 
 
Note: 
1. Peak plasma concentration observed following a 10 mg oral dose of loratadine. 
2. Peak plasma concentration observed following a 5 mg oral dose of desloratadine. 
 
Ki designates the dissociation constant determined in vitro, and is approximated by the IC50 for the inhibition of simvastatin and 
simvastatin acid; fu,inc, the fraction of unbound in incubation mixtures; Ki,u, unbound dissociation constant estimated by Ki * fu,inc; 
Cmax, the maximal plasma concentration of the precipitant drug at the highest proposed clinical dose; MW, the molecular weight of 
the precipitant drug; R value is estimated as  R = 1 + [I]/Ki,u. 
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Chapter 4. In vitro assessment of inhibition of OATPs 
 
1. Introduction 
a. Role of transporters in drug disposition 
 Approximately 900 transporter genes have been annotated in the human genome 
[228]. They encode for transporter proteins that are responsible for influx of essential 
nutrients and ions and the efflux of toxins, drugs and other xenobiotics. Transporter 
proteins thought to be involved in the pharmacokinetics and pharmacodynamics of drugs 
are from two superfamilies - the solute carrier (SLC) superfamily and the adenosine 
triphosphate (ATP) - binding cassette (ABC) superfamily [229]. Transporters important 
to pharmacokinetics generally are located in intestinal, renal and hepatic epithelia as well 
as in the endothelium of the blood–brain barrier, where they control the tissue distribution, 
selective absorption and elimination of drugs across cell membranes [83].  
Transporters that belong to the ABC superfamily rely on ATP hydrolysis to 
actively pump their substrates across the cell membrane. There are 49 genes that have 
been identified encoding ABC proteins that can be grouped into seven families from 
ABCA to ABCG [230]. Many ABC transporters mediate the efflux of drugs and their 
metabolites from the intracellular space of the epithelial cells. They prevent xenobiotics 
from reaching vital organs such as the brain, the cerebrospinal fluid, the testis and the 
fetus. Active efflux via ABC transporters thus acts as a defense mechanism that the body 
uses to decrease exposure to potentially toxic xenobiotics. On the other hand, ABC 
transporter-mediated active efflux impairs the absorption and distribution of drugs to 
their target sites. P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein 
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(BCRP, ABCG2) expressed on the intestinal luminal membrane reduce drug absorption 
by pumping drug molecules that have entered enterocytes back into the gastrointestinal 
lumen. P-gp, BCRP and multidrug resistance proteins (MRPs) expressed in brain 
capillary endothelial cells prevent the drugs from passing the blood-brain barrier [36, 
231]. Overexpressing efflux ABC transporters such as P-gp and BCRP is one of the 
mechanisms employed by cancer cells to develop resistance to chemotherapy. In addition, 
efflux via ABC transporters across the canalicular membrane of hepatocytes and the 
luminal membrane of kidney proximal tubule is an important mechanism for 
hepatobiliary and renal excretion of drugs and their metabolites [36, 83]. 
Transporters in the SLC superfamily mediate facilitated diffusion and active 
transporter of a variety of ions, endogenous compounds and xenobiotics. There are 315 
genes annotated for SLC transporter proteins in the human genome, which are grouped 
into 48 families [231]. Many SLC transporters serve as drug targets, including serotonin 
(5-HT) transporter and dopamine transporters. Some other SLC transporters, such as ones 
from SLCO, SLC15, SLC22 and SLC47 families, have been shown to play a role in the 
absorption, distribution and excretion of drugs and clinical DDIs [36]. For example, 
organic anion transporting polypeptides (OATPs) and peptide transporter 1 (PEPT1) 
expressed in the intestinal apical membrane mediate the absorption of drugs. OATPs, 
organic anion transporters (OATs) and organic cation transporter (OCTs) expressed on 
the hepatic sinusoidal membrane and the basolateral membrane of kidney proximal 
tubules that mediate the hepatic and renal uptake of drugs from the blood.  
 There has been an increasing recognition in recent years that transporters from the 
ABC and SLC superfamilies play an important role in drug disposition and clinical DDIs. 
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In a white paper published by the International Transporter Consortium [36], seven 
transporters were identified as having compelling clinical evidence of involvement in 
pharmacokinetics and DDIs. These transporters included P-gp, BCRP, OATP1B1, 
OATP1B3, OCT2, OAT1 and OAT3 [36]. The white paper and the FDA guideline 
recommend characterizing in vitro the role of these transporters in the disposition of 
investigational drugs during drug development to assess their potential for clinical DDIs 
[13, 36].  
 
b. OATPs: characteristics, role in drug disposition and clinical DDIs 
 Amongst the drugs transporters mentioned above, OATPs are of particular 
interest because they have been shown to be particularly important to pharmacokinetics 
and clinical DDIs. Also, OATPs have a broad substrate spectrum as discussed later. Since 
all the drugs involved in the significant DDIs identified previously are administered 
orally, it is possible that these drugs are substrates of OATPs and interact via inhibition of 
OATPs.  
 OATPs are a family of membrane transport proteins that mediate the sodium-
independent transport of a diverse range of amphipathic organic anions, neutral 
compounds and even some cations. OATPs belong to the solute carrier (SLC) 
superfamily as members of the solute carrier organic anion transporter family (SLCO) 
[232]. In humans, eleven members have been identified and grouped into six subfamilies. 
The general predicted OATP structure consists of thirteen transmembrane domains [233]. 
The mechanism of transport is believed to involve anion exchange by coupling the 
cellular uptake of substrate with the efflux of neutralizing anions such as bicarbonate, 
 126 
 
glutathione or glutathione-S-conjugates [232]. The endogenous substrates of OATPs 
include bile acids, steroid conjugates, thyroid hormones, prostaglandins and bilirubin 
glucuronide. OATPs are also responsible for the transport of a number of drugs and 
xenobiotic substances [234]. Table 4-1 provides a summary of characteristics of the 
OATPs in humans and examples of their substrates [235].  
Particular attention has been paid to OATP1B1, 1B3 and 2A1 as they are the 
transporter proteins demonstrated to this point to be most engaged in drug disposition 
[232]. The mechanisms of hepatic uptake include passive diffusion along an 
electrochemical gradient, active transport for anionic compounds, and facilitative 
diffusion for cationic compounds [235]. Expressed on the sinusoidal membrane of 
hepatocytes, OATP1B1, 1B3 and 2A1 contribute to the active uptake of drugs from the 
portal venous blood into hepatocytes [236]. The substrates of OATP1B1, 1B3 and 2B1 
are mainly anionic amphipathic compounds with relatively high molecular weights (>350) 
and low plasma-protein unbound fraction (<30%), such as bile salts (taurocholate), 
several conjugated metabolites of steroids including estradiol-17β-D-glucuronide 
(E217βDG), thyroid hormones (T3, T4), statins, angiotensin converting enzyme 
inhibitors, and angiotensin II receptor antagonists [237]. It is worth noting that there is a 
significant overlap in the substrate spectrum among these three OATPs. 
Hepatic uptake is the prerequisite for the subsequent hepatic metabolism of drugs 
and the elimination of drugs themselves via the bile. Once a compound is in the 
intracellular space of a hepatocyte, it can be eliminated through any of the three routes: 
metabolism by hepatic enzymes, excretion into bile, or return to the sinusoids via 
sinusoidal efflux. At a given time, the intra-hepatocyte concentration of an OATP 
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substrate reflects the net balance between its hepatic uptake via OATPs and its hepatic 
clearance through metabolism, biliary excretion or sinusoidal efflux. OATPs thus are a 
determinant of the hepatic exposure for their substrates [235].  
This explains the association of OATPs with pharmacokinetics, efficacy and 
toxicity of their substrate drugs. First, for a drug whose target site of action is in the liver, 
OATPs can affect its efficacy by determining its intracellular concentration in 
hepatocytes. One example is simvastatin which targets HMG-CoA reductase in 
hepatocytes. The active form of simvastatin, simvastatin acid, is a substrate of both 
OAP1B1 and 1B3 [238]. In individuals carrying the less functional variant allele at 
c.521T>C SNP of SLCO1B1, the gene that encodes for OATP1B1, the reduction in the 
LDL cholesterol following simvastatin therapy was 1.3% lower per variant allele [239]. 
Second, for a drug that is actively excreted into bile or rapidly metabolized in hepatocytes, 
its hepatic uptake is the rate-limiting step in its hepatic clearance. OATPs thus can play a 
major role in determining such a drug’s hepatic elimination. This can be observed from 
the following equation, 
𝐶𝐿𝑖𝑛𝑡,𝑎𝑙𝑙 = 𝑃𝑆𝑢𝑝𝑡𝑎𝑘𝑒 ×
𝑃𝑆𝑒𝑓𝑓+𝐶𝐿𝑚𝑒𝑡
𝑃𝑆𝑒𝑓𝑓+𝐶𝐿𝑚𝑒𝑡+𝑃𝑆𝑏𝑎𝑐𝑘
 Eq. 4-1 
Where CLint,all is the overall hepatic clearance,  PSuptake is the rate of hepatic uptake, PSeff 
is the rate of biliary excretion, CLmet is the clearance of hepatic metabolism, and PSback is 
the efflux rate from hepatocytes to sinusoids. The overall hepatic clearance (CLint,all) 
approaches the rate of hepatic uptake (PSuptake) when the sinusoidal efflux (PSback) is 
much smaller than the total clearance of hepatic metabolism and biliary excretion (PSeff + 
CLmet) [240]. This is exemplified by atorvastatin, a substrate of OATP1B1 and 2B1 
extensively metabolized by CYP3A4. In a study by Maeda et al., following an oral 
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microdose (33 µg) of atorvastatin in healthy volunteers, the dose-normalized AUC was 
increased by 22-fold with coadministration of rifampin (a strong inhibitor of 
OATP1B1/1B3) but remained unchanged with intravenous coadministration of 
itraconazole (a strong inhibitor of CYP3A4) [241]. These data suggested that the hepatic 
clearance of atorvastatin was mainly determined by the rate of its hepatic uptake in 
humans. When the function of OATPs is impaired, due to either inhibition by drugs or 
genetic variation, OATP substrate drugs that are primarily eliminated through hepatic 
metabolism are expected to have reduced hepatic clearance and increased systemic 
exposure, potentially resulting in increased risk of toxicity at peripheral tissues. Taking 
simvastatin as an example again, in patients with the C allele at SLCO1B1 rs4149056, the 
odds ratio for statin-induced myopathy was 4.5 per copy as compared with the wild type 
allele [239]. This observation is so clinically important that the Clinical 
Pharmacogenetics Implementation Consortium (CPIC) has published therapeutic 
guidelines for the use of simvastatin in the clinic based on the genotype of SLCO1B1 
[242].  
 It has been increasingly recognized that OATPs represents an important site of 
DDIs since mechanistic studies have revealed that the interaction between cerivastatin 
and cyclosporine was caused by inhibition of OATP1B1 [243, 244]. Potent inhibitors of 
OATPs, such as cyclosporine, rifampin, gemfibrozil and itraconazole, have been reported 
to cause significant clinical DDIs with the drugs that rely on OATPs for hepatic uptake. 
DDIs involving inhibition of hepatic uptake via OATPs often also involve inhibition of 
hepatic metabolism by CYPs, leading to a remarkable increase in the systemic exposure 
to the victim drugs and the risk of adverse events. A typical example is the interaction of 
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cerivastatin and gemfibrozil. The interaction is caused by both the inhibition of the 
hepatic uptake of cerivastatin via OATP1B1 by gemfibrozil, and the inhibition of 
cerivastatin metabolism through CYP2C8 by the glucuronide metabolite of gemfibrozil 
[245, 246]. Consequently, gemfibrozil increased the AUC of cerivastatin by 559% in a 
pharmacokinetic study [247]. It also increased the risk of rhabdomyolysis for cerivastatin 
by 5-fold in a population-based cohort study [52]. Another example is cyclosporine and 
atorvastatin. Cyclosporine not only inhibits the OATP1B1-dependent hepatic uptake of 
atorvastatin in vitro [248], but also inhibits atorvastatin metabolism by CYP3A4. 
Coadministration of cyclosporine was shown to increase the AUC of atorvastatin by 9- to 
-15- fold [235]. 
 
c. Experimental systems for assessing uptake transporter activity 
 Understanding and predicting the role of transporters in pharmacokinetics and 
DDIs require appropriate characterization of uptake and efflux kinetics in vitro. For 
uptake transporters, there are two general types of in vitro systems commonly used to 
study their kinetics, recombinant cell and whole-cell systems [249].  
Recombinant cells, including Xenopus laevis oocytes or immortalized cell lines, 
overexpressing transporter proteins of interest are commonly used to estimate the kinetics 
and inhibition of uptake transporters [27]. Oocyte systems are established by injecting 
cDNA of the transporter to allow overexpression [236]. Because of the large volume of 
oocytes, the time course of the compound accumulation in oocytes can remain linear for a 
long period of time. Oocyte systems therefore have the advantage of providing high 
signal-to-noise ratios in assessing uptake of drugs [237]. However, due to cDNA 
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injection, oocyte systems are not appropriate for high-throughput screening and often 
show a large variability in the expression level of the transporter [237]. More importantly, 
some data suggest that transporter kinetic parameters determined using oocytes are not 
always comparable to those generated in mammalian cells [249].  
Immortalized cell lines transfected with cDNAs and stably overexpressing single 
or multiple transporters are thus preferred over oocytes for studying uptake transporters 
[27]. They allow constitutive expression of the transporter proteins of interest under 
certain selection pressure. HEK293 and CHO cells are the two host mammalian cell lines 
most commonly used because they demonstrate low endogenous transporter activity and 
are easy to maintain [249]. Additional advantages of these cell lines include that they are 
cost-effective, easy to perform experiments, and applicable to high-throughput screening 
[249]. There are numerous examples demonstrating the value of these cell lines in 
studying DDIs involving hepatic uptake transporters. One such example is using HEK293 
cells stably overexpressing OATP1B1 and OATP1B3 to examine the inhibition of 
OATP-mediated pravastatin uptake by several widely prescribed oral antidiabetic drugs 
[250]. As noted above, transporters often have overlapping substrate spectrums. 
Therefore, cell lines transfected with a single transporter often lack the endogenous 
uptake or efflux transporters to provide a complete transport mechanism for a drug. It 
may even be challenging to predict the true in vivo situation using cell lines transfected 
with multiple transporters [251]. In addition, a large variability has been observed with 
the data generated using these recombinant cell lines due to inconsistency in cell handling 
and experimental procedures [249].  
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Whole-cell systems refer to those derived cell lines such as Caco-2 and MDCK, 
and primary human or rodent hepatocytes. Caco-2 and MDCK cell lines are often used to 
study efflux transporters or the interplay between uptake and efflux transporters 
expressed in the intestine and in the kidneys, respectively [249]. These cells lines can also 
stably or transiently overexpress the transporters of interest when cDNA transfection 
methods are used. The cells are seeded on a permeable membrane support to form a tight 
polarized cell monolayer, with uptake transporters localized in the basolateral membrane 
and efflux transporters localized in the apical membrane. The transport of drugs is 
determined by measuring the flux through the cell monolayer from the basolateral 
compartment to the apical compartment [252, 253]. Because apparent uptake in these 
models is confounded by apical efflux, one of the limitations is possible misidentification 
of uptake transporter substrates for non-substrates due to saturation of efflux transporters 
[249].  
Primary hepatocytes, either freshly isolated or cryopreserved, have been widely 
accepted as the gold-standard models for identification of substrates of hepatic uptake 
transporters and for prediction of hepatic clearance [249]. They can be optimized to 
estimate kinetic parameters specific to uptake, metabolism, or efflux, as well as the 
interplay of these processes [249]. Cryopreserved hepatocytes are more commonly used 
than freshly isolated hepatocytes because they are more available and the majority of 
hepatic drug transporters appear to be preserved [254]. For studying uptake transporters, 
primary hepatocytes are often used in suspension because transporter function decreases 
quickly when cells are plated [255]. However, technical difficulties may arise as the 
viability of suspended hepatocytes decreases more rapidly than that of plated hepatocytes 
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[256]. Primary hepatocytes have been shown to be valuable tools for mechanistic studies 
on DDIs. In a study by Noe et al, gemfibrozil inhibited the OATP1B1-, OATP2B1-, and 
OATP1B3-mediated fluvastatin transport in individually transfected cell lines by 97, 70, 
and 62%, respectively, whereas only 27% inhibition was observed for fluvastatin uptake 
into primary human hepatocytes [251]. This study highlighted the advantages of 
hepatocytes as compared with recombinant cell lines in investigating the role of uptake 
transporters in DDIs. The application of human primary hepatocytes to transporter studies 
has been greatly limited by hepatocyte availability. Rat hepatocytes are a useful substitute 
in some cases. There is no true homologue of human OATP1B1/1B3 in rodents, but 
rodent OATP1B2 has been found very similar in function and substrate specificity to 
those human isoforms [232, 257]. Another issue often encountered in transporter studies 
using hepatocytes is that, due to the lack of specific inhibitors and substrates, it is often 
challenging to determine which individual isoforms of specific uptake transporters are 
involved in uptake of compounds [249]. A common goal in this research is therefore to 
identify probe substrates and specific inhibitors for individual clinically important 
transporters and to set up standards for experimental procedures similar to those that are 
described previously for CYPs.  
 In addition to the in vitro systems discussed above, an oatp1b2-/- knockout mouse 
model and humanized OATP1B1 and OATP1B3 transgenic mouse models have been 
developed. These mouse models have contributed to a better understanding of the role of 
hepatic uptake transporters for the disposition of drugs in vivo [257-260].  
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d. Prediction of transporter-mediated DDIs 
 Current methods for the prediction of DDIs due to inhibition of hepatic uptake 
focus on inhibition of OATPs. These methods are extensions of those derived for CYP-
mediated DDIs and can be grouped into three classes, static models (R value), 
mechanistic static models and PBPK models [27]. 
The static model estimates an R value as R = 1 + [I]inlet,max /Ki, where [I]inlet,max is 
the maximum inhibitor concentration at the inlet to the liver, and Ki is the dissociation 
constant determined for the affected uptake transporter in vitro [27]. [I]inlet,max is 
estimated as [I]inlet,max = Cmax + (ka x Dose x FaFg/Qh), where Cmax is the maximum 
systemic plasma concentration of the inhibitor drug, dose is the highest dose of the 
inhibitor in clinical use, FaFg is the fraction of the inhibitor dose that reaches the liver, ka 
is the absorption rate constant of the inhibitor, and Qh is the estimated hepatic blood flow 
(1500 mL/min) [13]. When values of FaFg and ka are not available, the theoretical 
maximum of 1 and 0.1 min-1 are assumed, respectively, for a conservative prediction [13]. 
When IC50 is evaluated at a substrate concentration well below Km for the uptake 
transporter, Ki can be approximated by IC50 based on Ki = IC50 / (1 + [S]/Km) [261]. In 
contrast to CYPs, well-defined probe substrates and specific inhibitor are not yet 
available for uptake transporters, and this issue contributes to the huge variability in the 
reported IC50s for OATPs [27]. A universal cutoff for R value thus has not been identified 
[27]. The recommendation of the International Transporter Consortium is to determine 
IC50 with the relevant co-medication substrates and inhibitors [27]. The FDA sets an R 
cutoff of 1.25 for investigational drugs inhibiting OATP1B1 and OATP1B3, and requires 
a follow-up clinical study with rosuvastatin, pitavastatin or pravastatin as probe substrates 
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for a predicted R value ≥ 1.25 [13]. The R value approach assumes that the uptake of the 
victim drug is exclusively via the OATP under consideration, and that any other potential 
contributing factors are negligible. This assumption often leads to overestimation of the 
magnitude of DDI in vivo [27, 262].  
It has been observed that the contribution of OATPs to total hepatic uptake is 
substrate-dependent [27]. In predicting the risk of DDIs involving OATP1B1, to account 
for the differential contribution of OATP1B1, a mechanistic model has been developed 
which incorporates the fraction of drug transported via OATP1B1 only (fOATP1B1) and has 
the following form [27], 
𝐴𝑈𝐶𝑅 =
𝐴𝑈𝐶𝑖
𝐴𝑈𝐶
=
𝐶𝐿𝑎𝑐𝑡,𝑢𝑝𝑡𝑎𝑘𝑒
𝐶𝐿𝑎𝑐𝑡,𝑢𝑝𝑡𝑎𝑘𝑒(𝑖)
=
1
𝑓𝑂𝐴𝑇𝑃1𝐵1
1+
[𝐼]𝑖𝑛𝑙𝑒𝑡,𝑚𝑎𝑥,𝑢𝑛𝑏𝑜𝑢𝑛𝑑
𝐾𝑖
+ (1 − 𝑓𝑂𝐴𝑇𝑃1𝐵1)
  𝐸𝑞. 4 − 2 
This model assumes that other potential contributing factors, such as other uptake 
transporters, efflux transporters and metabolism, are not affected by the inhibitor drug 
[27]. The successful application of this model is limited by (1) the general lack of 
fOATP1B1 estimates for OATP1B1 substrates, and (2) the sensitivity of the predicted 
AUCR to the input value of fOATP1B1 [27]. Furthermore, this model has the same caveat as 
its counterpart for CYP-based DDIs, that is, it uses “a static estimate of in vivo inhibitor 
concentration to provide a point estimate of the average magnitude of change in the 
exposure to any victim drug” as pointed out by Einolf et al. [133]. 
 To address more complicated situations where DDIs involving multiple 
transporters and/or transporter-enzyme interplay, many scientists advocate the use of 
PBPK models [263]. There has been an increasing use of whole-body PBPK modeling to 
integrate estimates of active uptake, passive permeability, intracellular binding, 
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metabolism, and efflux measured in vitro to predict in vivo pharmacokinetics. Compared 
with static models, PBPK models have the advantage of being able to simulate the 
concentration–time course of the inhibitor drug at the actual site of interaction [136]. For 
example, PBPK models can simulate the intracellular concentration in enterocytes for 
predicting inhibition of efflux transporters and CYP3A4 expressed in the gut wall. It can 
also simulate hepatic inlet concentration for predicting inhibition of hepatic uptake, or 
intracellular concentration in hepatocytes for predicting inhibition of hepatic efflux 
transporters and metabolic enzymes. In addition, PBPK models can be extended to 
incorporate the effects of metabolites on relevant transporters or metabolic enzymes 
[136]. Examples of using PBPK models for prediction of transporter-mediated DDIs are 
limited. Nevertheless, the current mechanistic framework of PBPK models makes 
quantitative assessment of complex DDIs possible [27]. 
 
e. Hypothesis and aims 
 Since all the drugs involved in the significant DDIs identified previously are 
administered orally, it is possible that inhibition of hepatic uptake via OATP1B1/1B3 
contributes to these interactions. In this chapter, I hypothesize that inhibition of 
OATP1B1/1B3 contributes to the significant myopathic DDIs identified previously by 
reducing hepatic uptake and thus the subsequent hepatic clearance of drugs, leading to 
increased systemic exposure and the risk of myopathy. To test this hypothesis, each drug 
involved in the significant DDIs identified previously needs to be evaluated as both a 
substrate and an inhibitor of OATP1B1/1B3. This approach is, however, unfeasible as 
current experimental techniques require radio-labeling each individual drug involved. 
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Since an inhibitor of a transporter is often also a substrate, I examined the ability of those 
drugs to inhibit OATP1B1/1B3 to probe their potential to be substrates of these 
transporters. The drugs were first screened for the inhibition of E217βDG uptake in 
cryopreserved rat hepatocytes. E217βDG is a substrate of rOATP1B2, a functional 
homologue of human OATP1B1/1B3 in rodents. The risk of OATP1B1/1B3-mediated 
DDIs in humans was then inferred from the inhibitory potencies determined.  
 
2. Methods 
a. Materials 
 All drugs and metabolites were purchased from Toronto Research Chemicals Inc. 
(North York, ON, Canada). Tritium-labeled estradiol-17 β-D-glucuronide ([3H] E217βDG) 
was purchased from Perkin Elmer (Waltham, MA). Cryopreserved rat hepatocytes were 
purchased from Life Technologies (Grand Island, NY). Acetonitrile, methanol and 
components of Krebs-Henseleit buffer (KHB) were purchased from Sigma-Aldrich (St. 
Louis, MO). Phosphate-buffered saline (PBS) and ScintiSafe™ Econo Cocktail 
(Scintanalyzed™) were purchased from Fisher Scientific (Pittsburgh, PA).  
 
b. Screening for inhibition of E217βDG uptake 
 To examine the inhibitory potential of the drugs of interest for rOATP1B2, the 
uptake of E217βDG was determined in the presence of the drugs under study in 
suspended cryopreserved rat hepatocytes. [3H] E217βDG and the test drugs were 
dissolved in methanol and diluted to the desired concentrations in KHB buffer. Rat 
hepatocytes were thawed, washed and suspended in Krebs-Henseleit buffer containing 2 
 137 
 
g/L glucose. Following counting of the number of viable cells using trypan blue, the 
hepatocyte suspension was adjusted to a density of 2 x 106 viable cells per ml and kept on 
ice until the start of uptake. Aliquotes (100 μL) of cell suspension were then transferred 
to 2.5 mL tubes and were pre-warmed at 37 °C for 3 min in a shaker water bath, along 
with the solution containing radio-labeled E217βDG and the test drugs. The uptake was 
initiated with the addition of equal volume (100 μL) of the solution containing [3H] 
E217βDG and the test drugs to the cells. The hepatocytes were further incubated with [3H] 
E217βDG and the test drugs for a designated length of time at 37 °C. In parallel, the 
uptake studies were also performed on ice to estimate the rate of passive diffusion. The 
final concentration of [3H] E217βDG was 1 μM, 0.1 μCi. The final concentration of the 
test drugs were 100 μM, and each drug was tested in triplicate. The final concentration of 
hepatocytes was 0.2 x 102 per reaction (or 1 x 106 cells / mL). To ensure the consistency 
of uptake assays, 10 μM rifampin was used as a positive control in each experiment.  
Uptake was stopped with the addition of 1 mL ice-cold PBS and immediate 
centrifugation at 4500 rpm for 1 min at 4 °C. To wash off the residual substrate and test 
drugs, the cells were re-suspended with 1 mL ice-cold PBS and centrifuged again. After 
removing supernatants, the cell pellets were lysed with 200 μL of 50% acetonitrile in 
H2O, followed by vigorous vortexing. The cell lysates were then transferred to 
scintillation counting vials, 3 mL scintillation fluid was added, and radioactivity was 
determined by liquid scintillation counting in a LS 6500 multipurpose scintillation 
counter (Beckman Coulter, Fullerton, CA). 
 For data analysis, the total radioactivity was taken to be the sum of the 
radioactivity found in the supernatant and that of the hepatocyte lysates. The fraction of 
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total uptake was the ratio of the radioactivity of hepatocyte lysate to the total radioactivity. 
The fraction of active uptake was the obtained by subtracting the uptake at 0 °C from the 
total uptake at 37 °C. The fraction of inhibition was determined by comparing the active 
uptake in the presence of test drugs with that in the absence of any test drugs. 
 
c. Estimating IC50s 
 IC50 was determined for the drugs which yielded more than 50% inhibition of [
3H] 
E217βDG uptake into hepatocytes at 100 μM in the screening. To determine IC50s, uptake 
studies were performed as described previously, except that the inhibition of [3H] 
E217βDG uptake was evaluated at multiple inhibitor concentrations in triplicate. The 
selection of inhibitor concentrations was guided by the fraction of inhibition in the 
screening study. The fraction of inhibition was determined as described above. IC50s were 
estimated by fitting the fraction of inhibition to a two- (Eq. 3-2) or four- (Eq. 3-3) 
parameter log-logistic model using GraphPad Prism 5 software. 
 
d. Prediction of OATP1B1/1B3-mediated DDIs 
 Following the FDA guidelines, for each drug administered orally for which an 
IC50 was observed, an R value was estimated as R = 1 + [I]inlet,max /Ki. Because the 
concentration of E217βDG (1 μM) was well below its Km [264, 265], the Kis were 
approximated by the IC50s based on Ki = IC50 / (1 + [S]/Km) [261]. [I]inlet,max was 
estimated as Cmax + (ka x Dose x FaFg/Qh), where Cmax was the maximum systemic plasma 
concentration of the inhibitor drug obtained from the published literature (see Table 4-4), 
dose was the highest proposed clinical dose of the inhibitor drug, FaFg was the fraction of 
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the inhibitor dose that reaches the liver, ka was the absorption rate constant of the 
inhibitor obtained from the published literature, and Qh was the estimated hepatic blood 
flow (1500 mL/min). For the drugs whose FaFg and ka were not available, these 
parameters were assumed to be 1 and 0.1 min-1. For simvastatin acid, the Cmax and dose 
were assumed to be equal to those of simvastatin. Because rifampin is usually given as an 
intravenous injection, its R value was estimated as R = 1 + [I]/Ki, where [I] is the Cmax 
following an injection at the highest proposed clinical dose (600 mg). Ki was similarly 
approximated by the IC50. 
 
3. Original experimental results 
a. Screening for inhibition of E217βDG uptake 
 Cryopreserved rat hepatocytes were used to examine the potential of the drugs of 
interest to inhibit OATPs. The hepatic uptake of E217βDG is known to be mediated by 
OATP1B1 and 1B3 in humans, and by rOATP1B2 in rodents [264, 265]. E217βDG 
uptake has been widely used as a marker activity of those OATPs in vitro. To examine 
the potential of the thirteen drugs involved in the significant myopathic DDIs and their 
active metabolites (e.g. simvastatin acid and desloratadine) for inhibition of OATPs, 
these compounds were screened for inhibition of E217βDG uptake in cryopreserved rat 
hepatocytes. 
 Because E217βDG uptake via rOATP1B2 in rat hepatocytes follows Michaelis-
Menten kinetics [264], uptake measured beyond the early linear phase can be confounded 
by efflux and metabolism [249]. Selection of appropriate time points in the initial linear 
phase is therefore critical for accurate determination of inhibitory potential. In 
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preliminary studies, I found that the velocity of E217βDG uptake into rat hepatocytes was 
linear for up to 1 min (Figure 4-1). All the subsequent uptake studies were thus 
performed within the 1 min linear phase.  
 The inhibition of 1 μM E217βDG uptake into rat hepatocytes by the compounds 
tested is summarized in Table 4-2. A bar plot showing the remaining uptake (%) as 
compared to the controls is displayed in Figure 4-2. Six drugs were found to inhibit more 
than 50% of E217βDG uptake at 100 μM, and they were simvastatin acid, quetiapine, 
risperidone, omeprazole, duloxetine and alprazolam. Noticeably, simvastatin acid 
inhibited E217βDG uptake completely (103.3 ± 0.5%) at 100 μM. Quetiapine also 
exhibited potent inhibition of E217βDG uptake (95.5 ± 0.4%) at 100 μM.  
 
b. IC50 estimates 
 For the six drugs that yielded more than 50% of inhibition of E217βDG uptake in 
the screening studies, IC50s were further determined and are shown in Figure 4-3 and 
Table 4-3. Because the interaction of simvastatin and loratadine was of particular interest, 
the IC50 of desloratadine was also determined although it only exhibited 45% of 
inhibition for E217βDG uptake in the screening studies. Rifampin, a known inhibitor of 
OATPs, served as a positive control inhibitor, and its IC50 (95% CI) was 8.9 (6.6, 12) μM. 
Simvastatin acid and quetiapine exhibited potent inhibition for E217βDG uptake in the 
screening studies and their IC50s were 4.3 (3.5, 5.3) and 16.9 (11.7, 24.4) μM, 
respectively. The IC50s of duloxetine, omeprazole, alprazolam, desloratadine and 
risperidone were relatively large and suggested only weak inhibition of rOATP1B2 at 
clinically relevant concentrations.  
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c. Predicted risk of OATP1B1/1B3- mediated DDIs 
 Following the FDA guidelines, an R value was predicted for each drug for which 
an IC50 was observed (Table 4-4). Assuming that the Cmax and dose of simvastatin acid 
are equal to those of simvastatin, the R value for simvastatin acid was 3.85. The R values 
of quetiapine, omeprazole and duloxetine were 5.28, 1.2 and 1.2, respectively, also higher 
than the FDA recommended cutoff of 1.1 [13]. The R values of simvastatin acid and 
quetiapine were larger than that of rifampin (R value 3.4), a known inhibitor of 
OATP1B1/1B3 that can cause clinical DDIs by inhibiting OATP1B1/1B3. Since 
rOATP1B2 is a functional homologue of human OATP1B1/1B3, these data suggest that 
simvastatin acid, quetiapine, duloxetine and omeprazole may inhibit the transport activity 
of OATP1B1/1B3 in humans, and interact with drugs whose hepatic uptake is primarily 
mediated by OATP1B1/1B3. The predicted R values for the other drugs were close to 
unity, indicating a negligible risk of OATP1B1- and OATP1B3- mediated DDIs in vivo. 
 
4. Discussion 
 In this chapter, I have addressed the hypothesis that the DDIs identified 
previously were caused, in part, by the inhibition of hepatic uptake via OATP1B1/1B3. 
The drugs and their relevant active metabolites were screened for inhibition of E217βDG 
uptake, a marker activity of rOATP1B2, in cryopreserved rat hepatocytes. Six drugs, 
namely, simvastatin acid, quetiapine, duloxetine, omeprazole, alprazolam and risperidone 
exhibited more than 50% of inhibition at 100 μM. IC50s were further determined for these 
drugs and the risk of OATP-mediated DDIs was predicted. The IC50 of desloratadine was 
determined too as its inhibition was close to 50% and the interaction between loratadine 
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and simvastatin was of particular interest. Simvastatin acid and quetiapine exhibited 
relatively potent inhibition of E217βDG uptake with IC50s of 4.3, and 16.9 μM, 
respectively. Omeprazole and duloxetine exhibited moderate inhibition of E217βDG 
uptake with IC50s of 84.3 μM and 56.8 μM, respectively. The predicted R values of 
simvastatin acid, quetiapine, omeprazole and duloxetine were 3.85, 5.28, 1.2 and 1.2, 
respectively, indicating that these drugs may interact with drugs that rely on 
OATP1B1/1B3 for hepatic uptake in vivo. It is worth noting that the predicted R values 
of simvastatin acid and quetiapine were larger than that of rifampin, indicating that these 
two drugs have more potential to cause clinical DDIs by inhibiting OATP1B1/1B3 than 
rifampin, a drug that is known to interact with OATP1B1/1B3 substrates. 
 The inhibitory potencies observed here are consistent with those published 
previously, demonstrating the validity of the experimental system. Rifampin, a known 
inhibitor of OATP1B1/1B3, inhibited E217βDG uptake with an IC50 of 8.9 μM, which is 
consistent with the reported inhibitory activity of rifampin in vivo [266]. Simvastatin acid 
inhibited E217βDG uptake with an IC50 of 4.3 μM. This is in line with the previous 
observation that simvastatin acid is a substrate of OATP1B1/1B3 in humans and inhibits 
the OATP1B1/1B3-dependent pravastatin uptake [7]. On the other hand, simvastatin 
lactone only reduced E217βDG uptake by 36.3%, consistent with the observation that 
simvastatin is not a substrate of OATP1B1/1B3 [267]. 
 The other compounds tested here have never been reported to inhibit 
OATP1B1/1B3. Many of them, such as omeprazole and duloxetine, are clinically 
important drugs that are often involved in significant clinical DDIs. My data are the first 
to describe their potential to inhibit rOATP1B2 and shed light on their potential to be 
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involved in OATP-mediated DDIs in humans. Future studies are needed to confirm the 
inhibitory potentials observed for these drugs and to integrate these considerations into 
clinical thinking about drug interactions.  
 Quetiapine draws particular attention as it was identified as a relatively potent 
inhibitor of rOATP1B2, thus a potential inhibitor of human OATP1B1/1B3. The IC50 of 
quetiapine (16.9 μM) was close to that of a known potent OATP1B1/1B3 inhibitor, 
rifampin. The high predicted R value of 5.28 underscored its potential to cause DDIs by 
inhibiting OATP1B1/1B3-mediated hepatic uptake. Future studies are required to 
characterize in detail the inhibition of human OATP1B1/1B3 by quetiapine and to 
investigate its potential to cause clinical DDIs. 
 Overall, the data indicate that the inhibition of hepatic uptake via OATP1B1/1B3 
is not the major mechanism for the DDIs identified previously. Other than simvastatin 
acid and quetiapine, the drugs involved in those DDIs exhibited only relatively weak or 
moderate inhibition of OATP1B1/1B3. Since the drugs were screened for inhibition at 
100 µM, a concentration that is much higher than the hepatic input concentration of any 
drug at clinical doses, a relatively weak or moderate inhibition indicates that the chance 
of inhibiting OATP1B1/1B3 in vivo is minimal. The majority of the DDIs identified 
previously therefore cannot be explained by inhibition of hepatic uptake via 
OATP1B1/1B3.  
 The predicted R value of simvastatin acid was 3.85, indicating a risk of 
OATP1B1/1B3-mediated DDI in vivo. For the interaction between simvastatin and 
loratadine, loratadine and its active metabolite, desloratadine, exhibited only relatively 
weak and moderate inhibition for E217βDG uptake, respectively. Since the predicted R 
 144 
 
value of desloratadine was close to unity, both loratadine and desloratadine are unlikely 
to increase the risk of simvastatin-induced myopathy by inhibiting the hepatic uptake of 
simvastatin acid via OATP1B1/1B3. On the other hand, the inhibition of E217βDG 
uptake by desloratadine suggests that desloratadine might be a substrate of 
OATP1B1/1B3. With an R value of 3.85, simvastatin acid can potentially inhibit the 
uptake of desloratadine, thereby increasing the risk of loratadine-induced myalgia. 
However, as I assume that the Cmax and dose of simvastatin acid is equal to those of 
simvastatin, the R value of simvastatin acid is likely an overestimate because a fraction of 
dose and Cmax exists in the form of simvastatin which inhibited E217βDG uptake with 
much less potency. Future mechanistic studies are needed to examine whether 
desloratadine is a substrate of OATP1B1/1B3, and to explore the possibility that the 
inhibitory effects of simvastatin acid on the hepatic uptake of desloratadine contributes to 
the interaction of simvastatin with loratadine. 
 Both duloxetine and omeprazole were predicted to interact with OATP1B1/1B3 
substrate drugs with a relatively small risk (R value 1.2). Their inhibitory effects on 
OATP1B1/1B3 might contribute to their interactions with loratadine as they may inhibit 
the hepatic uptake of desloratadine. However, since the predicted R values are small and 
likely over-estimated, these inhibitions may have only small effects on the 
pharmacokinetics of loratadine.  
 The predicted R value of quetiapine was 5.28, indicating a risk of OATP1B1/1B3-
mediated DDI in vivo. However, chloroquine and its active metabolite, 
hydroxychloroquine, only caused 26.3% and 27.7% inhibition of E217βDG uptake, 
respectively, indicating that they are unlikely to be substrates of OATP1B1/1B3. 
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Therefore, the interaction between quetiapine and chloroquine is unlikely to be due to the 
inhibition of hepatic uptake of chloroquine or quetiapine via OATP1B1/1B3. For similar 
reasons, the interactions of duloxetine with chloroquine and hydroxychloroquine cannot 
be attributed to the inhibition of OATP1B1/1B3 by duloxetine, although duloxetine was 
predicted with a small risk of interacting with OATP1B1/1B3 substrate drugs (R value 
1.2). 
 Using E217βDG uptake as a functional marker, I was able to provide mechanistic 
insights into the DDIs identified previously with respect to inhibition of hepatic uptake 
via OATP1B1/1B3. On the other hand, I was not able to evaluate the overall effect of a 
perpetrator drug on the hepatic uptake of a victim drug for those DDIs. Such information 
can only be obtained via examining the uptake of a victim drug into hepatocytes in the 
absence and presence of a perpetrator drug.  
 Since the R value approach assumes that other potential contributing factors, such 
as uptake via other transporters, metabolism and efflux, are negligible, and that the 
inhibitor drugs concentration is constantly as high as the maximal hepatic inlet 
concentration at the highest proposed clinical dose, the R values are likely be 
overestimates of risk [27]. This approach is thus only appropriate for providing an initial 
assessment and for ruling out drugs that are unlikely to be involved in DDIs. Since the 
fraction of uptake via OATP1B1/1B3 is unknown for the drugs of interest, the AUCR 
approach cannot be applied. To obtain more accurate estimates of the risk of OATP-
mediated DDIs in vivo for simvastatin acid and quetiapine, more comprehensive models 
such as PBPK models may be required. 
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 Although my data demonstrate E217βDG uptake in rat hepatocytes as a useful 
model for evaluating inhibition of OATP1B1/1B3, there are a few caveats inherent to this 
model which limit the interpretation of the results. First, there is a concern that the 
species difference between rat and human hepatocytes, more specifically, between 
rOATP1B2 and human OATP1B1/1B3, may limit the extrapolation of uptake data from 
rats to humans. Indeed, the uptake kinetics of E217βDG in cryopreserved rat hepatocytes 
were found to be different from those in cryopreserved human hepatocytes. While the Km 
of E217βDG uptake in cryopreserved rat (12.9 μM) was very similar to that human 
hepatocytes (8.4 μM), the Vmax in rat hepatocytes (1300 pmol/min/106 cells) was 34-fold 
higher than that in human hepatocytes (33.1 pmol/min/106 cells), and the CLuptake in rat 
hepatocytes was 20-fold higher than that in human hepatocytes [32]. In fact, however, the 
inhibitory potential of rifampin for E217βDG uptake determined here in rat hepatocytes 
was consistent with that determined in cryopreserved human hepatocyte suspensions by 
De Bruyn et al., who reported that rifampin inhibited 70% of E217βDG (1 μM) uptake at 
25 μM [30]. Extrapolating from an IC50 of 8.9 μM determined here in rat hepatocytes, 
rifampin would inhibit 73.7% of E217βDG uptake (1 μM) at 25 μM (based on inhibition 
(%) = 1 / (1 + IC50 / [I]) [33]). These data indicate that IC50s may be more dependent on 
the affinity than on the abundance of transporter proteins on the hepatocyte membrane. 
This observation may not be generalizable since the inhibition of E217βDG uptake by the 
other compounds of interest has never been similarly tested in human hepatocytes. A 
similar concern also arises from using cryopreserved hepatocytes instead of fresh isolated 
hepatocytes. It has been shown that the Km of E217βDG uptake remained unchanged 
whereas the Vmax and CLuptake decreased on average by 47% after cryopreservation of 
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human hepatocytes [34]. It is possible that there is a discrepancy between IC50s 
determined in cryopreserved rat hepatocytes and in fresh isolated human hepatocytes as a 
result of species difference and cryopreservation. Since IC50s provide the basis for 
estimating R values, there is a possibility that this discrepancy translates into an 
underestimated or overestimated risk of OATP1B1/1B3-mediated DDIs. Future studies 
are thus warranted to confirm the inhibitory potencies of those drugs in fresh isolated 
human hepatocytes in order to predict the risk of OATP-mediated DDIs with more 
confidence. 
 In addition, the experimental procedure used here is different from the standard 
oil-filtration method with respect to stopping an uptake reaction. Using the oil-filtration 
method, uptake reactions are stopped by centrifuging samples that allow cells to pass 
through a thin layer of oil while leaving the aqueous incubation medium on the top of oil. 
A small number of cells may fail to pass through the oil layer, resulting in an 
underestimate of total uptake. Large variability has been observed using this method, 
partly due to the difficulties in sampling cells for radio-activity determination. Using my 
method, uptake reactions were stopped with the addition of ice-cold PBS followed by 
immediate centrifugation. Addition of ice-cold PBS, theoretically, would bring the 
temperature of incubation mixture down to close to 0 ◦C and would significantly reduce 
the rate of substrate concentration- and temperature-dependent active uptake. However, 
uptake may continue while the samples are kept on ice before centrifugation. Also, a 
small number of hepatocytes may be removed along with supernatant, potentially leading 
to an underestimate of total uptake. Further studies may be needed to compare the two 
methods. Nevertheless, using my methods, I was able to obtain data with consistency and 
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relatively small variability. The inhibitory potentials were consistent with those published 
previously, further providing the evidence for the validity of this method. 
 Lastly, there is debate as to the best approach to assessing the contribution of 
passive diffusion to overall uptake. The traditional approach, as used here, assumes that 
active uptake is negligible at 0 °C, and that passive diffusion can be approximated by 
total uptake at 0 °C. This approach is confounded by the fact that membrane fluidity and 
thus the rate of passive diffusion is temperature-dependent. Approximation of passive 
diffusion at 37 °C by total uptake at 0 °C may lead to underestimation of passive 
diffusion at 37 °C. Since active uptake is estimated by the difference between total uptake 
and passive diffusion, this approach likely leads to overestimation of active uptake at 
37 °C. In my case, this may result in underestimated inhibitory potencies.  
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Table 4-1. Summary of characteristics of clinically important OATPs in humans [235]. 
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Figure 4-1. The rate of E217βDG uptake in cryopreserved rat hepatocytes. The uptake of 
E217βDG was linear up to 1 min. 
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Table 4-2. Inhibition (%) of E217βDG uptake at 100 μM 
Drug % Inhibition  
Simvastatin Acid 103.3 ± 0.5 
Quetiapine 95.5 ± 0.4 
Risperidone 64.0 ± 5.9 
Omeprazole 60.1 ± 4.8 
Duloxetine 55.8 ± 0.9 
Alprazolam 54.5 ± 0.3 
Trazodone 48.4 ± 4.3 
Desloratadine 44.9 ± 14.2 
Simvastatin 36.3 ± 6.0 
Hydroxychloroquine 27.7 ± 8.7 
Chloroquine 26.3 ± 14.5 
Tegaserod 24.6 ± 15.3 
Ropinirole 23.7 ± 2.7 
Loratadine 18.1 ± 10.9 
Promethazine 17.7 ± 7.7 
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Figure 4-2. Inhibition of E217βDG uptake in cryopreserved rat hepatocytes at 100 
μM. 
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Table 4-3. IC50s for the inhibition of E217βDG uptake 
Drug IC50 (μM) 95% CI 
Simvastatin Acid 4.3 3.5, 5.3 
Rifampin 8.9 6.6, 12 
Quetiapine 16.9 11.7, 24.4 
Duloxetine 56.8 45.1, 71.4 
Omeprazole 84.3 49.8, 142.9 
Alprazolam 99.5 79.5, 124.6 
Desloratadine 140.5 111.4, 177.1 
Risperidone 234.6 204, 269.8 
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Figure 4-3. IC50 curves for the inhibition of E217βDG uptake. 
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Table 4-4. Predicted R values 
Drug 
IC50 
(μM) 
Dose 
(mg) 
MW 
(g/mol) 
Dose 
(mmol) 
Cmax 
(ng/ml) 
Cmax 
(μM) 
ka  
(min-1) 
FaFg 
[I]inlet 
(μM) 
R Reference 
Quetiapine 16.9 400 383.5 1.043 1080 2.816 0.1 1 72.349 5.3 [203] 
Simvastatin 
Acid 
4.3 80 436.6 0.183 25.4 0.058 0.1 1 12.274 3.9 [202] 
Rifampin 8.9  823  17400 21.143    3.4 [268] 
Omeprazole 84.3 80 345.4 0.232 1432 4.146 0.1 1 19.586 1.2 [269] 
Duloxetine 56.8 60 297.4 0.202 53.2 0.179 0.1 1 13.628 1.2 [270] 
Alprazolam 99.5 3 308.8 0.010 102.9 0.333 0.1 1 0.981 1.0 [271] 
Desloratadine 140.5 5 310.8 0.016 4.7 0.015 0.1 1 1.088 1.0 [272] 
Risperidone 234.6 4 410.5 0.010 89.1 0.217 0.1 1 0.867 1.0 [198] 
 
Note: Dose is the highest proposed clinical dose; Cmax is the maximal plasma concentration at the highest proposed clinical dose; ka is 
the absorption rate constant; FaFg is the fraction of the inhibitor dose that reaches the liver; [I]inlet,max is the maximal inlet 
concentration of the inhibitor and was estimated as Cmax + (ka x Dose x FaFg/Qh), where Qh is the hepatic blood flow (1500 mL/min). 
Because the values of ka and FaFg were not available conservative predictions, for conservative predictions, they were assumed to 
equal to the theoretical maxima of 0.1 min-1 and 1, respectively. 
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Chapter 5. In vitro assessment of direct myotoxicity 
 
1. Introduction 
a. Pathogenic mechanisms underlying drug-induced myopathy 
 Drug-induced myopathy is among the most common causes of muscle disease. 
The clinical presentation of drug-induced myopathy ranges from asymptomatic muscle 
enzyme elevation to chronic myopathy with severe weakness and to massive 
rhabdomyolysis with acute renal failure. Over 150 drugs have been associated with 
rhabdomyolysis [49-51]. Mechanisms underlying drug-induced myopathy can be grossly 
classified as direct myotoxicity or immunologically induced inflammatory myopathy. 
Drugs that have been found to have direct myotoxicity include lipid-lowering drugs such 
as statins and fibrates, antimalarials such as chloroquine and hydroxychloroquine, 
glucocorticoids, cocaine, colchicine, antipsychotics such as phenothiazines, 
antiretrovirals such as zidovudine, and ipecac. Drugs that induce inflammatory myopathy 
through immunological system include statins, interferon alpha and penicillamine [273, 
274]. Here, I limit the discussion to myopathies induced by statins and antimalarials only 
as they are the most relevant to the work described previously. 
 The mechanism underlying statin-induced myopathy has been extensively studied 
but remains unclear. The existing evidence suggests that it is likely to be multifactorial. 
Statins inhibit the conversion from HMG-CoA to mevalonate by HMG-CoA reductase 
(HMGCR), which is the rate-limiting step in cholesterol synthesis. By reducing 
mevalonate production, statins decrease endogenous cholesterol synthesis which 
contributes to their lipid-lowering effects. However, mevalonate is a precursor of 
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isoprenoids such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate, both of 
which are required for modification of proteins by prenylation. Protein prenylation is 
important for producing many functional proteins such as small G proteins (e.g. Rho and 
Rab) that are essential for cell survival [275, 276]. The decreased protein prenylation by 
statins eventually causes increases in cytosolic calcium which lead to the activation of the 
proteolytic enzyme caspase-3 and to cell apoptosis. Importantly, the treatment with 
geranylgeranyl pyrophosphate blocked the toxic effects of the statins in vascular smooth 
muscle cells [277]. These data suggest that statin-induced myotoxicity may be mediated, 
at least in part, through apoptosis caused by depletion of isoprenoid intermediates and 
subsequent dysfunction of small G proteins. 
 Mevalonate also serves as a precursor for coenzyme Q10 (CoQ10, ubiquinone), 
an important component of the mitochondrial electron transport chain. This leads to the 
hypothesis that statin-induced CoQ10 deficiency is involved in the pathogenesis of statin 
myopathy. Indeed, circulating levels of CoQ10 has been found to be lower during statin 
treatment.  However, the effect of statins on intramuscular levels of CoQ10 is 
controversial, and data on intramuscular CoQ10 levels in symptomatic patients with 
statin-induced myopathy are scarce. Although CoQ10 supplementation increases the 
circulating level of CoQ10, its effect on myopathic symptoms are contradictory. There is 
therefore insufficient evidence to conclude that there exists an etiologic role for CoQ10 
deficiency in statin-induced myopathy [278-280].  
 Atrogen-1 can also be affected by statin-induced changes in lipid metabolism. 
Atrogen-1 is a muscle-specific ubiquitin protein ligase and a key player in skeletal 
muscle atrophy. The expression of atrogen-1 was found to be upregulated in muscle 
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biopsies from patients with statin induced-myopathy [281]. The knockdown of atrogen-1 
in mice and in zebrafish abolished the myotoxicity of statins. Furthermore, statin-induced 
atrogen-1 expression and muscle damage in both of these systems were prevented by the 
treatment with geranylgeranol, a cell permeable precursor of geranylgeranyl 
pyrophosphate [282]. Thus, it has been speculated that statin myopathy may occur when 
an isoprenylation deficiency results in ineffective suppression of atrogen-1 [283]. 
 Another suggested mechanism of statin-induced myopathy due to reduced lipid 
levels is destabilization of the sarcolemmal membrane in myocytes [284]. There is 
normally a dynamic equilibrium between plasma lipids and the myocyte membrane 
which can be disturbed by the depletion of plasma cholesterol due to statin treatment. 
However, this theory seems at odds with the observations that myotoxicity did not occur 
when cholesterol was lowered due to inhibition of squalene synthetase, an enzyme in the 
distal cholesterol synthesis pathway, in human skeletal myotubes [285]. In addition, 
patients with genetic variations resulting in cholesterol biosynthetic defects do not 
present with skeletal myopathy clinically [286]. These data suggest that statin-induced 
myopathy is more likely a consequence of isoprenoid depletion rather than reductions in 
membrane cholesterol content per se. 
 Mitochondrial dysfunction seems to be a phenotypic presentation that results from 
various molecular mechanisms in statin-induced myopathy. In addition to potentially 
impaired mitochondrial respiratory chain due to deficiency of CoQ10, the activities of 
citrate synthase and respiratory enzymes in mitochondria were reduced in patients taking 
statins [287]. Statins can trigger Ca2+-induced opening of the permeability transition 
pore and loss of mitochondrial membrane potential, followed by cytochrome c release 
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and cell apoptosis [288]. A recent study by Kwak et al. found that simvastatin induces 
myotube atrophy and cell loss associated with impaired ADP-stimulated maximal 
mitochondrial respiratory capacity, mitochondrial oxidative stress, and apoptosis in 
primary human skeletal myotubes, suggesting that mitochondrial dysfunction may 
underlie statin-induced myopathy [289].  
 In most cases, patients with statin-induced myopathy can completely recover 
within weeks or months after statins are discontinued. The observation that myopathy 
persists or progresses in some patients even after statin discontinuation suggests that 
inhibition of cholesterol synthesis is not the only mechanism underlying statin-induced 
myopathy. A subgroup of patients with persistent statin-induced myopathy was 
diagnosed with necrotizing autoimmune myopathy, a subtype of idiopathic inflammatory 
myopathy characterized by myocyte necrosis without significant inflammation. Statins 
were found to upregulate the expression of HMGCR, the major target of autoantibodies 
in patients with statin-induced necrotizing autoimmune myopathy. Regenerating muscle 
cells express high levels of HMGCR, which may sustain the immune response even after 
statins are discontinued [290]. This finding potentially provides a diagnostic test to help 
differentiate immune from non-immune statin myopathy.  
 Unlike statins, the antimalarial drugs chloroquine and hydroxychloroquine induce 
myopathy through their lysosomotropic effects [291]. Chloroquine and 
hydroxychloroquine have significant lysosomal affinity and can mediate autophagic 
protein degradation in lysosomes.  Long term administration may result in the 
accumulation of these drugs which promotes accumulation of sequestered materials in 
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autophagic lysosomes [291]. This eventually leads to the development of the hallmark 
rimmed vacuoles in several tissues including muscles [292, 293].  
 
b. Rat L6 myotubes as a model system to assess myotoxicity  
 Commonly used in vitro cell models of skeletal muscles include primary cell lines 
and immortalized cell lines such as rat L6 myotubes and mouse C2C12 myotubes [294]. 
Primary skeletal muscle cell lines developed from muscle biopsies can retain the 
metabolic characteristics of the donor tissue and are particularly useful for studying the 
effects of metabolic diseases on skeletal muscles [294]. Those developed from patients 
with myopathy can retain phenotypic traits of the donor related to myopathy pathogenesis 
[294]. Although primary skeletal muscle cell lines are a valuable in vitro model of 
skeletal muscles, their use has been limited by availability and their limited replicative 
potential in culture [295]. In contrast to primary cell lines, undifferentiated immortalized 
skeletal muscle cell lines can replicate indefinitely in culture. Cells can continue to 
undergo mitotic divisions and expand rapidly when maintained under appropriate culture 
conditions. In addition, immortalized skeletal muscle cell lines are able to retain many 
physiological functions similar to those of primary skeletal muscle cell lines. These cell 
lines therefore provide a readily available and replicable experimental model that is 
alternative to primary skeletal muscle cell lines [295].  
 The rat L6 cell line is the best in vitro cell model to study glucose uptake 
involving GLUT4 in muscle cells [296]. This is because rat L6 myotubes are most similar 
to human muscle cells in terms of translocation of GLUT4 upon insulin stimulation when 
compared to other cell models [296]. This cell line is also one of the most commonly 
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used in vitro cell models to investigate myogenesis as the underlying molecular 
mechanisms governing myogenesis are conserved from rats to humans [297]. The L6 cell 
line was established from embryonic or newborn rat thigh skeletal muscle cells and 
immortalized by treatment with a carcinogen, methyl cholanthrene [298]. The treatment 
with methyl cholanthrene enabled L6 myoblasts to last for months in a continuous state 
of replication without losing their potential to differentiate [298]. The undifferentiated 
myoblasts are mononucleated, spindle-shaped cells that can proliferate when cultured 
with a serum-rich medium. When they are confluent or are starved with less serum, they 
withdraw from the cell cycle, elongate, adhere and begin to differentiate [297]. Myocytes 
at this stage still have the ability to return to the cell cycle and proliferate. Those that 
commit to differentiation can elongate, migrate and fuse into postmitotic multinucleated 
myotubes that are terminally differentiated. Further differentiation of myotubes to form 
myofibers is associated with the appearance of cross-striation and contractility [295, 298]. 
 Skeletal-muscle differentiation is a complex process coordinated by a number of 
factors. In addition to the extracellular matrix, which plays an important role in myocyte 
migration and fusion, many transcription factors that promote myogenesis have been 
discovered. Those include the members of the MyoD transcription factor family such as 
myogenin (Myog), Myf5 and Mef2. Under the regulation of P38/MAPK, Wnt and Sonic 
hedgehog, and the Notch/Delta pathway [297], the expression of myogenin increases 
during myoblast differentiation [299]. Also increasingly expressed are a number of 
muscle enzymes that closely associate with the metabolic capability of myofibers, 
including creatine kinase muscle type (CKM) [300, 301]. Creatine kinase is an enzyme 
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that catalyzes the conversion of creatine to create phosphocreatine and often used as a 
biomarker for differentiated myotubes [297]. 
 The rat L6 cell line has been shown to be a useful model to evaluate myotoxicity 
of drugs. Itagaki et al. used L6 myotubes to investigate potential mechanisms underlying 
statin-induced myopathy, and found that hydrophobic simvastatin and fluvastatin 
decreased cell viability in a dose-dependent manner via apoptosis characterized by 
typical nuclear fragmentation and condensation as well as caspase-3 activation [277]. 
Sakamoto et al. identified Oatp1a4 and Oatp2b1 as the transporters mediating the uptake 
of pravastatin into L6 myotubes, suggesting a potential role of these transporters in statin-
induced myopathy [302]. 
 
c. Methods to evaluate pharmacodynamic drug interactions 
 Two or more drugs that produce overtly similar effects can either produce 
exaggerated or diminished effects when used in combination [20]. When the combined 
effect is greater or less than that predicted by their individual effects, the combination is 
called synergism and antagonism, respectively [303]. Synergistic drug combinations are 
commonly used in the treatment of cancer, infectious diseases and pain so that desirable 
therapeutic effects can be achieved and adverse reactions can be avoided with lower 
doses [304]. When two drugs have synergistic toxicity, the adverse reactions could be 
exacerbated. 
 A number of methods have been developed to assess the nature and intensity of 
drug interactions. Greco et al. have summarized them as a strategy consisting of three 
steps [305]. The first step is to choose a good concentration-effect (dose-response) 
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structural model for each drug when applied individually [305]. A common choice is the 
Hill (or logistic) model (Eq. 5-1).  
𝐸 =
𝐸𝑚𝑎𝑥(
𝐷
𝐷𝑚
)𝑚
1+(
𝐷
𝐷𝑚
)𝑚
 Eq. 5-1 
In Eq. 5-1, E is the measured effect (response), D is concentration of drug; Emax is the full 
range of response that can be affected by the drug; Dm is the median effect dose or 
concentration of drug (e.g. IC50 and ED50), and m is a slope parameter [305]. Because 
data from real experiments rarely fit perfectly to an ideal curve, the second step is to 
choose an appropriate error model [305]. For example, a normal distribution is usually 
assumed for response measurements that are continuous; a binomial distribution can be 
assumed for proportions of failures or successes. A composite model then can be 
constructed from one structural model and one error model and used for fitting to 
experimental data. In the third step, one group of methods favored by mathematicians fits 
a combined action model to all of the data and estimates a parameter indicating the nature 
and intensity of an interaction. Another group of methods favored by pharmacologists is 
used more commonly. Such methods compare the observed combined effect with that 
predicted from a null reference model assuming no interaction [305]. Two commonly 
used null reference models are the Loewe additivity model and the Bliss independence 
model. The Loewe additivity model is in general considered a better reference model 
[305]. It is based on the idea that one drug cannot interact with itself. More specifically, 
in a sham experiment where a drug is combined with a diluted version of itself, the 
results would be additive [306]. A general mathematical description of Loewe additivity 
is shown in Eq. 5-2.  
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d. 1 =
𝐷1
𝐼𝐷𝑋,1
+
𝐷2
𝐼𝐷𝑋,2
 Eq. 5-2 
In Eq.5-2, IDX,1, IDX,2 are the concentrations of drugs to result in X% of effect for each 
respective drug alone, and D1, D2 are concentrations of each drug in the mixture that 
yield X% inhibition.  
 Developed and introduced by Loewe et al. [306], the isobologram is the most 
famous and widely accepted method to assess the nature of two drug interactions. It 
applies the first two steps of the above strategy implicitly by estimating IC50s using a Hill 
model and assuming normal distributions for continuous response data. In an 
isobologram, the diagonal NW-SE line connecting the IC50s of two drugs when applied 
alone is the line of Loewe additivity. Points below the line indicate Loewe synergism and 
those above the line indicate Loewe antagonism. This approach has the advantages of 
being simple, flexible, intuitive and inexpensive. The disadvantages, though, include 1) it 
lacks objective statistical measures and intensity measures of an interaction; 2) scattered 
points around the additivity line may lead to false conclusions; 3) isobolograms often 
lead to waste of data since IC50s cannot be estimated for dose-response curves with less 
than 50% effect, and consequently, it in general requires a large amount of data; and 4) 
many drug combinations have interactions that are not monotonically synergistic or 
antagonistic, and thus several isobols at particular effect levels (e.g. 10%, 25%, 50%, 
75%, 90%) may not capture the nature of interaction entirely and may lead to false 
conclusion [305]. 
 An algebraic analog of the isobologram is the method of Berenbaum et al. [307], 
in which an interaction index, I, is estimated using Eq. 5-3 to provide a quantitative 
measure of the intensity of an interaction.  
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𝐼 =
𝐷1
𝐼𝐷𝑋,1
+
𝐷2
𝐼𝐷𝑋,2
 Eq. 5-3 
When I > 1, Loewe antagonism is claimed; when I < 1, Loewe synergism is claimed. This 
method shares similar strengths and limitations with the use of an isobologram [305].  
 In the spirit of Berenbaum et al.’s method, a widely used method developed by 
Chou et al. also provides a quantitative measure of the nature and intensity of an 
interaction [308]. The Chou’s method involves estimating IC50s and the slope parameter, 
m, for each drug when applied alone using the median effect equation (Eq. 5-4) [308] or 
its log-linearized form (Eq. 5-5) [308], where fa is the fraction of effect affected by drug, 
fu is the fraction remains unchanged and equal to (1 - fa).  
𝑓𝑎
𝑓𝑢
= (
𝐷
𝐷𝑚
)𝑚 Eq. 5-4 
log
𝑓𝑎
𝑓𝑢
= 𝑚 × log(𝐷) − 𝑚 × log (𝐷𝑚) Eq. 5-5 
The median effect equation (Eq. 5-4) is equivalent to the Hill model depicted in Eq. 5-1 
but is derived from mass action enzyme kinetics. Assuming the two drugs are mutually 
exclusive, a combination index (CI) is then estimated using Eq. 5-6 [308]. A CI > 1 
indicates antagonism; a CI = 1 indicates additivity; and a CI between 0 and 1 indicates 
synergism. A CI – fa plot is often produced by plotting CI values on y axis and fas on x 
axis. 
𝐶𝐼 =
𝐷1/(𝐷1+𝐷2)
𝐷𝑚1(
𝑓𝑎
𝑓𝑢
)1/𝑚1
+
𝐷2/(𝐷1+𝐷2)
𝐷𝑚2(
𝑓𝑎
𝑓𝑢
)1/𝑚2
 Eq. 5-6 
 The fundamental equation of this approach, the median effect equation (Eq. 5-4), 
is derived from basic mass action enzyme kinetics [308]. Thus, the estimable parameters 
have the potential to be biologically meaningful. This represents a major improvement 
since all the methods published previously have used empirical equations to describe 
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dose-response relationships. Also, the experimental design using this approach requires 
fewer data than other designs which are intended to be analyzed by isobolograms and 
other methods [308]. A CI – fa plot is able to provide a comprehensive view on the nature 
and intensity of interaction across the entire spectrum of effect [308]. However, this 
method also suffers from a number of limitations. The Eq. 5-6 is based on the assumption 
that the effects of two drugs are mutually exclusive [308]. This may not hold in cases 
involving complex biological systems [305]. As the method involved logarithmic 
transformation, the data points with more than 100% of effect produce a computational 
difficulty and have to be discarded. More importantly, large CI values often appear in the 
region near fa = 0, indicating a strong antagonism, which has been proven an artifact 
when the interaction is truly synergistic [305].  
 
d. Hypothesis and aims 
 I hypothesize that the significant myopathic DDIs identified previously are due, at 
least in part, to direct myotoxicity brought by individual drugs or their combinations. To 
test this hypothesis, the following aims are pursued: 
1) Evaluate individual myotoxicity of the drugs involved in the significant DDIs, and 
their important metabolites, to differentiated rat L6 myotubes; 
2) Examine the combined effects of drug pairs in which both drugs are significantly 
myotoxic. 
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2. Methods  
a. Materials 
 Rat L6 myotubes were a generous gift from Dr. Jeffrey Elmendorf (Indiana 
University School of Medicine, Indianapolis, IN). All the drugs and the metabolites were 
purchased from Toronto Research Chemicals (Toronto, Canada). Fetal bovine serum 
(FBS) and Dulbecco's phosphate buffered saline (DPBS) were from Thermo ScientificTM 
HyCloneTM (Waltham, MA). 24-well FalconTM tissue culture plates were from Corning 
Life Sciences (Tewksbury MA). BioWhittakeTM phosphate buffered saline (PBS) without 
calcium and magnesium were from Lonza (Walkersville, MD). CellTiter 96TM AQueous 
MTS reagent powder was from PromegaTM (Madison, WI). Phenazine methosulfate 
(PMS), methanol and DMSO were from SigmaTM (St. Louis, MO). RNeasy mini kit and 
QuantiTect reverse transcription kit were from Qiagen Inc (Valencia, CA). α-Minimum 
essential medium (α-MEM), Gibco® antibiotic-antimycotic and 0.25% trypsin-EDTA 
(1X), TaqMan® gene expression master mix, Qubit RNA BR assay kit, MicroAmp fast 
optical 96-well reaction plate, MicroAmp optical adhesive film, TaqMan gene expression 
assay for CKM (assay ID Rn01644605_m1), myogenin (assay ID Rn01490689_g1), and 
GAPDH (assay ID Rn01775763_g1) were obtained from Life Technologies Corporation 
(Grand Island, NY). 
 
b. Cell culture and drug treatment 
 Rat L6 muscle cells were cultured as previously detailed by Klip et al. [309] with 
slight modifications. Myoblast cells were maintained in continuous passages by 
trypsinization of subconfluent cultures using 0.25% trypsin. Cells were seeded at 7500 
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cells/well in 24-well plates, and were maintained in monolayer culture in α-MEM 
containing 10% FBS and 1% antibiotic-antimycotic solution (10,000 U/ml penicillin G, 
10 mg/ml streptomycin and 25 mg/ml amphotericin B) in an atmosphere of 5% CO2 at 
37°C. Five days after seeding, myoblasts were differentiated into multinucleated 
myotubes with 2% FBS. Cells were fed fresh medium every other day. All drug 
treatments were initiated when the majority of cells were differentiated myotubes (5 days 
after the initiation of differentiation and 10 days after seeding) and continued for 5 days. I 
chose this time window because it allows the longest possible time within the optimal 
drug treatment time window as determined by the expression profiles of CKM and Myog 
(see below).  
 
c. Gene expression of CKM and Myog 
 The expression of creatine kinase muscle type (CKM) and myogenin (Myog) 
mRNA in rat L6 muscle cells on day 0 through day 13 after the initiation of 
differentiation was measured by real-time PCR. Cells were removed from culture on 24-
well plates by trypsinization using 0.25% trypsin, and were stored immediately at -80 ◦C 
before extraction of total RNA. Total RNA of muscle cells was isolated using RNeasy 
mini kit in accordance with the manufacturer’s instructions. The isolated RNA was 
quantified using the Qubit RNA BR assay kit and a Qubit® 2.0 fluorometer (Life 
Technologies Corporation, Grand Island, NY), immediately followed by reverse 
transcription. For each sample, cDNA was reverse-transcribed from 1 µg of total RNA 
using QuantiTect reverse transcription kit following the manufacturer’s instructions. The 
cDNAs were stored at -80 ◦C before use.  
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 Real-time PCR was performed in triplicate for each sample. GAPDH served as an 
endogenous control to which the expression of CKM and Myog were normalized. Each 
reaction was carried out as a duplex reaction, employing a combination of a FAM-labeled 
CKM or Myog assay and a VIC dye-labeled GAPDH assay. All reactions were 
performed in MicroAmp fast optical 96-Well reaction plates covered by MicroAmp 
optical adhesive film. The final total volume was 20 µL per well, consisting of 1 µL of 
CKM or myog primer, 1 µL of GAPDH primer, 1 µL of cDNA, 10 µL of TaqMan master 
mix (2X) and 7 µL of nuclease-free water. Real-time PCR plates were run on a Bio-rad 
iCycler iQ PCR Thermal Cycler (Hercules, CA). Cycling conditions were 10 min / 95 °C 
initial denaturation / polymerase activation and 40 cycles each consisting of 15 s / 95 °C 
denaturation and 1min/60 °C annealing and elongation. 
 The gene expressions of CKM and Myog were quantified using the comparative 
CT (ΔΔCT) method. Briefly, for each sample, the ΔCT value was calculated as ΔCT = CT 
target – CT reference, where CT target is the CT value of CKM or Myog, and CT reference is the CT 
value of GAPDH. The ΔΔCT value was calculated by ΔΔCT = ΔCT test sample – ΔCT calibrator 
sample. For Myog, the calibrator sample was the cells sampled on the day of differentiation 
(day 0). For CKM, because the gene expression was undetectable for the samples on day 
0, 1 and 2, the cells sampled on day 3 since differentiation served as the calibrator sample. 
The standard error (SE) of ΔΔCT was same as that of ΔCT, and was calculated as SE 
(ΔCT) = SE (ΔΔCT) = [SE (CT target)2 + SE (CT reference)2]1/2. The fold-change of gene 
expression relative to a calibrator sample was calculated as 2–ΔΔCt, with 
2ΔΔ𝐶𝑇 + SE (ΔΔ𝐶𝑇) and 2ΔΔ𝐶𝑇− SE (ΔΔ𝐶𝑇) as the upper and lower bound of standard error. 
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d. MTS/PMS assay 
 The CellTiter 96® aqueous non-radioactive cell proliferation (MTS/PMS) assay 
was used to measure cell viability after drug treatment. Similar to XTT and MTT assays, 
this assay involves bioreduction of a tetrazolium compound, MTS, by dehydrogenase 
enzymes in metabolically active cells in the presence of PMS. The resulting formazan 
product is soluble in cell culture medium and can be quantitated by the amount of light 
absorbance at 490 nm. The number of viable cells has a linear relationship with light 
absorbance at 490 nm [310].  
 A MTS solution (2 mg/mL) was prepared by dissolving MTS reagent powder in 
DPBS in a light-protected container. The solution was adjusted to pH 6 to 6.5 with 1N 
HCl, followed by filtration through a 0.2 μm filter into a sterile, light-protected container. 
Similarly, a PMS solution (0.92 mg/mL) was prepared by dissolving PMS in DPBS 
followed by filtration through a 0.2 μm filter into a sterile, light-protected container. Both 
MTS and PMS solutions were stored at –20°C and protected from light before use.  
 For each 24-well plate to be assayed, 2 mL of MTS solution and 100 µL of PMS 
solution were added to 10 mL of α-MEM medium containing 2% FBS. 500 µL of this 
MTS/PMS-containing medium were added to each well. After incubating the plate for 3 
hours in an atmosphere of 5% CO2 at 37°C, the light absorbance at 490 nm was recorded 
using Molecular Devices Spectramax M2e (Sunnyvale, CA). The assay was also carried 
out at the same time on an empty plate without any cells to estimate the background 
absorbance. For data analysis, the net absorbance was calculated as the difference 
between the absorbance of the samples and the background absorbance. Cell viability 
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was calculated as the net absorbance of treated cells divided by that of the DMSO treated 
control cells. The MTS/PMS assay is linear  
 
e. Screening for the inhibition of L6 myotube viability 
 The compromise of L6 myotube viability was screened using the drugs involved 
in the significant myopathic DDIs identified previously, and using simvastatin acid, 3-
hydroxy simvastatin (3OH simvastatin), desloratadine and 3-hydroxy desloratadine (3OH 
desloratadine), the important major metabolites of simvastatin and loratadine, 
respectively. The drugs and metabolites were dissolved in methanol and diluted in 
DMSO to desired concentrations before addition to α-MEM with 2% FBS. The final 
concentration was 10 µM for all drugs, except for alprazolam and 3OH desloratadine 
which were tested at 5 µM due to limited aqueous solubility. Each drug was tested in six 
replicate wells on the same plate. Cells treated with 0.1% DMSO on the same plate 
served as controls. The final concentration of DMSO was kept at 0.1% for all treatments. 
Cells were treated for 5 days from day 5 to day 10 after the initiation of differentiation. 
Experiments were repeated three times with different passages (passage #11 to #14) to 
ensure reproducibility of results. 
 
f. Determining concentration – cell viability relationships 
 The viability of L6 myotubes at different concentrations was evaluated for drugs 
that yielded more than 50% inhibition in the screening study. These included tegaserod, 
desloratadine and simvastatin. For tegaserod, cells were treated at 0, 1, 2, 3, 4, 5, 6, 7, 8, 
9 and 10 µM. For desloratadine, cells were treated at 0, 1, 5, 7.5, 11, 17, 25 and 50 µM. 
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For simvastatin, cells were treated at 0, 0.5, 1, 2, 5 and 10 µM. Each concentration was 
tested column-wise in four replicate wells on a 24-well plate. For tegaserod and 
desloratadine, concentrations were tested with two plates of cells from the same passage. 
Cells treated with 0.1% DMSO served as controls. All the treatments started on day 5 and 
ended on day 10 after the initiation of differentiation. The experiments were repeated 
multiple times with different passages (passage #11 to #14) of myotubes to ensure 
reproducibility of results. Cell viability was calculated as described above. IC50s were 
estimated by fitting cell viability (%) and concentrations to a two- (Eq. 3-2) or four- (Eq. 
3-3) parameter logistic model using GraphPad Prism V5. 
 
g. Determining the combined effect of simvastatin and desloratadine 
 Fully differentiated myotubes were treated with simvastatin and desloratadine in 
combination on day 5 through day 10. The experimental design is displayed in Table 5-1. 
For 24-well plates 1 to 5, the dose response of simvastatin was tested column-wise at 
final concentrations of 0, 0.5, 1, 2, 4 and 8 µM, in the presence of desloratadine row-wise 
at final concentrations of 0, 5, 7.5, 10, 15 and 25 µM. Plates 6 to 10 were arranged 
similarly at the same concentration combinations except that the dose response of 
desloratadine was tested column-wise instead. 
 On plate 1 through 5, desloratadine at 0 µM was tested in row 1, 2, 3, 4 and 1 
respectively. Simvastatin at 0 µM was tested similarly on plate 6 to 10. This design has 
several advantages. First, it is relatively balanced in that it provides eight replicates for 
each concentration combination involving 0 µM and six replicates for those otherwise. 
Second, it helps to control for potential batch effect among different plates by including 
 173 
 
the combination (0 µM, 0 µM) on each plate which serves as the control for that plate. 
Third, the control combination (0µM, 0 µM) appears in each row across plates, which 
helps to reduce confounding of an edge effect observed occasionally in the wells at 
corners. Lastly, the concentrations are evenly spaced on a logarithmic scale which helps 
with computation of interaction measures. 
 Combination index (CI) values were calculated as described by Chou et al. [308]. 
Cell viability, in this case was also the fraction unaffected (fu), was first calculated as 
described above. Fractional inhibition (fi) was calculated as 1 – fa. The slope factor m and 
IC50 of simvastatin and desloratadine were estimated by fitting the data of each drug 
when applied alone to Eq. 5-5. CI values were calculated using Eq. 5-6. A CI - fa was 
constructed by plotting CI values and fa on y and x axis, respectively.   
 
3. Original experimental results 
a. Gene expression of CKM and Myog 
 At any given time during myoblast differentiation, cells are a heterogeneous 
population consisting of proliferating myoblast, differentiating myocytes and terminally 
differentiated myotubes. I am most interested in the effects of drugs on differentiated 
myotubes as they are the victim of myotoxicity in vivo. Since the composition of a cell 
population may affect a drug’s myotoxicity, I sought to select an optimal drug treatment 
window within which the majority of viable cells were healthy, fully differentiated 
myotubes that were not too senescent to confound the measurement of cell viability.  
The expression of CKM and Myog are commonly used in skeletal muscle cell lines as 
biomarkers of myogenesis. For this reason, I examined the mRNA expression profile of 
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CKM and Myog in rat L6 muscle cells at various times after the initiation of 
differentiation. The results are presented in Figure 4-1. The expression of Myog (Figure 
4-1, A) is expressed as fold-change relative to that on day 0 when differentiation was 
initiated. Because the mRNA expression was undetectable for CKM on day 0, 1 and 2, its 
mRNA levels are expressed as fold-change relative to that on day 3 after differentiation 
(Figure 4-1, B). The expression of Myog increased dramatically (645-fold) during the 
first three days of differentiation, then gradually decreased to 200-fold on the 10th day of 
differentiation, and remained relatively stable thereafter up to the 13th day. The change in 
the expression level of CKM was smaller than that of Myog. The expression of CKM 
increased beginning on the third day and spiked on the sixth day, followed by a gradual 
decrease thereafter.  
 These data are consistent with the results observed previously indicating that L6 
myoblasts begin to express genes promoting differentiation upon the initiation of 
differentiation [297, 299, 300]. The gradual decrease in the expression of CKM and 
Myog may be due to an aging cell population. These expression profiles suggest that 
myotubes can be treated as early as day 5 and up to day 10 after the initiation of 
differentiation. Because I sought to test the worst-case scenario of drug myotoxicity, and 
because many of the drugs of interest are long-term treatments, I selected the longest 
possible time window, from day 5 to day 10 after the initiation of differentiation, as the 
treatment window for the subsequent experiments.  
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b. Screening for the inhibition of myotube viability 
 Cell viability was evaluated after 5 days of treatment with the drugs and 
metabolites of interest. Apart from alprazolam and 3OH desloratadine, which had limited 
aqueous solubility and were tested at 5 µM, all the other drugs were tested at a final 
concentration of 10 µM. Myotubes treated with tegaserod, simvastatin, desloratadine and 
simvastatin acid exhibited significantly decreased viability as compared to those treated 
with DMSO (Figure 5-2). Tegaserod was the most potent myotoxin (97.98% cell death), 
followed by desloratadine (73.66%), simvastatin (73.28%) and simvastatin acid (32.95%) 
at 10 µM (Table 5-1). It is worth noting that several drugs seemed to improve cell 
viability significantly after 5 days of treatment. Cells treated with chloroquine, 
hydroxychloroquine and promethazine were 46.8%, 43.4% and 42.1% more viable than 
those treated with DMSO as measured using the MTS/PMS assay. The data from three 
repeated experiments with myotubes of different passages were consistent.  
 
c. Concentration-cell viability relationships of tegaserod, desloratadine and simvastatin  
 Because treatment with tegaserod, simvastatin and desloratadine resulted in more 
than 50% myotube death, their concentration-effect curves were characterized with 
myotubes treated at various concentrations. Tegaserod inhibited myotube viability with 
an IC50 (95% CI) of 4.32 µM (4.15, 4.49) (Figure 5-3 A). Its concentration-effect curve 
was characterized by a steep drop between 3 µM to 6 µM. The IC50s (95% CI) of 
desloratadine and simvastatin were 10.94 µM (9.24, 12.96), and 1.64 µM (1.05, 2.56), 
respectively (Figure 5-3 B and C).  
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d. The combined effect of simvastatin and desloratadine 
 To test whether there is a myotoxic interaction between simvastatin and 
desloratadine, their combined effect on myotube viability was examined by treating 
myotubes with a range of concentrations of both drugs. In general, the concentration-
effect curves of simvastatin shifted leftward with increasing concentration of 
desloratadine (Figure 5-4, A). The same trend was observed with the concentration 
curves of desloratadine in the presence of simvastatin (Figure 5-4, B). Using the method 
of Chou et al. [308], combination index (CI) values indicating the intensity of interaction 
were calculated and plotted against fractional inhibitory effect on myotube viability (fa). 
The CI – fa plot is shown in Figure 5-5, in which the points above the horizontal line at 
CI = 1 indicate antagonism, and those below the line indicate synergism. Most CI values 
were greater than zero and less than unity, indicating that the interaction between 
simvastatin and desloratadine was synergistic, such that the drugs notably increased each 
other’s myotoxic effect. It follows that examination of each individual drug’s effect 
would have underestimated the toxicity of the combination.  
 
4. Discussion 
 In this chapter, I have addressed the hypothesis that direct myotoxicity of the 
individual drugs or their combinations contributes to the significant DDIs identified 
previously. An optimal drug treatment window between day 5 and day 10 after the 
initiation of differentiation was selected for rat L6 myotubes, based on the gene 
expression profiles of CKM and Myog, two maker genes of myogenesis. After 5 days of 
treatment, tegaserod, desloratadine and simvastatin caused significant decreases in the 
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viability of fully differentiated myotubes at 10 µM. Their IC50s for inhibition of viability 
were 4.32 µM, 10.94 µM and 1.64 µM, respectively. Simvastatin and desloratadine were 
further found to have a synergistic myotoxic interaction when applied in combination. 
 Both simvastatin and simvastatin acid induced cell death after 5 days of treatment, 
whereas 3-hydroxy simvastatin, one of the major circulating metabolites, was well 
tolerated by myotubes under these conditions. Simvastatin-induced myotoxicity observed 
here was consistent with the data of Kawk et al., who found that simvastatin induced 60% 
- 80% cell death at 10 µM in primary skeletal muscle cells after 2 days of treatment using 
the MTS/PMS assay [289]. At 10 µM, simvastatin was about 2-fold more myotoxic than 
simvastatin acid. This is consistent with the observation of Skottheim et al., who found 
that simvastatin lactone was 37-fold more potent in inducing of myotoxicity than its acid 
form in human primary skeletal myotubes [311]. These data suggest that simvastatin-
induced myopathy is due mainly to simvastatin lactone, rather than its downstream 
metabolites. 
 Unlike simvastatin, loratadine-induced myopathy seems largely due to its active 
metabolite desloratadine. Both loratadine and 3-hydroxy desloratadine were well 
tolerated by myotubes at concentrations up to 10 µM. Its major metabolite desloratadine 
caused 73.66% of cell death at 10 µM after 5 days of treatment. Neither loratadine nor 
desloratadine has been reported before to be toxic to muscle cells of any type. My data 
are the first suggesting that desloratadine myotoxicity may be responsible for myopathy 
associated with loratadine and desloratadine. The data showing that desloratadine is more 
myotoxic than loratadine in L6 myotubes seems consistent with the higher occurrence of 
myalgia in patients treated with desloratadine than in those treated with loratadine. In 
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randomized clinical trials, 2.1% of subjects treated with desloratadine experienced 
myalgia, whereas less than 2% of subjects treated with loratadine experienced the same 
side effect [88, 89]. The myotoxicity of desloratadine and its association with myalgia in 
humans need to be further evaluated both in human muscle cells and in vivo. 
 This thesis also provides the first description of the myotoxicity of tegaserod. 
Tegaserod induced myotube death with an IC50 of 4.36 µM. Its concentration – cell 
viability curve was characterized by a steep decrease between 3 and 6 µM, indicating that 
tegaserod may induce cell death through a mechanism that requires tegaserod 
concentration to cross a certain threshold. Tegaserod is a partial 5-hydroxytryptamine 
receptor 4 (5-HT4) agonist and a potent (5-HT2B) antagonist. There are a number of 
published studies investigating its inotropic effect on cardiomyocytes [312] and smooth 
muscle cells [313], which may be related to its toxicity to L6 myotubes. Future studies 
are needed to investigate whether tegaserod has similar effects on human muscle cells.  
 The drugs were screened for myotoxicity at 10 µM, a concentration that is much 
higher than the circulating concentration of any of these drugs. This concentration is also 
likely higher than the intramuscular concentrations of these drugs except for those of 
chloroquine and hydroxychloroquine, which are known to accumulate in tissues 
including muscle [185]. This high screening concentration allowed me to rule out the 
possibility of myotoxicity in vivo for the drugs that did not cause significant myotube 
death in vitro. Therefore, for those non-myotoxic drugs, direct myotoxicity is unlikely the 
mechanism for the relevant DDIs. On the other hand, this high concentration limits the 
interpretation of the myotoxicity of simvastatin, desloratadine and tegaserod in a clinical 
setting. It is possible that at clinical doses, the intramuscular concentrations of these three 
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drugs are never as high as those used in my experiments, and their toxicity to human 
muscle cells in vivo are minimal.  It is, however, also possible that at clinical doses, these 
drug are toxic enough to induce certain molecular changes that contribute to clinical 
myopathy in humans, but not as toxic as to induce apoptosis of muscle cells as 
determined here. Future studies should evaluate the actual myotoxicity of these drugs in 
humans at clinical doses.  
 Chloroquine and hydroxychloroquine are known to be toxic to muscle cells. 
However, my data show that, instead of being myotoxic, they were able to improve the 
viability of myotubes after 5 days of treatment. The MTS/PMS assay used to evaluate 
cell viability depends on dehydrogenase enzymes in metabolically active cells. As 
dehydrogenase enzymes are mostly located in mitochondria, this assay largely measures 
the collective metabolic activity of mitochondria in the cell population being assayed. 
Since the myotoxicity of chloroquine and hydroxychloroquine are caused by their 
lysosomotropic effects, the MTS/PMS assay may not be able to detect myotoxicity of 
such drugs. This implies that the MTS/PMS assay is only appropriate for evaluating 
myotoxicity induced by changes in mitochondrial activity. Future studies are warranted to 
assess the possibility that these drugs induce myotoxicity through other mechanisms. 
 As was the case for chloroquine and hydroxychloroquine, ropinirole, trazodone, 
quetiapine and promethazine also seemed to improve cell viability. Considering the high 
screening concentration that should, in theory, be toxic to cells, the data on these drugs 
might be an artifact of the MTS/PMS assay. The increased signal at the end of treatment 
might be cause by dehydrogenase activation of these drugs. They might be able to 
improve the overall metabolic activity of mitochondria, or to change the 
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microenvironment in mitochondria, so that dehydrogenase is more efficient in converting 
MTS to the light-absorbing product.  
 There are a number of limitations inherent to the use of rat L6 myotubes as the 
model system. Although rat L6 myotubes are a good model for investigating muscular 
glucose uptake [296] and myogenesis [297], they may not be the most appropriate model 
for evaluating drug-induced myopathy. In addition, although these cells have been used 
by other groups for in vitro evaluation of myotoxicity of statins [277, 302] and fibrates 
[314], they have never been used to examine myotoxicity of other drug or any drug 
combinations. The validity of this cell model may need to be further assessed, especially 
for evaluation of myotoxicity resulting from drug combinations. The species difference 
between rat and human would limit the interpretation of the data in a clinical setting. 
Future studies using primary human muscle cells may be helpful to further evaluate the 
myotoxicity of the drugs of interest.    
 Using Chou et al’s CI method, I identified a synergistic interaction between 
simvastatin and desloratadine in inducing myotube death. Most CI values are between 
zero and unity, and tend to decrease with increasing inhibition of cell viability. This 
suggests that at higher concentrations of simvastatin and desloratadine, where their 
combined toxic effect on myotubes are larger, the synergism between them is also 
stronger. There are a few large CI values indicating a strong antagonism in the region 
near fa=0. As pointed out by Greco et al., these may be an artifact resulting from 
methodological flaw. I could not obtain an isobologram for this drug combination 
because most of the concentration-effect curves could not provide reliable estimates of 
IC50s. Further analysis of the response surface may provide a more comprehensive view 
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of the nature and intensity of this interaction. Nonetheless, my data suggest that the 
synergistic myotoxicity of simvastatin and desloratadine may contribute to the interaction 
between simvastatin and loratadine. Because the data were obtained using concentrations 
likely much higher than the intramuscular concentrations at the clinical doses, future 
studies are needed to validate my results in vivo and in humans. As discussed in chapter 3, 
both simvastatin and loratadine are clinically important drugs that are used by a huge 
number of patients. If this synergistic toxicity is confirmed to be clinically relevant, 
simvastatin and loratadine should probably not be used together as they commonly are. 
Patients may need to switch to other statins or other antihistamines to avoid the harm of 
this synergistic interaction while achieving favorable therapeutic effects. 
  
  
1
8
2
 
Table 5-1. The experimental design to evaluate the combined effect of simvastatin and desloratadine 
Note: The concentration combination in each well is shown as simvastatin concentration µM * desloratadine concentration µM. 
Dose-response of simvastatin in the presence of desloratadine Dose-response of desloratadine in the presence of simvastatin 
 A B C D E F  A B C D E F 
 Plate 1  Plate 6 
1 0 * 0 0.5 * 0 1 * 0 2 * 0 4 * 0 8 * 0 1 0 * 0 0 * 5 0 * 7.5 0 * 10 0 * 15 0 * 25 
2 0 * 5 0.5 * 5 1 * 5 2 * 5 4 * 5 8 * 5 2 0.5 * 0 0.5 * 5 0.5 * 7.5 0.5 * 10 0.5 * 15 0.5 * 25 
3 0 * 7.5 0.5 * 7.5 1 * 7.5 2 * 7.5 4 * 7.5 8 * 7.5 3 1 * 0 1 * 5 1 * 7.5 1 * 10 1 * 15 1 * 25 
4 0 * 10 0.5 * 10 1 * 10 2 * 10 4 * 10 8 * 10 4 2 * 0 2 * 5 2 * 7.5 2 * 10 2 * 15 2 * 25 
 Plate 2  Plate 7 
1 0 * 5 0.5 * 5 1 * 5 2 * 5 4 * 5 8 * 5 1 0.5 * 0 0.5 * 5 0.5 * 7.5 0.5 * 10 0.5 * 15 0.5 * 25 
2 0 * 0 0.5 * 0 1 * 0 2 * 0 4 * 0 8 * 0 2 0 * 0 0 * 5 0 * 7.5 0 * 10 0 * 15 0 * 25 
3 0 * 7.5 0.5 * 7.5 1 * 7.5 2 * 7.5 4 * 7.5 8 * 7.5 3 1 * 0 1 * 5 1 * 7.5 1 * 10 1 * 15 1 * 25 
4 0 * 15 0.5 * 15 1 * 15 2 * 15 4 * 15 8 * 15 4 4 * 0 4 * 5 4 * 7.5 4 * 10 4 * 15 4 * 25 
 Plate 3  Plate 8 
1 0 * 7.5 0.5 * 7.5 1 * 7.5 2 * 7.5 4 * 7.5 8 * 7.5 1 1 * 0 1 * 5 1 * 7.5 1 * 10 1 * 15 1 * 25 
2 0 * 10 0.5 * 10 1 * 10 2 * 10 4 * 10 8 * 10 2 2 * 0 2 * 5 2 * 7.5 2 * 10 2 * 15 2 * 25 
3 0 * 0 0.5 * 0 1 * 0 2 * 0 4 * 0 8 * 0 3 0 * 0 0 * 5 0 * 7.5 0 * 10 0 * 15 0 * 25 
4 0 * 25 0.5 * 25 1 * 25 2 * 25 4 * 25 8 * 25 4 8 * 0 8 * 5 8 * 7.5 8 * 10 8 * 15 8 * 25 
 Plate 4  Plate 9 
1 0 * 10 0.5 * 10 1 * 10 2 * 10 4 * 10 8 * 10 1 2 * 0 2 * 5 2 * 7.5 2 * 10 2 * 15 2 * 25 
2 0 * 15 0.5 * 15 1 * 15 2 * 15 4 * 15 8 * 15 2 4 * 0 4 * 5 4 * 7.5 4 * 10 4 * 15 4 * 25 
3 0 * 25 0.5 * 25 1 * 25 2 * 25 4 * 25 8 * 25 3 8 * 0 8 * 5 8 * 7.5 8 * 10 8 * 15 8 * 25 
4 0 * 0 0.5 * 0 1 * 0 2 * 0 4 * 0 8 * 0 4 0 * 0 0 * 5 0 * 7.5 0 * 10 0 * 15 0 * 25 
 Plate 5  Plate 10 
1 0 * 0 0.5 * 0 1 * 0 2 * 0 4 * 0 8 * 0 1 0 * 0 0 * 5 0 * 7.5 0 * 10 0 * 15 0 * 25 
2 0 * 5 0.5 * 5 1 * 5 2 * 5 4 * 5 8 * 5 2 0.5 * 0 0.5 * 5 0.5 * 7.5 0.5 * 10 0.5 * 15 0.5 * 25 
3 0 * 15 0.5 * 15 1 * 15 2 * 15 4 * 15 8 * 15 3 4 * 0 4 * 5 4 * 7.5 4 * 10 4 * 15 4 * 25 
4 0 * 25 0.5 * 25 1 * 25 2 * 25 4 * 25 8 * 25 4 8 * 0 8 * 5 8 * 7.5 8 * 10 8 * 15 8 * 25 
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Figure 5-1. Gene expression of Myog (A) and CKM (B). The mRNA expression of Myog 
and CKM is expressed as fold-change relative to that on day 0 when differentiation was 
initiated. 
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Figure 5-2. Cell viability (%) after 5 days of treatment as compared with DSMO controls. 
The drugs were tested with six replicates at 10 µM except for alprazolam and 3OH 
desloratadine which were tested at 5 µM. 
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Note: All the drugs were tested at 10 µM except for alprazolam and 3OH desloratadine 
which were tested at 5 µM.  
Table 5-2. Myotube death after 5 days of treatment. 
Drug % Cell death (± SEM) 
Tegaserod 97.9 ± 0.4 
Desloratadine 73.7 ± 2.6 
Simvastatin 73.3 ± 1.1 
Simvastatin Acid 33 ± 2.1 
3OH Desloratadine -3 ± 11.8 
Loratadine -9.1 ± 5.6 
Duloxetine -9.2 ± 6.2 
Risperidone -9.3 ± 2 
Omeprazole -11.4 ± 7.1 
3OH Simvastatin -11.6 ± 6 
Alprazolam -18 ± 6.5 
Ropinirole -21.3 ± 6.9 
Trazodone -28 ± 7.5 
Quetiapine -28 ± 8.4 
Hydroxychloroquine -42.1 ± 7.2 
Promethazine -43.4 ± 5.1 
Chloroquine -46.8 ± 6.649 
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Figure 5-3. Concentration-cell viability relationship of tegaserod (A), desloratadine (B), 
and simvastatin (C). Fully differentiated myotubes were treated at 1, 2, 3, 4, 5, 6, 7, 8, 9 
and 10 µM of tegaserod, 1, 5, 7.5, 11, 17, 25 and 50 µM of desloratadine, and 0.5, 1, 2, 5 
and 10 µM of simvastatin for 5 days with at least four replicates. 
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Figure 5-4. Concentration-effect curves of simvastatin and desloratadine in combination. 
The concentration-inhibition (%) curves of simvastatin in the presence of desloratadine 
are shown in panel A and those of desloratadine in the presence of simvastatin are shown 
in panel B. 
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Figure 5-6. Combination index (CI) – fraction of inhibition (fa) plot. The points above the 
horizontal dash line at CI = 1 indicate antagonism, and those below the line indicate 
synergism. 
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Chapter 6. Summary  
 
 In this thesis, I have tested the hypothesis that the combination of data mining and 
in vitro mechanistic studies can identify and shed mechanistic light on new DDIs that are 
associated with an increased risk of clinical myopathy.  
 Text mining of the published literature identified 232 drugs as either substrates or 
inhibitors of the major CYPs. 13,197 pairs of drugs were predicted to have metabolic 
interactions via inhibition of CYPs, 3670 of which were subjected to a 
pharmacoepidemiology study using a synergistic model and the data from an EMR 
database. Fifteen drug pairs were identified to be significantly associated with an 
increased risk of myopathy as compared to the additive risk from taking either of the 
drugs alone. These significant myopathic DDIs involved thirteen clinically important 
drugs including alprazolam, chloroquine, duloxetine, hydroxychloroquine, loratadine, 
omeprazole, promethazine, quetiapine, risperidone, ropinirole, trazodone and simvastatin.   
Many of these thirteen drugs were identified as inhibitors of the major CYPs in vitro. 
Their mechanisms and potencies were further characterized across eighteen inhibitory 
reactions that yielded IC50s less than 20 µM. Duloxetine, promethazine, risperidone, 
ropinirole, quetiapine and chloroquine were predicted to potentially act as precipitant 
drugs and cause clinical DDIs. When these interactions were carefully examined using 
the AUCR approach, the AUCR for the interaction between quetiapine and chloroquine 
was 1.25, indicating a weak clinical drug interaction. The risk of clinical DDIs for the 
other inhibitory reactions was predicted to be negligible. 
 190 
 
 Detailed studies on the interaction between loratadine and simvastatin revealed 
that loratadine and desloratadine were able to inhibit the metabolism of simvastatin and 
simvastatin acid, and that simvastatin and simvastatin acid were able to inhibit the 
metabolism of loratadine. However, these inhibitory reactions were relatively weak or 
moderate, and were unlikely to result in any clinically meaningful effect.  
 Simvastatin acid and quetiapine were identified as relatively potent inhibitors of 
E217βDG uptake via OATP1B1/1B3. Their predicted R values were 3.85 and 5.28, 
respectively, larger than that of rifampin (R value 3.4), a drug that is known to cause 
clinical DDIs by inhibiting OATP1B1/1B3. These data suggest that simvastatin acid and 
quetiapine may interact with drugs that rely on OATP1B1/1B3 for hepatic uptake in vivo. 
The inhibitory effect of simvastatin acid may contribute to the interaction between 
simvastatin and loratadine by inhibiting the hepatic uptake of desloratadine via 
OATP1B1/1B3.  
 Tegaserod, desloratadine and simvastatin were able to induce significant 
apoptosis in fully differentiated myotubes. Their IC50s for inhibition of viability were 
4.32 µM, 10.94 µM and 1.64 µM, respectively. Simvastatin and desloratadine were 
further found to have a synergistic myotoxic interaction when applied in combination, 
which may contribute to the interaction between simvastatin and loratadine.  
 These data suggest that the interaction between quetiapine and chloroquine may 
be due to the inhibition of the metabolism of chloroquine by quetiapine. The data also 
suggest that the interaction between simvastatin and loratadine may result from the 
inhibition of OATP1B1/1B3 by simvastatin acid and from synergistic myotoxicity of 
simvastatin and desloratadine.  
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 Finally, with these data, I have demonstrated that our approach, that combines 
literature mining using bioinformatics algorithms, ADR detection using a 
pharmacoepidemiology design, and mechanistic studies employing in vitro experimental 
models, can identify and shed mechanistic light on new DDIs that are associated with an 
increased risk of clinical myopathy. 
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Appendix: Permission to Reuse Table 4-1 
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2013  Adaptive Clinical Trials in Drug Development Pre-conference, ASCPT 
2013  Clinical Pharmacology Curriculum Review Course Post-conference,  
  ASCPT 
2013  AAPS Workshop on Drug Transporters in ADME, Bethesda, MD 
 
CONFERENCES  
2010 March  ASCPT Annual Meeting; Atlanta, GA 
2011 April  ASOP Annual Meeting; San Diego, CA 
2012 March  ASCPT Annual Meeting; Washington DC 
  
2012 October  AAPS Annual Meeting and Exhibition; Chicago, IL 
2012 November BPS Annual Meeting; London UK 
2012 December IQPC 3rd Annual Clinically Relevant Drug Transporters; London,  
   UK  
2013 March  ASCPT Annual Meeting; Indianapolis, IN 
 
